



(86) Date de dépôt PCT/PCT Filing Date: 2011/08/26
(87) Date publication PCT/PCT Publication Date: 2012/03/01
(85) Entrée phase nationale/National Entry: 2013/02/08
(86) N° demande PCT/PCT Application No.: US 2011/049403
(87) N° publication PCT/PCT Publication No.: 2012/027698
(30) Priorités/Priorities: 2010/08/26 (US61/377,248);
2010/12/30 (US61/428,277)

(51) Cl.Int./Int.Cl. *C12N 15/54* (2006.01),
C12P 7/64 (2006.01)
(71) Demandeur/Applicant:
E. I. DU PONT DE NEMOURS AND COMPANY, US
(72) Inventeurs/Inventors:
BOSTICK, MICHAEL W., US;
DAUBERT, MELISSA D., US;
HE, HONGXIAN, US;
HONG, SEUNG-PYO, US;
POLLAK, DANA M. WALTERS, US;
SHARPE, PAMELA L., US;
WANG, YEHONG JAMIE, US;
...
(74) Agent: TORYS LLP

(54) Titre : DELTA-5 DESATURASES A MOTIF HPGG ET A MOTIF HDASH MUTES ET LEUR UTILISATION DANS LA
FABRICATION D'ACIDES GRAS POLYINSATURES
(54) Title: MUTANT HPGG MOTIF AND HDASH MOTIF DELTA-5 DESATURASES AND THEIR USE IN MAKING
POLYUNSATURATED FATTY ACIDS

(57) **Abrégé/Abstract:**

Mutant delta 5 desaturases, having the ability to convert dihomo-gamma-linolenic acid [DGLA; 20:3 omega-6] to arachidonic acid [ARA; 20:4 omega-6] and/or eicosatetraenoic acid [ETA; 20:4 omega-3] to eicosapentaenoic acid [EPA; 20:5 omega-3] and possessing at least one mutation within the HPGG (SEQ ID NO:7) motif of the cytochrome b 5-like domain and at least one mutation within the HDASH (SEQ ID NO:8) motif are disclosed. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding delta 5 desaturases, along with a method of making long chain polyunsaturated fatty acids ["PUFAs"], are also disclosed.



(72) Inventeurs(suite)/Inventors(continued): XUE, ZHIXIONG, US; YADAV, NARENDRA S., US; ZHANG, HONGXIANG, US;
ZHU, QUN, US

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 March 2012 (01.03.2012)



(10) International Publication Number
WO 2012/027698 A1

(51) International Patent Classification:

C12N 15/54 (2006.01) C12P 7/64 (2006.01)

(21) International Application Number:

PCT/US2011/049403

(22) International Filing Date:

26 August 2011 (26.08.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/377,248 26 August 2010 (26.08.2010) US
61/428,277 30 December 2010 (30.12.2010) US

(71) Applicant (for all designated States except US): **E.I. DU PONT DE NEMOURS AND COMPANY** [US/US]; 1007 Market Street, Wilmington, Delaware 19898 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOSTICK, Michael, W.** [US/US]; 2650 Bittersweet Drive, Wilmington, Delaware 19810 (US). **DAUBERT, Melissa, D.** [US/US]; 139 Acorn Drive, Mount Royal, New Jersey 08061 (US). **HE, Hongxian** [CN/US]; 120 Tuckaway Drive, Wilmington, Delaware 19803 (US). **HONG, Seung-Pyo** [AU/US]; 9 Pierson's Ridge, Hockessin, Delaware 19707 (US). **POLLAK, Dana, M., Walters** [US/US]; 321 Lea Drive, West Chester, Pennsylvania 19382 (US). **SHARPE, Pamela, L.** [US/US]; 232 Cayman Court, Wilmington, Delaware 19808 (US). **WANG, Yehong, Jamie** [US/US]; 197 Harriet Court, Newark, Delaware 19711 (US). **XUE, Zhixiong** [CN/US]; 111 Harvey Lane, Chadds Ford, Pennsylvania 19317-9728 (US). **YADAV, Narendra, S.** [US/US]; 126 Tuckaway Drive, Wilmington, Delaware 19803 (US). **ZHANG, Hongxiang** [US/US]; 3808 Rotherfield Lane, Chadds Ford, Pennsyl-

vania 19317 (US). **ZHU, Qun** [US/US]; 544 Revere Road, West Chester, Pennsylvania 19382 (US).

(74) Agent: **CHRISTENBURY, Lynne, M.**; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 4417 Lancaster Pike, Wilmington, Delaware 19805 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MUTANT HPGG MOTIF AND HDASH MOTIF DELTA-5 DESATURASES AND THEIR USE IN MAKING POLYUNSATURATED FATTY ACIDS

(57) Abstract: Mutant delta 5 desaturases, having the ability to convert dihomo-gamma-linolenic acid [DGLA; 20:3 omega-6] to arachidonic acid [ARA; 20:4 omega-6] and/or eicosatetraenoic acid [ETA; 20:4 omega-3] to eicosapentaenoic acid [EPA; 20:5 omega-3] and possessing at least one mutation within the HPGG (SEQ ID NO:7) motif of the cytochrome *b*₅-like domain and at least one mutation within the HDASH (SEQ ID NO:8) motif are disclosed. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding delta 5 desaturases, along with a method of making long chain polyunsaturated fatty acids ["PUFAs"], are also disclosed.



WO 2012/027698 A1

TITLE

MUTANT HPGG MOTIF AND HDASH MOTIF DELTA-5 DESATURASES AND THEIR USE IN MAKING POLYUNSATURATED FATTY ACIDS

This application claims the benefit of U.S. Provisional Application
5 No. 61/377248, filed August 26, 2010, and U.S. Provisional Application No.
61/428277, filed December 30, 2010, the disclosures of which are hereby
incorporated by reference in their entireties.

FIELD OF THE INVENTION

This invention is in the field of biotechnology. More specifically, this
10 invention pertains to making nucleic acid fragments encoding mutant
delta-5 fatty acid desaturases (wherein at least one mutation occurs within
the HPGG [SEQ ID NO:7] motif of the cytochrome *b*₅-like domain and at
least one mutation occurs within the HDASH [SEQ ID NO:8] motif).

BACKGROUND OF THE INVENTION

15 A variety of different hosts including plants, algae, fungi,
stramenopiles and yeast are being investigated as means for commercial
polyunsaturated fatty acid ["PUFA"] production. Genetic engineering has
demonstrated that the natural abilities of some hosts (even those natively
limited to linoleic acid [LA; 18:2 omega-6] and α -linolenic acid [ALA; 18:3
20 omega-3] fatty acid production) can be substantially altered to result in
high-level production of various long-chain omega-3/ omega-6 PUFAs.
Whether this is the result of natural abilities or recombinant technology,
production of arachidonic acid [ARA; 20:4 omega-6], eicosapentaenoic
acid [EPA; 20:5 omega-3] and docosahexaenoic acid [DHA; 22:6 omega-
25 3] may all require expression of a delta-5 desaturase gene.

Thus, the instant invention concerns new delta-5 desaturases
having high activity that are well suited for integration into PUFA
biosynthetic pathways in commercially useful host cells.

SUMMARY OF THE INVENTION

30 In a first embodiment, the invention concerns a mutant polypeptide
having delta-5 desaturase activity comprising:

(a) an amino acid motif as set forth in SEQ ID NO:34 [HxGx],
wherein SEQ ID NO:34 [HxGx] is not identical to SEQ ID
NO:7 [HPGG]; and,

(b) an amino acid motif as set forth in SEQ ID NO:1 [HxxxH],
5 wherein SEQ ID NO:1 [HxxxH] is not identical to SEQ ID
NO:8 [HDASH].

In a second embodiment, the amino acid motif of (a) is selected
from the group consisting of: SEQ ID NO:9 [HgGG], SEQ ID NO:10
[HhGG], SEQ ID NO:11 [HPGs], SEQ ID NO:12 [HcGG], SEQ ID NO:13
10 [HwGG] and SEQ ID NO:14 [HaGG]; and, the amino acid motif of (b) is
selected from the group consisting of: SEQ ID NO:15 [HDgSH], SEQ ID
NO:16 [HDsSH], SEQ ID NO:17 [HDAaH], SEQ ID NO:18 [HDAgH] and
SEQ ID NO:19 [HeASH].

In a third embodiment, the mutant polypeptide has at least 90%
15 sequence identity based on a BLASTP method of alignment when
compared to a polypeptide having a sequence selected from the group
consisting of: SEQ ID NO:21, SEQ ID NO:25 and SEQ ID NO:29.

In a fourth embodiment, the amino acid sequence of the mutant
polypeptide is selected from the group consisting of: SEQ ID NO:139
20 [EgD5R*-34g157g], SEQ ID NO:141 [EgD5R*-34g158a], SEQ ID NO:143
[EgD5R*-34g158g], SEQ ID NO:145 [EgD5R*-34h158a], SEQ ID NO:147
[EgD5R*-34h158g], SEQ ID NO:149 [EgD5R*-36s158a], SEQ ID NO:151
[EgD5R*-36s158g], SEQ ID NO:153 [EgD5M, codon-optimized EgD5R*-
34g158g], SEQ ID NO:157 [EgD5M1, codon-optimized EgD5R*-
25 34g158g347s], SEQ ID NO:181 [EgD5S-36s156e], SEQ ID NO:183
[EgD5S-36s157g], SEQ ID NO:185 [EgD5S-36s158a], SEQ ID NO:187
[EgD5S-36s158g], SEQ ID NO:213 [EaD5S-35a158g], SEQ ID NO:215
[EaD5S-35a158s], SEQ ID NO:217 [EaD5S-35a159g], SEQ ID NO:255
[EgD5R-34g158g], SEQ ID NO:260 [EgD5R-34g158a], SEQ ID NO:271
30 [EaD5-35g159g], and SEQ ID NO:276 [EaD5-35g159a].

In a fifth embodiment, the mutant polypeptide has a dihomo- γ -
linolenic acid to arachidonic acid conversion efficiency that is at least 64%
of the dihomo- γ -linolenic acid to arachidonic acid conversion efficiency of

the parent polypeptide, said parent polypeptide comprising an amino acid motif identical to SEQ ID NO:7 [HPGG] and an amino acid motif identical to SEQ ID NO:8 [HDASH].

In a sixth embodiment, the invention concerns an isolated nucleic acid molecule encoding any of the the mutant polypeptides described above. Preferably, the isolated nucleic acid molecule has a nucleotide sequence selected from the group consisting of: SEQ ID NO:138 [EgD5R*-34g157g], SEQ ID NO:140 [EgD5R*-34g158a], SEQ ID NO:142 [EgD5R*-34g158g], SEQ ID NO:144 [EgD5R*-34h158a], SEQ ID NO:146 [EgD5R*-34h158g], SEQ ID NO:148 [EgD5R*-36s158a], SEQ ID NO:150 [EgD5R*-36s158g], SEQ ID NO:152 [EgD5M, codon-optimized EgD5R*-34g158g], SEQ ID NO:156 [EgD5M1, codon-optimized EgD5R*-34g158g347s], SEQ ID NO:180 [EgD5S-36s156e], SEQ ID NO:182 [EgD5S-36s157g], SEQ ID NO:184 [EgD5S-36s158a], SEQ ID NO:186 [EgD5S-36s158g], SEQ ID NO:212 [EaD5S-35a158g], SEQ ID NO:214 [EaD5S-35a158s], SEQ ID NO:216 [EaD5S-35a159g], SEQ ID NO:254 [EgD5R-34g158g], SEQ ID NO:259 [EgD5R-34g158a], SEQ ID NO:270 [EaD5-35g159g], and SEQ ID NO:275 [EaD5-35g159a].

In a seventh embodiment, the invention concerns a transformed host cell expressing any of the the mutant polypeptides. Preferably, the transformed host cell is selected from the group consisting of; microbes, most preferably oleaginous yeast; and plants, most preferably, oilseed plants.

In an eighth embodiment, the transformed host cell produces a polyunsaturated fatty acid selected from the group consisting of omega-6 fatty acids and omega-3 fatty acids.

BIOLOGICAL DEPOSITS

The following biological material has been deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, and bears the following designation, accession number and date of deposit.

Biological Material	Accession No.	Date of Deposit
<i>Yarrowia lipolytica</i> Y8412	ATCC PTA-10026	May 14, 2009

The biological material listed above was deposited under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. The listed deposit will be maintained in the indicated international depository for at least 30
5 years and will be made available to the public upon the grant of a patent disclosing it. The availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by government action.

Yarrowia lipolytica Y9502 was derived from *Yarrowia lipolytica*
10 Y8412, according to the methodology described in U.S. Pat. Appl. Pub. No. 2010-0317072-A1.

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE LISTINGS

FIG. 1A and FIG. 1B illustrate the omega-3/ omega-6 fatty acid
15 biosynthetic pathway and should be viewed together when considering the description of this pathway below.

FIG. 2 is a predicted topological model of the *Euglena gracilis* delta-5 desaturase enzyme.

FIG. 3A, 3B, 3C and 3D show an alignment of the DNA sequences
20 of the wildtype delta-5 desaturase gene from *Euglena gracilis* (i.e., EgD5 [SEQ ID NO:20]) with a variant wildtype *E. gracilis* delta-5 desaturase gene that contains a S347R mutation (i.e., EgD5R [SEQ ID NO:24]).

FIG. 4A, 4B and 4C illustrate the construction of plasmid pDMW367-M4.

25 FIG. 5 shows a sequence alignment of the 5' portion of the variant wildtype delta-5 desaturase gene from *E. gracilis* (i.e., EgD5R [SEQ ID NO:24]) with the first 204 bp of the synthetic mutant delta-5 desaturase, derived from *E. gracilis* and codon-optimized for expression in *Yarrowia lipolytica*, and comprising HgGG [SEQ ID NO:9] and HDAgH [SEQ ID
30 NO:18] motifs (i.e., EgD5M [SEQ ID NO:152]).

FIG. 6 provides plasmid maps for the following: (A) pEgD5M and (B) pDMW367-5M.

FIG. 7 illustrates development of *Yarrowia lipolytica* strain Z1978.

FIG. 8 provides a plasmid map of the following: (A) pZKUM and (B) pZKL3-9DP9N.

FIG. 9 illustrates development of *Yarrowia lipolytica* strains Z8001 through Z8054.

5 FIG. 10A schematically illustrates a homologous recombination reaction with pYPS234, while FIG. 10B provides a plasmid map of pYPS234.

FIG. 11A schematically illustrates a homologous recombination reaction with pYPS233, while FIG. 11B provides a plasmid map of
10 pYPS233.

FIG. 12A schematically illustrates a homologous recombination reaction with pYPS241, while FIG. 12B provides a plasmid map of pYPS241.

FIG. 13 provides plasmid maps of the following: (A) pZR5AU-555
15 and (B) pZR5AU-555M.

The invention can be more fully understood from the following detailed description and the accompanying sequence descriptions, which form a part of this application.

The following sequences comply with 37 C.F.R. §1.821-1.825
20 (“Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures - the Sequence Rules”) and are consistent with World Intellectual Property Organization (WIPO) Standard ST.25 (1998) and the sequence listing requirements of the EPO and PCT (Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of the
25 Administrative Instructions). The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

SEQ ID NOs:1-311 are ORFs encoding genes or proteins (or portions thereof), primers or plasmids, as identified in Table 1.

Table 1. Summary Of Nucleic Acid And Protein SEQ ID Numbers

Description	Nucleic acid SEQ ID NO.	Protein SEQ ID NO.
His-rich motif: H(X) ₃ H	--	1
His-rich motif: H(X) ₄ H	--	2
His-rich motif: H(X) ₂ HH	--	3
His-rich motif: H(X) ₃ HH	--	4
His-rich motif: (H/Q)(X) ₂ HH	--	5
His-rich motif: (H/Q)(X) ₃ HH	--	6
HPGG motif	--	7
HDASH motif	--	8
HgGG motif	--	9
HhGG motif	--	10
HPGs motif	--	11
HcGG motif	--	12
HwGG motif	--	13
HaGG motif	--	14
HDgSH motif	--	15
HDsSH motif	--	16
HDAaH motif	--	17
HDAgH motif	--	18
HeASH motif	--	19
<i>Euglena gracilis</i> delta-5 desaturase ("EgD5")	20 (1350 bp)	21 (449 AA)
Synthetic delta-5 desaturase, derived from <i>Euglena gracilis</i> , codon-optimized for expression in <i>Yarrowia lipolytica</i> ("EgD5S")	22 (1350 bp)	23 (449 AA)
Variant <i>Euglena gracilis</i> delta-5 desaturase, comprising an arginine residue at amino acid position 347 ("EgD5R")	24 (1350 bp)	25 (449 AA)
Modified variant <i>Euglena gracilis</i> delta-5 desaturase comprising an arginine residue at amino acid position 347, with four coding region restriction enzyme sites removed ("EgD5R*")	26 (1350 bp)	27 (449 AA)
<i>Euglena anabaena</i> delta-5 desaturase ("EaD5")	28 (1362 bp)	29 (454 AA)
Synthetic delta-5 desaturase, derived from <i>Euglena anabaena</i> , codon-optimized for expression in <i>Yarrowia lipolytica</i> ("EaD5S")	30 (1362 bp)	31 (454 AA)
HxGG motif	--	32
HPGx motif	--	33
HxGx motif	--	34
HxASH motif	--	35
HDxSH motif	--	36
HDAXH motif	--	37
Plasmid pDMW367	38 (8438 bp)	--
Plasmid pDMW367-M4	39 (8438 bp)	--
Oligonucleotide primer pairs utilized to mutate the	40-43	--

native <i>EcoRI</i> and <i>BglII</i> restriction enzyme sites of the EgD5R coding region to generate pDMW367-M4		
Plasmid pDMW367-M2	44 (8438 bp)	--
Oligonucleotide primer pairs utilized to mutate the native <i>HindIII</i> and <i>NcoI</i> restriction enzyme sites of the EgD5R coding region to generate pDMW367-M4	45-48	--
Oligonucleotide primers utilized to individually mutate the Ala residue of the HDASH [SEQ ID NO:8] motif of EgD5R* by site-directed mutagenesis	49-86	--
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-HDgSH")	--	87 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-HDsSH")	--	88 (449 AA)
Oligonucleotide primers utilized to individually mutate the Ser residue of the HDASH [SEQ ID NO:8] motif of EgD5R* by site-directed mutagenesis	89-126	
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-HDAaH")	--	127 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-HDAgH")	--	128 (449 AA)
Plasmid pDMW367M4-157g	129 (8438 bp)	--
Plasmid pDMW367M4-158a	130 (8438 bp)	--
Plasmid pDMW367M4-158g	131 (8438 bp)	--
Oligonucleotide primers utilized to individually mutate either the Pro residue or the second Gly residue of the HPGG [SEQ ID NO:7] motif of mutant delta-5 desaturase genes in pDMW367M4-157g, pDMW367M4-158a, and pDMW367M4-158g by site-directed mutagenesis	132-137	--
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-34g157g") (i.e., comprising HgGG and HDgSH motifs)	138 (1350 bp)	139 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-34g158a") (i.e., comprising HgGG and HDAaH motifs)	140 (1350 bp)	141 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-34g158g") (i.e., comprising HgGG and HDAgH motifs)	142 (1350 bp)	143 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-34h158a") (i.e., comprising HhGG and HDAaH motifs)	144 (1350 bp)	145 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-34h158g") (i.e., comprising HhGG and HDAgH motifs)	146 (1350 bp)	147 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-36s158a") (i.e., comprising HPGs and HDAaH motifs)	148 (1350 bp)	149 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-36s158g") (i.e.,	150 (1350 bp)	151 (449 AA)

comprising HPGs and HDAgH motifs)		
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-34g158g") (i.e., comprising HgGG and HDAgH motifs), codon-optimized for expression in <i>Yarrowia lipolytica</i> ("EgD5M")	152 (1350 bp)	153 (449 AA)
Plasmid pEgD5M	154 (4070 bp)	--
Plasmid pDMW367-5M, comprising EgD5M	155 (8438 bp)	--
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R*-34g158g347s") (i.e., comprising HgGG and HDAgH motifs, and a Ser residue at amino acid position 347) ("EgD5M1")	156 (1350 bp)	157 (449 AA)
Plasmid pEgD5M1	158 (4070 bp)	--
Plasmid pDMW367-5M1, comprising EgD5M1	159 (8438 bp)	--
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> and codon optimized for expression in <i>Yarrowia lipolytica</i> ("EgD5S-36s") (i.e., comprising a HPGs motif)	--	160 (449 AA)
Plasmid pDMW369S	161 (8438 bp)	--
Oligonucleotide primers utilized to individually mutate the Asp, Ala, or Ser residue of the HDASH [SEQ ID NO:8] motif of EgD5S-HPGs by site-directed mutagenesis	162-179	--
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> and codon optimized for expression in <i>Yarrowia lipolytica</i> ("EgD5S-36s156e") (i.e., comprising HPGs and HeASH motifs)	180 (1350 bp)	181 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> and codon optimized for expression in <i>Yarrowia lipolytica</i> ("EgD5S-36s157g") (i.e., comprising HPGs and HDgSH motifs)	182 (1350 bp)	183 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> and codon optimized for expression in <i>Yarrowia lipolytica</i> ("EgD5S-36s158a") (i.e., comprising HPGs and HDAaH motifs)	184 (1350 bp)	185 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> and codon optimized for expression in <i>Yarrowia lipolytica</i> ("EgD5S-36s158g") (i.e., comprising HPGs and HDAgH motifs)	186 (1350 bp)	187 (449 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena anabaena</i> and codon optimized for expression in <i>Yarrowia lipolytica</i> ("EaD5S-35a") (i.e., comprising a HaGG motif)	--	188 (454 AA)
Plasmid pZuFmEaD5S-A(S)	189 (8357 bp)	--
Oligonucleotide primers utilized to individually mutate the Asp, Ala, or Ser residue of the HDASH [SEQ ID NO:8] motif of EaD5S-35a by site-directed	190-211	--

mutagenesis		
Synthetic mutant delta-5 desaturase, derived from <i>Euglena anabaena</i> and codon optimized for expression in <i>Yarrowia lipolytica</i> ("EaD5S-35a158g") (i.e., comprising HaGG and HDgSH motifs)	212 (1365 bp)	213 (454 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena anabaena</i> and codon optimized for expression in <i>Yarrowia lipolytica</i> ("EaD5S-35a158s") (i.e., comprising HaGG and HDsSH motifs)	214 (1365 bp)	215 (454 AA)
Synthetic mutant delta-5 desaturase, derived from <i>Euglena anabaena</i> and codon optimized for expression in <i>Yarrowia lipolytica</i> ("EaD5S-35a159g") (i.e., comprising HaGG and HDAGH motifs)	216 (1365 bp)	217 (454 AA)
Plasmid pZKUM	218 (4313 bp)	--
Plasmid pZKL3-9DPN9N	219 (13565 bp)	--
Synthetic mutant delta-9 elongase derived from <i>Euglena gracilis</i> ("EgD9eS-L35G")	220 (777 bp)	221 (258 AA)
<i>Yarrowia lipolytica</i> delta-9 desaturase ("YID9")	222 (1449 bp)	223 (482 AA)
<i>Yarrowia lipolytica</i> choline-phosphate cytidyltransferase ("YIPCT")	224 (1101 bp)	225 (366 AA)
Plasmid pZKSL-5S5A5	226 (13975 bp)	
Plasmid pZP2-85m98F	227 (14619 bp)	
993 bp stuffer fragment	228 (993 bp)	--
Plasmid pYPS234	229 (7338 bp)	--
1019 bp stuffer fragment	230 (1019 bp)	--
Plasmid pYPS233	231 (7364 bp)	--
Plasmid pYSP241	232 (9211 bp)	--
Plasmid pZR5AU-555	233 (13926 bp)	--
Plasmid pZR5AU-555M	234 (13926 bp)	--
HDgnH motif	--	235
HDAnH motif	--	236
HefaH motif	--	237
HeftH motif	--	238
HemgH motif	--	239
HeAgH motif	--	240
HDfgH motif	--	241
HDygH motif	--	242
HDschH motif	--	243
HDAcH motif	--	244
Primer EgD5-5	245	--
Primer EgD5 M1-3	246	--

Primer EgD5 M1-5	247	--
Primer EgD5-3	248	--
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R-34g") (i.e., comprising a HgGG motif)	249 (1347 bp)	250 (449 AA)
Primer EgD5 M2-3	251	--
Primer EgD5 M2-5	252	--
Plasmid pLF336	253 (5050 bp)	--
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R-34g158g") (i.e., comprising HgGG and HDAgH motifs)	254 (1347 bp)	255 (449 AA)
Primer EgD5 M3-3	256	--
Primer EgD5 M3-5	257	--
Primer pLF337	258 (5050 bp)	--
Synthetic mutant delta-5 desaturase, derived from <i>Euglena gracilis</i> ("EgD5R-34g158a") (i.e., comprising HgGG and HDAaH motifs)	259 (1347 bp)	260 (449 AA)
Primer EaD5-5	261	--
Primer EaD5 M1-3	262	--
Primer EaD5 M1-5	263	--
Primer EaD5-3	264	--
Synthetic mutant delta-5 desaturase, derived from <i>Euglena anabaena</i> ("EaD5-35g") (i.e., comprising a HgGG motif)	265 (1362 bp)	266 (454 AA)
Primer EaD5 M2-3	267	--
Primer EaD5 M2-5	268	--
Plasmid pLF338	269 (5007 bp)	--
Synthetic mutant delta-5 desaturase, derived from <i>Euglena anabaena</i> ("EaD5-35g159g") (i.e., comprising HgGG and HDAgH motifs)	270 (1362 bp)	271 (454 AA)
Primer EaD5 M3-3	272	--
Primer EaD5 M3-5	273	--
Plasmid pLF339	274 (5007 bp)	--
Synthetic mutant delta-5 desaturase, derived from <i>Euglena anabaena</i> ("EaD5-35g159a") (i.e., comprising HgGG and HDAaH motifs)	275 (1362 bp)	276 (454 AA)
HDcSH motif	--	277
HDdSH motif	--	278
HDeSH motif	--	279
HDfSH motif	--	280
HDhSH motif	--	281
HDiSH motif	--	282
HDkSH motif	--	283
HDISH motif	--	284
HDmSH motif	--	285
HDnSH motif	--	286
HDpSH motif	--	287
HDqSH motif	--	288

HDrSH motif	--	289
HDtSH motif	--	290
HDvSH motif	--	291
HDwSH motif	--	292
HDySH motif	--	293
HDAcH motif	--	294
HDAhH motif	--	295
HDAeH motif	--	296
HDAfH motif	--	297
HDAhH motif	--	298
HDAiH motif	--	299
HDAkH motif	--	300
HDAIH motif	--	301
HDAmH motif	--	302
HDAnH motif	--	303
HDApH motif	--	304
HDAqH motif	--	305
HDArH motif	--	306
HDAtH motif	--	307
HDAvH motif	--	308
HDAwH motif	--	309
HDAyH motif	--	310
HDxxH motif	--	311

DETAILED DESCRIPTION OF THE INVENTION

All patent and non-patent literature cited herein is hereby
5 incorporated by reference in their entirety.

In this disclosure, a number of terms and abbreviations are used. Standard three-letter codes or single-letter codes are used to refer to amino acids. The following definitions are provided.

- “Open reading frame” is abbreviated as “ORF”.
- 10 “Polymerase chain reaction” is abbreviated as “PCR”.
- “American Type Culture Collection” is abbreviated as “ATCC”.
- “Polyunsaturated fatty acid(s)” is abbreviated as “PUFA(s)”.
- “Triacylglycerols” are abbreviated as “TAGs”.
- “Total fatty acids” are abbreviated as “TFAs”.
- 15 “Fatty acid methyl esters” are abbreviated as “FAMES”.
- “Dry cell weight” is abbreviated as “DCW”.

The motif having an amino acid sequence as set forth in SEQ ID NO:7 (i.e., His-Pro-Gly-Gly) is abbreviated as “HPGG”.

The motif having an amino acid sequence as set forth in SEQ ID NO:8 (i.e., His-Asp-Ala-Ser-His) is abbreviated as "HDASH".

As used herein the term "invention" or "present invention" is intended to refer to all aspects and embodiments of the invention as described in the claims and specification herein and should not be read so as to be limited to any particular embodiment or aspect.

The term "fatty acids" refers to long chain aliphatic acids (alkanoic acids) of varying chain lengths, from about C₁₂ to C₂₂, although both longer and shorter chain-length acids are known. The predominant chain lengths are between C₁₆ and C₂₂. The structure of a fatty acid is represented by a simple notation system of "X:Y", where X is the total number of carbon ["C"] atoms in the particular fatty acid and Y is the number of double bonds. Additional details concerning the differentiation between "saturated fatty acids" versus "unsaturated fatty acids", "monounsaturated fatty acids" versus "polyunsaturated fatty acids" ["PUFAs"], and "omega-6 fatty acids" ["ω-6" or "n-6"] versus "omega-3 fatty acids" ["ω-3"] or ["n-3"] are provided in U.S. Pat. 7,238,482, which is hereby incorporated herein by reference.

Nomenclature used to describe PUFAs herein is shown below in Table 2. In the column titled "Shorthand Notation", the omega-reference system is used to indicate the number of carbons, the number of double bonds and the position of the double bond closest to the omega carbon, counting from the omega carbon (which is numbered 1 for this purpose). The remainder of the Table summarizes the common names of omega-3 and omega-6 fatty acids and their precursors, the abbreviations that will be used throughout the specification and the chemical name of each compound.

Table 2. Nomenclature Of Polyunsaturated Fatty Acids And Precursors

Common Name	Abbreviation	Chemical Name	Shorthand Notation
Myristic	--	tetradecanoic	14:0
Palmitic	Palmitate	hexadecanoic	16:0
Palmitoleic	--	9-hexadecenoic	16:1
Stearic	--	octadecanoic	18:0
Oleic	--	<i>cis</i> -9-octadecenoic	18:1

Linoleic	LA	<i>cis</i> -9, 12-octadecadienoic	18:2 ω -6
γ -Linolenic	GLA	<i>cis</i> -6, 9, 12-octadecatrienoic	18:3 ω -6
Eicosadienoic	EDA	<i>cis</i> -11, 14-eicosadienoic	20:2 ω -6
Dihomo- γ -Linolenic	DGLA	<i>cis</i> -8, 11, 14- eicosatrienoic	20:3 ω -6
Arachidonic	ARA	<i>cis</i> -5, 8, 11, 14- eicosatetraenoic	20:4 ω -6
α -Linolenic	ALA	<i>cis</i> -9, 12, 15- octadecatrienoic	18:3 ω -3
Stearidonic	STA	<i>cis</i> -6, 9, 12, 15- octadecatetraenoic	18:4 ω -3
Eicosatrienoic	ETrA	<i>cis</i> -11, 14, 17- eicosatrienoic	20:3 ω -3
Eicosa- tetraenoic	ETA	<i>cis</i> -8, 11, 14, 17- eicosatetraenoic	20:4 ω -3
Eicosa- pentaenoic	EPA	<i>cis</i> -5, 8, 11, 14, 17- eicosapentaenoic	20:5 ω -3
Docosa- tetraenoic	DTA	<i>cis</i> -7, 10, 13, 16- docosatetraenoic	22:4 ω -6
Docosa- pentaenoic	DPAn-6	<i>cis</i> -4, 7, 10, 13, 16- docosapentaenoic	22:5 ω -6
Docosa- pentaenoic	DPA	<i>cis</i> -7, 10, 13, 16, 19- docosapentaenoic	22:5 ω -3
Docosa- hexaenoic	DHA	<i>cis</i> -4, 7, 10, 13, 16, 19- docosahexaenoic	22:6 ω -3

Although the omega-3/ omega-6 PUFAs listed in Table 2 are the most likely to be accumulated in the oil fractions of microbial and plant hosts using the methods described herein, this list should not be construed as
5 limiting or as complete.

The term “oil” refers to a lipid substance that is liquid at 25 °C; the oil is hydrophobic but is soluble in organic solvents. In oleaginous organisms, oil constitutes a major part of the total lipid. “Oil” is composed primarily of triacylglycerols but may also contain other neutral lipids,
10 phospholipids and free fatty acids. The fatty acid composition in the oil and the fatty acid composition of the total lipid are generally similar; thus, an increase or decrease in the concentration of PUFAs in the total lipid will correspond with an increase or decrease in the concentration of PUFAs in the oil, and vice versa.

15 “Neutral lipids” refer to those lipids commonly found in cells in lipid bodies as storage fats and are so called because, at cellular pH, the lipids bear no charged groups. Generally, they are completely non-polar with no affinity for water. Neutral lipids generally refer to mono-, di-, and/or

triesters of glycerol with fatty acids, also called monoacylglycerol, diacylglycerol or triacylglycerol, respectively, or collectively, acylglycerols. A hydrolysis reaction must occur to release free fatty acids from acylglycerols.

5 The term “triacylglycerols” [“TAGs”] refers to neutral lipids composed of three fatty acyl residues esterified to a glycerol molecule. TAGs can contain long chain PUFAs and saturated fatty acids, as well as shorter chain saturated and unsaturated fatty acids.

 The term “total fatty acids” [“TFAs”] herein refer to the sum of all
10 cellular fatty acids that can be derivitized to fatty acid methyl esters [“FAMES”] by the base transesterification method (as known in the art) in a given sample, which may be the biomass or oil, for example. Thus, total fatty acids include fatty acids from neutral lipid fractions (including diacylglycerols, monoacylglycerols and TAGs) and from polar lipid
15 fractions (including the phosphatidylcholine and phosphatidylethanolamine fractions) but not free fatty acids.

 The term “total lipid content” of cells is a measure of TFAs as a percent of the dry cell weight [“DCW”], although total lipid content can be approximated as a measure of FAMES as a percent of the DCW
20 [“FAMES % DCW”]. Thus, total lipid content [“TFAs % DCW”] is equivalent to, e.g., milligrams of total fatty acids per 100 milligrams of DCW.

 The concentration of a fatty acid in the total lipid is expressed herein as a weight percent of TFAs [“% TFAs”], e.g., milligrams of the given fatty acid per 100 milligrams of TFAs. Unless otherwise specifically
25 stated in the disclosure herein, reference to the percent of a given fatty acid with respect to total lipids is equivalent to concentration of the fatty acid as % TFAs, e.g., % EPA of total lipids is equivalent to EPA % TFAs.

 The terms “lipid profile” and “lipid composition” are interchangeable and refer to the amount of individual fatty acids contained in a particular
30 lipid fraction, such as in the total lipid or the oil, wherein the amount is expressed as a weight percent of TFAs. The sum of each individual fatty acid present in the mixture should be 100.

The term "PUFA biosynthetic pathway" refers to a metabolic process that converts oleic acid to omega-6 fatty acids such as LA, EDA, GLA, DGLA, ARA, DTA and DPAn-6 and omega-3 fatty acids such as ALA, STA, ETrA, ETA, EPA, DPA and DHA. This process is well described in the literature. See e.g., U.S. Pat. 7,932,077. Briefly, this process involves elongation of the carbon chain through the addition of carbon atoms and desaturation of the molecule through the addition of double bonds, via a series of special elongation and desaturation enzymes termed "PUFA biosynthetic pathway enzymes" that are present in the endoplasmic reticulum membrane. More specifically, "PUFA biosynthetic pathway enzymes" refer to any of the following enzymes (and genes which encode said enzymes) associated with the biosynthesis of a PUFA, including: delta-4 desaturase, delta-5 desaturase, delta-6 desaturase, delta-12 desaturase, delta-15 desaturase, delta-17 desaturase, delta-9 desaturase, delta-8 desaturase, delta-9 elongase, C_{14/16} elongase, C_{16/18} elongase, C_{18/20} elongase and/or C_{20/22} elongase.

The term "desaturase" refers to a polypeptide that can desaturate, i.e., introduce a double bond, in one or more fatty acids to produce a fatty acid or precursor of interest. Despite use of the omega-reference system throughout the specification to refer to specific fatty acids, it is more convenient to indicate the activity of a desaturase by counting from the carboxyl end of the substrate using the delta-system. Of particular interest herein are delta-5 desaturases that desaturate a fatty acid between the fifth and sixth carbon atom numbered from the carboxyl-terminal end of the molecule and that can, for example, catalyze the conversion of DGLA to ARA and/or ETA to EPA. Other fatty acid desaturases include, for example: delta-8 desaturases, delta-6 desaturases, delta-4 desaturases, delta-12 desaturases, delta-15 desaturases, delta-17 desaturases and delta-9 desaturases. In the art, delta-15 and delta-17 desaturases are also occasionally referred to as "omega-3 desaturases", "w-3 desaturases" and/or "ω-3 desaturases", based on their ability to convert omega-6 fatty acids into their omega-3 counterparts (e.g., conversion of LA into ALA and ARA into EPA, respectively). It may be desirable to empirically determine

the specificity of a particular fatty acid desaturase by transforming a suitable host with the gene for the fatty acid desaturase and determining its effect on the fatty acid profile of the host.

The term “EgD5” refers to a delta–5 desaturase (SEQ ID NO:21) from *Euglena gracilis*, encoded by SEQ ID NO:20 herein. Similarly, the term “EgD5S” refers to a synthetic delta–5 desaturase derived from *E. gracilis* that is codon-optimized for expression in *Yarrowia lipolytica* (i.e., SEQ ID NOs:22 and 23). Further details concerning EgD5 and EgD5S are described in U.S. Pat. 7,678,560. The term “EgD5R” (i.e., SEQ ID NOs:24 and 25) refers to a variant wildtype EgD5 wherein the amino acid residue at position 347 is arginine. The term “EgD5R*” (i.e., SEQ ID NOs:26 and 27) refers to a modified variant of the wildtype EgD5R, wherein four restriction enzyme sites are removed from the wildtype coding region. The amino acid sequences of EgD5R and EgD5R* are identical.

The term “EaD5” refers to a delta–5 desaturase (SEQ ID NO:29) from *Euglena anabaena*, encoded by SEQ ID NO:28 herein. Similarly, the term “EaD5S” refers to a synthetic delta–5 desaturase derived from *E. anabaena* that is codon-optimized for expression in *Yarrowia lipolytica* (i.e., SEQ ID NOs:30 and 31). Further details concerning EaD5 and EaD5S are described in U.S. Pat. 7,943,365.

The term “conserved domain” or “motif” means a set of amino acids conserved at specific positions along an aligned sequence of evolutionarily related proteins. While amino acids at other positions can vary between homologous proteins, amino acids that are highly conserved at specific positions indicate that these amino acids may be important in the structure, the stability, or the activity of a protein. Because they are identified by their high degree of conservation in aligned sequences of a family of protein homologues, they can be used as identifiers, or “signatures”, to determine if a protein with a newly determined sequence belongs to a previously identified protein family. Motifs that are universally found in delta–5 desaturase enzymes of animal, plants and fungi include three histidine boxes (i.e., H(X)_{3–4}H [SEQ ID NOs:1 and 2], H(X)_{2–3}HH [SEQ ID NOs:3 and 4] and H/Q(X)_{2–3}HH [SEQ ID NOs:5 and 6]) and a heme-

binding motif (i.e., His-Pro-Gly-Gly or HPGG [SEQ ID NO:7]) within the fused cytochrome *b*₅ domain at the N-terminus. An additional motif (i.e., His-Asp-Ala-Ser-His or HDASH [SEQ ID NO:8]) appears to be conserved in some delta-5 desaturase genes.

5 The terms “mutant delta-5 desaturase” and “double mutant” refers to a delta-5 desaturase as described herein that has at least one mutation within the HPGG motif (SEQ ID NO:7) of the cytochrome *b*₅ domain and at least one mutation within the HDASH motif (SEQ ID NO:8), wherein said mutations result in an amino acid substitution, either conservative or non-
10 conservative. Although the mutations may include any amino acid substitution, the mutant delta-5 desaturase preferably comprises a mutant HPGG (SEQ ID NO:7) motif having a sequence of His-Xaa-Gly-Xaa or “HxGx” (SEQ ID NO:34) (wherein Xaa can be any amino acid) and a mutant HDASH (SEQ ID NO:8) motif having a sequence of His-Xaa- Xaa-
15 Xaa-His or “HxxxH” (SEQ ID NO:1). More preferably, the mutant delta-5 desaturase comprises a mutant HPGG motif selected from the group consisting of HxGG (SEQ ID NO:32) and HPGx (SEQ ID NO:33), and a mutant HDASH motif selected from the group consisting of HxASH (SEQ ID NO:35), HDxSH (SEQ ID NO:36), and HDAXH (SEQ ID NO:37), where
20 the delta-5 desaturase activity of the mutant delta-5 desaturase is at least about functionally equivalent to the delta-5 desaturase activity of the wildtype delta-5 desaturase. More preferred, the mutant HPGG motif is selected from the group consisting of: SEQ ID NO:9 (HgGG), SEQ ID NO:10 (HhGG), SEQ ID NO:11 (HPGs), SEQ ID NO:12 (HcGG), SEQ ID NO:13 (HwGG) and SEQ ID NO:14 (HaGG), and the mutant HDASH motif
25 is selected from the group consisting of: SEQ ID NO:15 (HDgSH), SEQ ID NO:16 (HDsSH), SEQ ID NO:17 (HDAaH), SEQ ID NO:18 (HDAgH), and SEQ ID NO:19 (HeASH).

Each “mutant delta-5 desaturase” has a “corresponding wildtype
30 delta-5 desaturase”. Specifically, the mutant delta-5 desaturase and corresponding wildtype delta-5 desaturase share identical amino acid sequences, with the exception that the wildtype will comprise a HPGG motif (SEQ ID NO:7) within the cytochrome *b*₅ domain and an HDASH

motif (SEQ ID NO:8), while the mutant will comprise at least one mutation within each of these motifs (as described above).

A mutant delta-5 desaturase is “at least about functionally equivalent” to the corresponding wildtype delta-5 desaturase when enzymatic activity and specific selectivity of the mutant delta-5 sequence are essentially comparable to that of the corresponding wildtype delta-5 desaturase. Thus, a functionally equivalent mutant delta-5 desaturase will possess delta-5 desaturase activity that is not substantially reduced with respect to that of the corresponding wildtype delta-5 desaturase when the “conversion efficiency” of each enzyme is compared (i.e., a mutant delta-5 desaturase will have at least about 50-64%, more preferably at least 60-74%, more preferably at least about 75-85%, more preferably at least about 85-95%, and most preferably at least about 95% of the enzymatic activity of the wildtype delta-5 desaturase). Although preferred ranges are described above, useful examples of conversion efficiencies include any integer percentage from 50% to 100%, such as 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. The delta-5 desaturase activity of the two polypeptides may be substantially identical. Preferably, the mutant delta-5 desaturase will have increased enzymatic activity and specific selectivity when compared to that of the corresponding wildtype delta-5 desaturase, i.e., having at least about 101%, 102%, 103%, 104% or 105%, more preferably at least about 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114% or 115% and most preferably at least about 116% or more of the enzymatic activity of the wildtype delta-5 desaturase.

The terms “parent polypeptide” or “parent enzyme” refer to any polypeptide from which a mutant polypeptide or enzyme disclosed herein is derived. The term encompasses wild type, variant wild type, and modified variant wild type polypeptides possessing HPGG (SEQ ID NO:7) and HDASH (SEQ ID NO:8) amino acid motifs, as well as synthetic and codon-optimized polypeptides based thereon. The term further

encompasses versions of the foregoing polypeptides from which various restriction enzyme sites have been eliminated.

Mutant delta-5 desaturases are designated using two different nomenclature systems, although both describe the specific sequences of the mutant HPGG (SEQ ID NO:7) motif and HDASH (SEQ ID NO:8) motif in the mutant. The first system specifies the: 1) Wildtype, parent enzyme; 2) hyphen (-); 3) mutant HPGG motif; 4) underscore (_); 5) mutant HDASH motif. The mutant amino acid residue is shown in lower case lettering. Thus, for example, a mutant delta-5 desaturase comprising HaGG (SEQ ID NO:14) and HDgSH (SEQ ID NO:15) motifs, derived from the synthetic delta-5 desaturase that was derived from *Euglena gracilis* and codon-optimized for expression in *Yarrowia lipolytica* (i.e., "EgD5S") is referred to as "EgD5S-HPGs_HDgSH". Alternately, this same mutant delta-5 desaturase may also be referred to as "EgD5S-36s157g", using the second system of nomenclature. More specifically, the HPGG (SEQ ID NO:7) motif of EgD5S is located between amino acid residues 33-36, while the HDASH (SEQ ID NO:8) motif of EgD5S is located between amino acid residues 155-159. Thus, "36s" indicates that amino acid residue 36 was modified from the wildtype to Ser, while "157g" indicates that amino acid residue 157 was modified from the wildtype to Gly.

The terms "conversion efficiency" and "percent substrate conversion" refer to the efficiency by which a particular enzyme (e.g., a desaturase) can convert substrate to product. The conversion efficiency is measured according to the following formula:
$$\left(\frac{[\text{product}]}{[\text{substrate} + \text{product}]} \right) * 100$$
. Thus, "DGLA to ARA conversion efficiency" refers to the conversion efficiency by which the substrate, DGLA, is converted to the product, ARA.

The term "elongase" refers to a polypeptide that can elongate a fatty acid carbon chain to produce an acid two carbons longer than the fatty acid substrate that the elongase acts upon. This process of elongation occurs in a multi-step mechanism in association with fatty acid synthase, as described in U.S. Pat. 7,659,120. Examples of reactions

catalyzed by elongase systems are the conversion of GLA to DGLA, STA to ETA and EPA to DPA.

In general, the substrate selectivity of elongases is somewhat broad but segregated by both chain length and the degree and type of unsaturation. For example, a $C_{14/16}$ elongase will utilize a C_{14} substrate (e.g., myristic acid), a $C_{16/18}$ elongase will utilize a C_{16} substrate (e.g., palmitate), a $C_{18/20}$ elongase will utilize a C_{18} substrate (e.g., GLA, STA, LA, ALA) and a $C_{20/22}$ elongase [also referred to as a delta-5 elongase] will utilize a C_{20} substrate (e.g., ARA, EPA). For the purposes herein, two distinct types of $C_{18/20}$ elongases can be defined: a delta-6 elongase will catalyze conversion of GLA and STA to DGLA and ETA, respectively, while a delta-9 elongase is able to catalyze the conversion of LA and ALA to EDA and ETrA, respectively.

It is important to note that some elongases have broad specificity and thus a single enzyme may be capable of catalyzing several elongase reactions e.g., thereby acting as both a $C_{16/18}$ elongase and a $C_{18/20}$ elongase. It may be desirable to empirically determine the specificity of a fatty acid elongase by transforming a suitable host with the gene for the fatty acid elongase and determining its effect on the fatty acid profile of the host.

Generally, the term "oleaginous" refers to those organisms that tend to store their energy source in the form of oil (Weete, In: Fungal Lipid Biochemistry, 2nd Ed., Plenum, 1980). During this process, the cellular oil content of oleaginous microorganisms generally follows a sigmoid curve, wherein the concentration of lipid increases until it reaches a maximum at the late logarithmic or early stationary growth phase and then gradually decreases during the late stationary and death phases (Yongmanitchai and Ward, *Appl. Environ. Microbiol.*, 57:419-25 (1991)). For the purposes of the present application and when used with respect to microorganisms, the term "oleaginous" refers to those microorganisms that can accumulate at least about 25% of their DCW as oil.

The term “oleaginous yeast” refers to those oleaginous microorganisms classified as yeasts that can make oil, i.e., wherein the oil can accumulate in excess of about 25% of their DCW. Examples of oleaginous yeast include, but are no means limited to, the following
5 genera: *Yarrowia*, *Candida*, *Rhodotorula*, *Rhodospiridium*, *Cryptococcus*, *Trichosporon* and *Lipomyces*. The ability to accumulate oil in excess of about 25% of the DCW of the yeast may be through efforts of recombinant engineering or through the natural abilities of the organism.

Those plants that produce seed from which oil is expressed can be
10 referred to as “oilseed” plants or crops. Examples of oilseed plants include, but are not limited to soybeans, sunflower seed, canola, rapeseed, safflower, flaxseed, mustard seed, peanuts cottonseed, castor beans and sesame.

The term “conservative amino acid substitution” refers to a
15 substitution of an amino acid residue in a given protein with another amino acid, without altering the chemical or functional nature of that protein. For example, it is well known in the art that alterations in a gene that result in the production of a chemically equivalent amino acid at a given site (but do not affect the structural and functional properties of the encoded, folded
20 protein) are common. For the purposes herein, “conservative amino acid substitutions” are defined as exchanges within one of the following five groups:

1. Small aliphatic, nonpolar or slightly polar residues: Ala [A], Ser [S], Thr [T] (Pro [P], Gly [G]);
- 25 2. Polar, negatively charged residues and their amides: Asp [D], Asn [N], Glu [E], Gln [Q];
3. Polar, positively charged residues: His [H], Arg [R], Lys [K];
4. Large aliphatic, nonpolar residues: Met [M], Leu [L], Ile [I], Val [V] (Cys [C]); and,
- 30 5. Large aromatic residues: Phe [F], Tyr [Y], Trp [W].

Thus, Ala, a slightly hydrophobic amino acid, may be substituted by another less hydrophobic residue (e.g., Gly). Similarly, changes which result in substitution of one negatively charged residue for another (e.g.,

Asp for Glu) or one positively charged residue for another (e.g., Lys for Arg) can also be expected to produce a functionally equivalent product. As such, conservative amino acid substitutions generally maintain the structure of the polypeptide backbone in the area of the substitution, the charge or hydrophobicity of the molecule at the target site, or the bulk of the side chain. Additionally, in many cases, alterations of the N-terminal and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein.

The term “non-conservative amino acid substitution” refers to an amino acid substitution that is generally expected to produce the greatest change in protein properties. Thus, for example, a non-conservative amino acid substitution would be one whereby: 1) a hydrophilic residue is substituted for/by a hydrophobic residue (e.g., Ser or Thr for/by Leu, Ile, Val); 2) a Cys or Pro is substituted for/by any other residue; 3) a residue having an electropositive side chain is substituted for/by an electronegative residue (e.g., Lys, Arg or His for/by Asp or Glu); or, 4) a residue having a bulky side chain is substituted for/by one not having a side chain (e.g., Phe for/by Gly). Sometimes, non-conservative amino acid substitutions between two of the five groups will not affect the activity of the encoded protein.

The terms “polynucleotide”, “polynucleotide sequence”, “nucleic acid sequence”, “nucleic acid fragment” and “isolated nucleic acid fragment” are used interchangeably herein. These terms encompass nucleotide sequences and the like. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof. Nucleotides (usually found in their 5'-monophosphate form) are referred to by a single letter designation as follows: “A” for adenylate or deoxyadenylate (for RNA or DNA, respectively), “C” for cytidylate or deoxycytidylate, “G” for guanylate or deoxyguanylate, “U” for uridylate, “T” for deoxythymidylate,

“R” for purines (A or G), “Y” for pyrimidines (C or T), “K” for G or T, “H” for A or C or T, “I” for inosine, and “N” for any nucleotide.

A nucleic acid fragment is “hybridizable” to another nucleic acid fragment, such as a cDNA, genomic DNA, or RNA molecule, when a
5 single-stranded form of the nucleic acid fragment can anneal to the other nucleic acid fragment under the appropriate conditions of temperature and solution ionic strength. Hybridization and washing conditions are well known and exemplified in Sambrook, J., Fritsch, E. F. and Maniatis, T., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor
10 Laboratory: Cold Spring Harbor, NY (1989) (“Sambrook et al.”), which is hereby incorporated herein by reference, particularly Chapter 11 and Table 11.1. The conditions of temperature and ionic strength determine the “stringency” of the hybridization. Stringency conditions can be adjusted to screen for moderately similar fragments (such as homologous
15 sequences from distantly related organisms), to highly similar fragments (such as genes that duplicate functional enzymes from closely related organisms). Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X
20 SSC, 0.5% SDS at 45 °C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50 °C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60 °C. Another preferred set of
25 highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65 °C. An additional set of stringent conditions include hybridization at 0.1X SSC, 0.1% SDS, 65 °C and washes with 2X SSC, 0.1% SDS followed by 0.1X SSC, 0.1% SDS, for example.

Hybridization requires that the two nucleic acids contain
30 complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in

the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of thermal melting point [T_m] for hybrids of nucleic acids having those sequences. The relative stability, corresponding to higher T_m , of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating T_m have been derived (see Sambrook et al., *supra*, 9.50-9.51). For hybridizations with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., *supra*, 11.7-11.8). In one embodiment the length for a hybridizable nucleic acid is at least about 10 nucleotides. Preferably a minimum length for a hybridizable nucleic acid is at least about 15 nucleotides; more preferably at least about 20 nucleotides; and most preferably the length is at least about 30 nucleotides. Furthermore, the skilled artisan will recognize that the temperature and wash solution salt concentration may be adjusted as necessary according to factors such as length of the probe.

A “substantial portion” of an amino acid or nucleotide sequence is that portion comprising enough of the amino acid sequence of a polypeptide or the nucleotide sequence of a gene to putatively identify that polypeptide or gene, either by manual evaluation of the sequence by one skilled in the art, or by computer-automated sequence comparison and identification using algorithms such as Basic Local Alignment Search Tool [“BLAST”] (Altschul, S. F., et al., *J. Mol. Biol.*, 215:403-410 (1993)). In general, a sequence of ten or more contiguous amino acids or thirty or more nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene specific oligonucleotide probes comprising 20-30 contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12-15 bases may be used as amplification primers in PCR in order to

obtain a particular nucleic acid fragment comprising the primers.

Accordingly, a “substantial portion” of a nucleotide sequence comprises enough of the sequence to specifically identify and/or isolate a nucleic acid fragment comprising the sequence. The disclosure herein teaches

5 the complete amino acid and nucleotide sequence encoding particular desaturase proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the complete sequences as reported in the accompanying
10 Sequence Listing, as well as substantial portions of those sequences as defined above, are encompassed in the present disclosure.

The term “complementary” is used to describe the relationship between nucleotide bases that are capable of hybridizing to one another.

For example, with respect to DNA, adenosine is complementary to

15 thymine, and cytosine is complementary to guanine. Accordingly, isolated nucleic acid fragments that are complementary to the complete sequences as reported in the accompanying Sequence Listing, as well as those substantially similar nucleic acid sequences, are encompassed in the present disclosure.

20 The terms “homology” and “homologous” are used interchangeably. They refer to nucleic acid fragments or polypeptides that have similar, but not identical sequence. These terms sometimes also refer to modifications of the nucleic acid fragments (e.g., via deletion or insertion of one or more nucleotides) that do not substantially alter the functional
25 properties of the resulting nucleic acid fragment relative to the initial, unmodified fragment. It is therefore understood, as those skilled in the art will appreciate, that the invention encompasses more than the specific exemplary sequences.

Moreover, the skilled artisan recognizes that homologous nucleic

30 acid sequences are also defined by their ability to hybridize, under moderately stringent conditions, e.g., 0.5X SSC, 0.1% SDS, 60 °C, with the sequences exemplified herein, or to any portion of the nucleotide sequences disclosed herein and which are functionally equivalent thereto.

Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms.

5 The term "selectively hybridizes" includes reference to hybridization, under stringent hybridization conditions, of a nucleic acid sequence to a specified nucleic acid target sequence to a detectably greater degree (e.g., at least 2-fold over background) than its hybridization to non-target nucleic acid sequences and to the substantial exclusion of non-target nucleic
10 acids. Selectively hybridizing sequences typically have about at least 80% sequence identity, or 90% sequence identity, up to and including 100% sequence identity (i.e., fully complementary) with each other.

 "Sequence identity" or "identity" in the context of nucleic acid or polypeptide sequences refers to the nucleic acid bases or amino acid
15 residues in two sequences that are the same when aligned for maximum correspondence over a specified comparison window.

 Methods to determine "percent identity" and "percent similarity" are codified in publicly available computer programs. Percent identity and percent similarity can be readily calculated by known methods, including
20 but not limited to those described in: 1) Computational Molecular Biology (Lesk, A. M., Ed.) Oxford University: NY (1988); 2) Biocomputing: Informatics and Genome Projects (Smith, D. W., Ed.) Academic: NY (1993); 3) Computer Analysis of Sequence Data, Part I (Griffin, A. M., and Griffin, H. G., Eds.) Humana: NJ (1994); 4) Sequence Analysis in
25 Molecular Biology (von Heinje, G., Ed.) Academic (1987); and, 5) Sequence Analysis Primer (Gribskov, M. and Devereux, J., Eds.) Stockton: NY (1991).

 Sequence alignments and percent identity or similarity calculations may be determined using a variety of comparison methods designed to
30 detect homologous sequences including, but not limited to, the MegAlign™ program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences is performed using the "Clustal method of alignment" which encompasses

several varieties of the algorithm including the “Clustal V method of alignment” and the “Clustal W method of alignment” (described by Higgins and Sharp, *CABIOS*, 5:151-153 (1989); Higgins, D.G. et al., *Comput. Appl. Biosci.*, 8:189-191(1992)) and found in the MegAlign™
5 (version 8.0.2) program (*supra*). After alignment of the sequences using either Clustal program, it is possible to obtain a “percent identity” by viewing the “sequence distances” table in the program.

For multiple alignments using the Clustal V method of alignment, the default values correspond to GAP PENALTY=10 and GAP LENGTH
10 PENALTY=10. Default parameters for pairwise alignments and calculation of percent identity of protein sequences using the Clustal V method are KTUPLE=1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. For nucleic acids these parameters are KTUPLE=2, GAP PENALTY=5, WINDOW=4 and DIAGONALS
15 SAVED=4.

Default parameters for multiple alignment using the Clustal W method of alignment correspond to GAP PENALTY=10, GAP LENGTH PENALTY=0.2, Delay Divergent Seqs(%)=30, DNA Transition Weight=0.5, Protein Weight Matrix=Gonnet Series, DNA Weight
20 Matrix=IUB.

The “BLASTN method of alignment” is an algorithm provided by the National Center for Biotechnology Information [“NCBI”] to compare nucleotide sequences using default parameters, while the “BLASTP method of alignment” is an algorithm provided by the NCBI to compare
25 protein sequences using default parameters.

It is well understood by one skilled in the art that many levels of sequence identity are useful in identifying polypeptides, from other species, wherein such polypeptides have the same or similar function or activity. Suitable nucleic acid fragments, i.e., isolated polynucleotides according to
30 the disclosure herein, encode polypeptides that are at least about 70-85% identical, while more preferred nucleic acid fragments encode amino acid sequences that are at least about 85-95% identical to the amino acid sequences reported herein. Although preferred ranges are described

above, useful examples of percent identities include any integer percentage from 50% to 100%, such as 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. Also, of interest is any full-length or partial complement of this isolated nucleotide fragment.

Suitable nucleic acid fragments not only have the above homologies but typically encode a polypeptide having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids.

“Codon degeneracy” refers to the nature in the genetic code permitting variation of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide. Accordingly, described herein is any nucleic acid fragment that encodes all or a substantial portion of the amino acid sequence encoding the instant polypeptides as set forth in SEQ ID NOs:139, 141, 143, 145, 147, 149, 151, 153, 157, 181, 183, 185, 187, 213, 215, 217, 255, 260, 271 and 276.

The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

“Synthetic genes” can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These oligonucleotide building blocks are annealed and then ligated to form gene segments that are then enzymatically assembled to construct the entire gene. Accordingly, the genes can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the

likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell, where sequence information is available. For example, the codon usage profile for
5 *Yarrowia lipolytica* is provided in U.S. Pat. 7,125,672.

“Gene” refers to a nucleic acid fragment that expresses a specific protein, and that may refer to the coding region alone or may include regulatory sequences upstream and/or downstream to the coding region (e.g., 5' untranslated regions upstream of the transcription start site of the
10 coding region, 3' non-coding regions). “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are
15 derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene that is introduced into the host organism by gene
20 transfer. Foreign genes can comprise native genes inserted into a non-native organism, native genes introduced into a new location within the native host, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure. A “codon-optimized gene” is a gene having its frequency of codon usage designed
25 to mimic the frequency of preferred codon usage of the host cell.

“Coding sequence” refers to a DNA sequence that codes for a specific amino acid sequence. “Regulatory sequences” refer to nucleotide sequences located upstream of the coding sequence’s transcription start site, 5' untranslated regions and 3' non-coding regions, and which may
30 influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include, but are not limited to: promoters, enhancers, silencers, 5' untranslated leader

sequence, introns, polyadenylation recognition sequences, RNA processing sites, effector binding sites and stem-loop structures.

“Promoter” refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a promoter sequence is located 5’ upstream of a coding sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters that cause a gene to be expressed at almost all stages of cell growth and/or development are commonly referred to as “constitutive promoters”. It is further recognized that since in most cases the exact boundaries of regulatory sequences (especially at their 5’ end) have not been completely defined, DNA fragments of some variation may have identical promoter activity.

The terms “3’ non-coding sequences”, “transcription terminator”, “terminator” and “termination sequences” refer to DNA sequences located downstream of a coding sequence. This includes polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3’ end of the mRNA precursor. The 3’ region can influence the transcription, RNA processing or stability, or translation of the associated coding sequence.

“RNA transcript” refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript. A RNA transcript is referred to as the mature RNA when it is a RNA sequence derived from post-transcriptional processing of the primary transcript. “Messenger RNA” or “mRNA” refers to the RNA that is without introns and that can be translated into protein by

the cell. "cDNA" refers to a DNA that is complementary to, and synthesized from, a mRNA template using the enzyme reverse transcriptase. The cDNA can be single-stranded or converted into double-stranded form using the Klenow fragment of DNA polymerase I. "Sense" RNA refers to RNA transcript that includes the mRNA and can be translated into protein within a cell or *in vitro*. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA, and that blocks the expression of a target gene (U.S. Pat. 5,107,065).

10 The term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence, i.e., the coding sequence is under the transcriptional control of the promoter. Coding sequences can be operably linked to regulatory sequences in a sense or antisense orientation.

The term "recombinant" refers to an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by genetic engineering techniques.

The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA. Expression also includes translation of mRNA into a protein (either precursor or mature).

25 "Transformation" refers to the transfer of a nucleic acid molecule into a host organism, resulting in genetically stable inheritance. The nucleic acid molecule may be a plasmid that replicates autonomously, for example, or, it may integrate into the genome of the host organism. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic", "recombinant", "transformed" or "transformant" organisms.

The terms "plasmid" and "vector" refer to an extra chromosomal element often carrying genes that are not part of the central metabolism of

the cell, and usually in the form of circular double-stranded DNA fragments. Such elements may have autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, and may be linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing an expression cassette(s) into a cell.

The term “expression cassette” refers to a fragment of DNA comprising the coding sequence of a selected gene and regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence that are required for expression of the selected gene product. Thus, an expression cassette is typically composed of: 1) a promoter; 2) a coding sequence (i.e., ORF); and, 3) a terminator that usually contains a polyadenylation site in eukaryotes. The expression cassette(s) is usually included within a vector, to facilitate cloning and transformation. Different expression cassettes can be transformed into different organisms including bacteria, yeast, plants and mammalian cells, as long as the correct regulatory sequences are used for each host.

The terms “recombinant construct”, “expression construct”, “chimeric construct”, “construct”, and “recombinant DNA construct” are used interchangeably herein. A recombinant construct comprises an artificial combination of nucleic acid fragments, e.g., regulatory and coding sequences that are not found together in nature. For example, a recombinant construct may comprise one or more expression cassettes. In another example, a recombinant DNA construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. Such a construct may be used by itself or may be used in conjunction with a vector. If a vector is used, then the choice of vector is dependent upon the method that will be used to transform host cells as is

well known to those skilled in the art. For example, a plasmid vector can be used.

The skilled artisan is well aware of the genetic elements that must be present on the vector in order to successfully transform, select and propagate host cells comprising any of the isolated nucleic acid fragments described herein. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al., *EMBO J.*, 4:2411-2418 (1985); De Almeida et al., *Mol. Gen. Genetics*, 218:78-86 (1989)), and thus that multiple events must be screened in order to obtain strains or lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis, among others.

The terms "host cell" and "host organism" are used interchangeably herein and refer to any organism such as a microorganism or a plant (i.e., an oilseed plant) that is capable of receiving foreign or heterologous genes and capable of expressing those genes. A "recombinant host cell" refers to a host cell that has been recombinantly engineered.

The term "sequence analysis software" refers to any computer algorithm or software program that is useful for the analysis of nucleotide or amino acid sequences. "Sequence analysis software" may be commercially available or independently developed. Typical sequence analysis software will include, but is not limited to: 1) the GCG suite of programs (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, WI); 2) BLASTP, BLASTN, BLASTX (Altschul et al., *J. Mol. Biol.*, 215:403-410 (1990)); 3) DNASTAR (DNASTAR, Inc. Madison, WI); 4) Sequencher (Gene Codes Corporation, Ann Arbor, MI); and, 5) the FASTA program incorporating the Smith-Waterman algorithm (W. R. Pearson, *Comput. Methods Genome Res.*, [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Plenum: New York, NY). Within this description, whenever sequence analysis software is used for analysis,

the analytical results are based on the “default values” of the program referenced, unless otherwise specified. As used herein “default values” will mean any set of values or parameters that originally load with the software when first initialized.

5 Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook, et al.; by Silhavy, T. J., Bannan, M. L. and Enquist, L. W., Experiments with Gene Fusions, Cold Spring Harbor Laboratory: Cold Spring Harbor, NY (1984) (hereafter “Silhavy et al.”); and by Ausubel, F. M. et al.,
10 Current Protocols in Molecular Biology, published by Greene Publishing Assoc. and Wiley-Interscience, Hoboken, NJ (1987) (hereafter “Ausubel et al.”).

FIG. 1A and FIG. 1B together set forth multiple pathways for omega-3/ omega-6 fatty acid production, as described below. All
15 pathways require the initial conversion of oleic acid to linoleic acid ["LA"], the first of the omega-6 fatty acids, by a delta-12 desaturase. Then, using the “delta-9 elongase/ delta-8 desaturase pathway” and LA as substrate, long-chain omega-6 fatty acids are formed as follows: 1) LA is converted to eicosadienoic acid ["EDA"] by a delta-9 elongase; 2) EDA is converted
20 to dihomo-γ-linolenic acid ["DGLA"] by a delta-8 desaturase; 3) DGLA is converted to arachidonic acid ["ARA"] by a delta-5 desaturase; 4) ARA is converted to docosatetraenoic acid ["DTA"] by a C_{20/22} elongase; and, 5) DTA is converted to docosapentaenoic acid ["DPAn-6"] by a delta-4 desaturase.

25 The “delta-9 elongase/ delta-8 desaturase pathway” can also use alpha-linolenic acid ["ALA"] as substrate to produce long-chain omega-3 fatty acids as follows: 1) LA is converted to ALA, the first of the omega-3 fatty acids, by a delta-15 desaturase; 2) ALA is converted to eicosatrienoic acid ["ETrA"] by a delta-9 elongase; 3) ETrA is converted to
30 eicosatetraenoic acid ["ETA"] by a delta-8 desaturase; 4) ETA is converted to eicosapentaenoic acid ["EPA"] by a delta-5 desaturase; 5) EPA is converted to docosapentaenoic acid ["DPA"] by a C_{20/22} elongase;

and, 6) DPA is converted to docosahexaenoic acid ["DHA"] by a delta-4 desaturase. Optionally, omega-6 fatty acids may be converted to omega-3 fatty acids. For example, ETA and EPA are produced from DGLA and ARA, respectively, by delta-17 desaturase activity.

5 Alternate pathways for the biosynthesis of omega-3/ omega-6 fatty acids utilize a delta-6 desaturase and C_{18/20} elongase, that is, the "delta-6 desaturase/ delta-6 elongase pathway". More specifically, LA and ALA may be converted to GLA and stearidonic acid ["STA"], respectively, by a delta-6 desaturase; then, a C_{18/20} elongase converts GLA to DGLA and/or
10 STA to ETA. Downstream PUFAs are subsequently formed as described above.

 It is contemplated that the particular functionalities required to be introduced into a specific host organism for production of omega-3/ omega-6 fatty acids will depend on the host cell (and its native PUFA
15 profile and/or desaturase/elongase profile), the availability of substrate, and the desired end product(s). For example, expression of the delta-9 elongase/ delta-8 desaturase pathway may be preferred in some embodiments, as opposed to expression of the delta-6 desaturase/
delta-6 elongase pathway, since PUFAs produced via the former pathway
20 are devoid of GLA and/or STA.

 One skilled in the art will be able to identify various candidate genes encoding each of the enzymes desired for omega-3/ omega-6 fatty acid biosynthesis. Useful desaturase and elongase sequences may be derived from any source, e.g., isolated from a natural source (from bacteria, algae,
25 fungi, plants, animals, etc.), produced via a semi-synthetic route or synthesized *de novo*. Although the particular source of the desaturase and elongase genes introduced into the host is not critical, considerations for choosing a specific polypeptide having desaturase or elongase activity include: 1) the substrate specificity of the polypeptide; 2) whether the
30 polypeptide or a component thereof is a rate-limiting enzyme; 3) whether the desaturase or elongase is essential for synthesis of a desired PUFA; 4) co-factors required by the polypeptide; and/or, 5) whether the

polypeptide was modified after its production (e.g., by a kinase or a prenyltransferase). The expressed polypeptide preferably has parameters compatible with the biochemical environment of its location in the host cell (see U.S. Pat. 7,238,482 for additional details).

5 It will also be useful to consider the conversion efficiency of each particular desaturase and/or elongase. More specifically, since each enzyme rarely functions with 100% efficiency to convert substrate to product, the final lipid profile of unpurified oils produced in a host cell will typically be a mixture of various PUFAs consisting of the desired omega-3/
10 omega-6 fatty acid, as well as various upstream intermediary PUFAs. Thus, each enzyme's conversion efficiency is also a variable to consider, when optimizing biosynthesis of a desired fatty acid.

With each of the considerations above in mind, candidate genes having the appropriate desaturase and elongase activities (e.g., delta-6
15 desaturases, C_{18/20} elongases, delta-5 desaturases, delta-17 desaturases, delta-15 desaturases, delta-9 desaturases, delta-12 desaturases, C_{14/16} elongases, C_{16/18} elongases, delta-9 elongases, delta-8 desaturases, delta-4 desaturases and C_{20/22} elongases) can be identified according to publicly available literature (e.g., GenBank), the patent literature, and
20 experimental analysis of organisms having the ability to produce PUFAs. These genes will be suitable for introduction into a specific host organism, to enable or enhance the organism's synthesis of PUFAs.

Once fatty acids are synthesized within an organism (including saturated and unsaturated fatty acids and short-chain and long-chain fatty
25 acids), they may be incorporated into TAGs. TAGs are the primary storage unit for fatty acids.

Most delta-5 desaturase enzymes identified thus far have the primary ability to convert DGLA to ARA, with secondary activity in converting ETA to EPA. Several delta-5 desaturases have been
30 disclosed in both the open literature and the patent literature. General characteristics of delta-5 desaturases, based on desaturase evolution, are well-described by P. Sperling et al. (*Prostaglandins Leukot. Essent. Fatty*

Acids, 68:73–95 (2003). Along with delta–6, delta–8 and delta–4 desaturases, delta–5 desaturases are known as long-chain PUFA “front-end” desaturases (wherein desaturation occurs between a pre-existing double bond and the carboxyl terminus of the fatty acid’s acyl group, as opposed to methyl-directed desaturation). These desaturases are characterized by three histidine boxes [H(X)_{3–4}H (SEQ ID NOs:1 and 2), H(X)_{2–3}HH (SEQ ID NOs:3 and 4) and H/Q(X)_{2–3}HH (SEQ ID NOs:5 and 6)] and are members of the cytochrome *b*₅ fusion superfamily, since they possess a fused cytochrome *b*₅ domain at their N-terminus which serves as an electron donor. The cytochrome *b*₅ domain also contains a conserved heme-binding motif (i.e., a HPGG sequence [SEQ ID NO:7]), despite divergence of the remaining cytochrome *b*₅ domain sequences. An additional motif previously identified in some delta–5 desaturases also appears to be rich in histidine (i.e., a HDASH sequence [SEQ ID NO:8]), although the importance of the HDASH motif to enzymatic activity has yet to be elucidated.

A number of studies have suggested that the HPGG (SEQ ID NO:7) motif is implicated in enzyme activity. Sayanova, O. et al. (*Plant Physiol.*, 121:641 (1999)) performed site-directed mutagenesis to replace the His residue of the HPGG motif with an Ala residue in the delta–6 desaturase of borage. The mutant enzyme was expressed in *Arabidopsis*; however, no enzymatic activity could be measured, suggesting that the His residue of the HPGG (SEQ ID NO:7) motif in the cytochrome *b*₅ domain of the desaturase was important for function. A similar study was performed in a rat delta–6 desaturase, where an Ala for His substitution was engineered within the HPGG (SEQ ID NO:7) motif. The mutated protein also had no activity (Guillou, H., et al., *J. Lipid Res.*, 45:32-40 (2004)). More recently, Hongsthong, A. et al. (*Appl. Microbiol. Biotechnol.*, 72:1192-1201 (2006)) reported substitution of the His residue of the HPGG (SEQ ID NO:7) motif with an Ala residue in the delta–6 desaturase of *Spirulina*. As with previous reports, the mutation rendered the mutant enzyme unable to produce GLA in *E. coli*, suggesting that the cytochrome *b*₅ domain was important for activity and alterations at the His residue in the HPGG (SEQ

ID NO:7) motif will result in diminished enzyme activity. Although delta-5 desaturase enzymes are relatively common and well characterized, there remains a need for enzymes that are efficiently expressed at high levels in production host cells capable of making PUFAs.

5 As was mentioned above, delta-5 desaturases contain several conserved sequences. However, only the heme-binding motif (i.e., HPGG [SEQ ID NO:7]) and the HDASH motif (SEQ ID NO:8) lack variation within the sequence. These motifs were selected as targets for mutagenesis herein. Although the importance of the HDASH (SEQ ID NO:8) motif to
10 enzymatic function remains unclear, the literature suggests that at least the His residue within the HPGG (SEQ ID NO:7) motif is important for function. Consequently, substitutions for the His residues in either motif were avoided in favor of substitutions for the remaining residues.

U.S. Pat. Pub. No. 2010-0075386-A1 describes the site-directed
15 mutagenesis of the Pro and the second Gly residues within the HPGG (SEQ ID NO:7) motif of several delta-5 desaturases, followed by expression of the resulting mutant polypeptides and determination of their activities with respect to that of the wildtype enzyme. That application disclosed the creation of various mutant delta-5 desaturases comprising
20 amino acid mutant motifs including HxGG (SEQ ID NO:32) and HPGx (SEQ ID NO:33), where the delta-5 desaturase activity of the mutant delta-5 desaturase was functionally equivalent to the delta-5 desaturase activity of the corresponding wildtype delta-5 desaturase.

Numerous site-directed mutagenesis protocols exist [e.g., Ishii, T.
25 M., et al., *Methods Enzymol.*, 293:53-71 (1998); Ling M. M. and B.H. Robinson, *Anal. Biochem.*, 254:157-178 (1997); Braman J. (ed.) *In Vitro Mutagenesis Protocols*. 2nd Ed., Humana: Totowa, NJ (2002); Kunkel T. A., et al., *Methods Enzymol.*, 154:367-382 (1987); Sawano A. and Miyawaki, A. *Nucleic Acids Res.*, 28:e78 (2000)]; however, the
30 QuikChange® site-directed mutagenesis kit (Stratagene, La Jolla, CA) was selected for use based on its facile implementation and high efficiency. The basic procedure utilizes a supercoiled double-stranded DNA vector with an insert of interest and two synthetic oligonucleotide primers

containing the desired mutation. The oligonucleotide primers, each complementary to opposite strands of the vector, are extended during temperature cycling by a DNA polymerase. Incorporation of the oligonucleotide primers generates a mutated plasmid containing staggered
5 nicks. Following temperature cycling, the product is treated with *DpnI* endonuclease (specific for methylated and hemi-methylated DNA) as a means to digest the parental DNA template and to select for newly synthesized mutant DNA. The nicked vector DNA containing the desired mutations is then transformed and propagated in an *Escherichia coli* host.

10 Using the techniques described above, site-directed mutagenesis was independently performed on the Asp [D], Ala [A] and Ser [S] residues within the HDASH (SEQ ID NO:8) motif of several delta-5 desaturases, followed by expression of the resulting mutant polypeptides and determination of their activities with respect to that of the wildtype enzyme.
15 Surprisingly, various mutant delta-5 desaturases were created comprising amino acid mutant motifs including HxASH (SEQ ID NO:35), HDxSH (SEQ ID NO:36) and HDAxH (SEQ ID NO:37), where the delta-5 desaturase activity of the mutant delta-5 desaturase was functionally similar to the delta-5 desaturase activity of the corresponding wildtype delta-5
20 desaturase.

For example, all possible amino acid substitutions for the Ala residue within the HDASH (SEQ ID NO:8) motif were introduced by site-directed mutagenesis into a modified variant wildtype delta-5 desaturase derived from *Euglena gracilis* within a plasmid construct comprising a
25 chimeric FBAIN::EgD5R*::Pex20 gene (i.e., EgD5R* [SEQ ID NO:27], lacking four internal restriction enzyme sites within the gene and comprising an Arg at position 347 instead of a Ser, when compared to EgD5 [SEQ ID NO:21]). The plasmids with the mutated sequences were individually transformed into *E. coli*, sequenced and then transformed into
30 an appropriate strain of *Yarrowia lipolytica* previously engineered to produce ~18% DGLA. This enabled screening for delta-5 desaturase activity based on the production of ARA (i.e., by GC analyses).

Many mutations were identified that resulted in mutant delta-5 desaturases having substantially decreased delta-5 desaturase activities with respect to the wildtype enzyme. Surprisingly, however, the preliminary screening identified two amino acid residues that could be substituted for the Ala within the HDASH (SEQ ID NO:8) motif and that resulted in approximately equivalent or increased delta-5 desaturase activity in the mutant, when compared to the delta-5 desaturase activity in the corresponding wildtype enzyme (i.e., EgD5R*). Thus, this preliminary experimentation suggested that the Ala residue within the HDASH (SEQ ID NO:8) motif could be substituted with Gly or Ser without significantly affecting the delta-5 desaturase activity of EgD5R*.

Similar experimentation was performed using EgD5R* as the template in site-directed mutagenesis reactions, where the Ser residue of the HDASH (SEQ ID NO:8) motif was mutated. Analyses of the mutant enzymes determined that two amino acid residues (i.e., Ala or Gly) were sufficient to replace the wildtype amino acid (i.e., Ser) and resulted in a mutant EgD5R* enzyme having equivalent or improved delta-5 desaturase activity.

Once the preliminary analyses of amino acid substitutions in the HDASH (SEQ ID NO:8) motif of EgD5R* were completed as described above, oligonucleotide-mediated site-directed mutagenesis was further utilized to create specific point mutations within the HPGG (SEQ ID NO:7) motif in combination with several mutant HDASH motifs of delta-5 desaturases described above. Thus, various amino acid substitutions within the HPGG (SEQ ID NO:7) motif were introduced by site-directed mutagenesis into each of three of the mutant HDASH motif delta-5 desaturases described above (i.e., EgD5R*-157g [SEQ ID NO:87], EgD5R*-158a [SEQ ID NO:127] and EgD5R*-158g [SEQ ID NO:128]), within plasmids pDMW367M4-157g (SEQ ID NO:129), pDMW367M4-158a (SEQ ID NO:130), and pDMW367M4-158g (SEQ ID NO:131), respectively, thereby generating double mutants having a single mutation within each of the HPGG (SEQ ID NO:7) and HDASH (SEQ ID NO:8) motifs. The double mutants were amplified in *E. coli*, confirmed by DNA sequencing and then

transformed into an appropriate strain of *Y. lipolytica*. Again, screening for delta-5 desaturase activity based on the production of ARA (i.e., by GC analyses) was performed.

All of the double mutants possessed some detectable level of delta-5 desaturase activity with respect to the non-mutant wildtype EgD5R* enzyme. More specifically, all 7 of the mutant delta-5 desaturases functioned with at least 64% DGLA to ARA conversion efficiency with respect to the corresponding wildtype EgD5R* control, while 3 were able to convert DGLA to ARA with at least 83% conversion efficiency (Table 3, *infra*). The screening confirmed the Pro and the second Gly of the HPGG (SEQ ID NO:7) motif and the Ala and Ser of the HDASH (SEQ ID NO:8) motif could be simultaneously substituted and yield a double mutant having approximately equivalent delta-5 desaturase activity, when compared to the delta-5 desaturase activity in the corresponding wildtype enzyme (i.e., EgD5R*). Thus, this experimentation suggested 1) that the Pro residue within the HPGG [SEQ ID NO:7] motif can be substituted with Gly with simultaneous substitution of either: a) the Ala residue within the HDASH [SEQ ID NO:8] motif for Gly or b) the Ser residue within the HDASH [SEQ ID NO:8] motif for Ala or Gly; 2) the Pro residue within the HPGG [SEQ ID NO:7] motif can also be substituted with His with simultaneous substitution of the Ser within the HDASH [SEQ ID NO:8] motif for either Ala or Gly; and, 3) the second Gly residue within the HPGG [SEQ ID NO:7] motif can be substituted with Ser with simultaneous substitution of the Ser within the HDASH [SEQ ID NO:8] motif for either Ala or Gly, without significantly affecting the delta-5 desaturase activity of EgD5R*.

The N-terminus of the gene encoding the double mutant EgD5R* delta-5 desaturase identified as having the highest conversion efficiency as compared to EgD5R* (i.e., EgD5R*-34g158g; SEQ ID NO:142) was codon-optimized for expression in *Yarrowia lipolytica* (i.e., EgD5M; SEQ ID NO:152). EgD5M was then modified to encode a Ser at position 347 (i.e., EgD5M1; SEQ ID NO:156) in order to analyze the effect of the R347S mutation on delta-5 desaturase activity. Plasmids comprising

either EgD5M (i.e., pDMW367-5M; SEQ ID NO:155) or EgD5M1 (i.e., pDMW367-5M1; SEQ ID NO:159) were separately transformed into an appropriate strain of *Y. lipolytica*, and the delta-5 desaturase activity and conversion efficiency were measured and compared to that of wild-type
5 EgD5R*.

Both double mutant delta-5 desaturases, i.e., EgD5M and EgD5M1, had increased activity compared to the wild-type EgD5R* (Table 3, *infra*). Surprisingly, EgD5M1 demonstrated improved delta-5 desaturase activity as compared to EgD5M, suggesting that a Ser at amino acid residue 347
10 improved the enzymatic activity.

Using the techniques described above, single amino acid substitutions were then individually introduced by site-directed mutagenesis into the Asp, Ala, or Ser residues of the HDASH (SEQ ID NO:8) motif of a synthetic delta-5 desaturase having a mutant HPGs
15 (SEQ ID NO:11) motif, which was codon-optimized for expression in *Yarrowia lipolytica* and derived from *Euglena gracilis* (i.e., EgD5S-36s [SEQ ID NO:160]; U.S. Pat. Appl. Pub. No. 2010-0075386-A1), within a plasmid construct comprising a chimeric FBAIN::EgD5S-36s::Pex20 gene. The protocol was repeated using a synthetic delta-5 desaturase having a
20 mutant HaGG (SEQ ID NO:14) motif, which was codon-optimized for expression in *Y. lipolytica* and derived from *Euglena anabaena* (i.e., EaD5S-35a [SEQ ID NO:188]; U.S. Pat. Appl. Pub. No. 2010-0075386-A1). The plasmids with double mutants were separately amplified in *E. coli*, confirmed by DNA sequencing, and then transformed into an appropriate
25 strain of *Y. lipolytica* for delta-5 desaturase activity screening based on the production of ARA (i.e., by GC analyses). Double mutant delta-5 desaturases were obtained from each experiment, comprising HxGx (SEQ ID NO:34) and HxxxH (SEQ ID NO:1) motifs and having suitable delta-5 desaturase activity (see Examples for additional details and Table 3, *infra*).

Table 3. Preferred Mutant Delta-5 Desaturases Comprising HxGx (SEQ ID NO:34) and HxxxH (SEQ ID NO:1) Motifs

Mutant Delta-5 Desaturase (SEQ ID NO)	Mutant HPGG Motif	Mutant HDASH Motif	Delta-5 Desaturase Activity
EgD5R*-34g157g (SEQ ID NO:139)	HgGG (SEQ ID NO:9)	HDgSH (SEQ ID NO:15)	83% ^a
EgD5R*-34g158a (SEQ ID NO:141)	HgGG (SEQ ID NO:9)	HDAaH (SEQ ID NO:17)	88% ^a
EgD5R*-34g158g (SEQ ID NO:143)	HgGG (SEQ ID NO:9)	HDAgH (SEQ ID NO:18)	97% ^a
EgD5M (codon-optimized EgD5R*-34g158g) (SEQ ID NO:153)	HgGG (SEQ ID NO:9)	HDAgH (SEQ ID NO:18)	106.9% ^a
EgD5M1 (codon-optimized EgD5R*-34g158g347s) (SEQ ID NO:157)	HgGG (SEQ ID NO:9)	HDAgH (SEQ ID NO:18)	111.3% ^a
EgD5S-36s157g (SEQ ID NO:183)	HPGs (SEQ ID NO:11)	HDgSH (SEQ ID NO:15)	79.9% ^b
EgD5S-36s158a (SEQ ID NO:185)	HPGs (SEQ ID NO:11)	HDAaH (SEQ ID NO:17)	85.4% ^b
EgD5S-36s158g (SEQ ID NO:187)	HPGs (SEQ ID NO:11)	HDAgH (SEQ ID NO:18)	74.9% ^b
EgD5S-36s156e (SEQ ID NO:181)	HPGs (SEQ ID NO:11)	HeASH (SEQ ID NO:19)	79.0% ^b
EaD5S-35a158g (SEQ ID NO:213)	HaGG (SEQ ID NO:14)	HDgSH (SEQ ID NO:15)	76.3% ^c
EaD5S-35a158s (SEQ ID NO:215)	HaGG (SEQ ID NO:14)	HDsSH (SEQ ID NO:16)	73.7% ^c
EaD5S-35a159g (SEQ ID NO:217)	HaGG (SEQ ID NO:14)	HDAgH (SEQ ID NO:18)	71.2% ^c

^a Delta-5 desaturase activity is with respect to the corresponding wildtype enzyme having a HPGG (SEQ ID NO:7) and a HDASH (SEQ ID NO:8) motif.

^b Delta-5 desaturase activity is with respect to the corresponding parent enzyme having only a mutant HPGs (SEQ ID NO:11) motif.

^c Delta-5 desaturase activity is with respect to the corresponding parent enzyme having only a mutant HaGG (SEQ ID NO:14) motif.

The above studies do not suggest a consensus with respect to which particular simultaneous amino acid substitutions in the HPGG (SEQ ID NO:7) and HDASH (SEQ ID NO:8) motifs are sufficient to produce a mutant polypeptide having acceptable delta-5 desaturase activity.

However, contrary to previous reports in the art, the data is surprising in demonstrating that substitutions for either the Pro or Gly residues of the HPGG (SEQ ID NO:7) motif combined with substitutions for the Asp, Ala or Ser residues of the HDASH (SEQ ID NO:8) motif may result in an
 5 enzyme having functionally equivalent or improved delta-5 desaturase activity, as compared to its wildtype parent.

Accordingly, it is within the scope of the present invention to provide a polypeptide having delta-5 desaturase activity comprising a first amino acid motif selected from the group consisting of: SEQ ID NO:9 (HgGG),
 10 SEQ ID NO:10 (HhGG), SEQ ID NO:11 (HPGs), SEQ ID NO:12 (HcGG), SEQ ID NO:13 (HwGG) and SEQ ID NO:14 (HaGG); and a second amino acid motif selected from the group consisting of: SEQ ID NO:15 (HDgSH), SEQ ID NO:16 (HDsSH), SEQ ID NO:17 (HDAaH), SEQ ID NO:18 (HDAgH) and SEQ ID NO:19 (HeASH).

15 More preferably, the mutant delta-5 desaturase described above (i.e., comprising a HxGx [SEQ ID NO:34] motif and a mutant HxxxH [SEQ ID NO:1] motif additionally has delta-5 desaturase activity that is at least 64% of that of the corresponding wildtype delta-5 desaturase having both an HPGG (SEQ ID NO:7) and HDASH (SEQ ID NO:8) amino acid motif.

20 The mutant delta-5 desaturase polypeptide comprising a mutant HPGG motif and a mutant HDASH motif may have at least 90% sequence identity, and more preferably at least 95% sequence identity, based on the BLASTP method of alignment when compared to a polypeptide having a sequence selected from the group consisting of: SEQ ID NO:21, SEQ ID
 25 NO:25 and SEQ ID NO:29.

In some embodiments, the polypeptide has an amino acid sequence selected from the group consisting of: SEQ ID NO:139, SEQ ID NO:141, SEQ ID NO:143, SEQ ID NO:145 [EgD5R*-34h158a], SEQ ID NO:147 [EgD5R*-34h158g], SEQ ID NO:149 [EgD5R*-36s158a], SEQ ID
 30 NO:151 [EgD5R*-36s158g], SEQ ID NO:153, SEQ ID NO:157, SEQ ID NO:181, SEQ ID NO:183, SEQ ID NO:185, SEQ ID NO:187, SEQ ID NO:213, SEQ ID NO:215, SEQ ID NO:217, SEQ ID NO:255 [EgD5R-

34g158g], SEQ ID NO:260 [EgD5R-34g158a], SEQ ID NO:271 [EaD5-35g159g] and SEQ ID NO:276 [EaD5-35g159a].

It will be appreciated by one of skill in the art that useful mutant delta-5 desaturases are not limited to the mutations described above.

5 Instead, the results suggest that similar experimentation could be performed using any delta-5 wildtype desaturase enzyme having a HPGG (SEQ ID NO:7) motif within the cytochrome *b*₅ domain and an HDASH motif (SEQ ID NO:8), to thereby engineer a mutant delta-5 desaturase having suitable delta-5 desaturase activity wherein the mutation would
10 result in a mutant HxGG (SEQ ID NO:32) or a HPGx motif (SEQ ID NO:33) and a mutant HxASH (SEQ ID NO:35), HDxSH (SEQ ID NO:36) or HDxH motif (SEQ ID NO:37). A mutant enzyme having suitable delta-5 desaturase activity can be useful to enable increased production of omega-3/ omega-6 fatty acids.

15 For example, *in vitro* mutagenesis and selection or error prone PCR (Leung et al., *Techniques*, 1:11-15 (1989); Zhou et al., *Nucleic Acids Res.*, 19:6052-6052 (1991); Spee et al., *Nucleic Acids Res.*, 21:777-778 (1993); Melnikov et al., *Nucleic Acids Res.*, 27(4):1056-1062 (February 15, 1999)) could also be employed as a means to obtain mutations of naturally
20 occurring delta-5 desaturase genes, wherein the mutations may include deletions, insertions and point mutations, or combinations thereof. The principal advantage of error-prone PCR is that all mutations introduced by this method will be within the desired desaturase gene, and any change may be easily controlled by changing the PCR conditions. Alternatively,
25 *in vivo* mutagenesis may be employed using commercially available materials such as the *E. coli* XL1-Red strain and *Epicurian coli* XL1-Red mutator strain from Stratagene (La Jolla, CA; Greener and Callahan, *Strategies*, 7:32-34 (1994)). This strain is deficient in three of the primary DNA repair pathways (*mutS*, *mutD* and *mutT*), resulting in a mutation rate
30 5000-fold higher than that of wildtype. *In vivo* mutagenesis does not depend on ligation efficiency (as with error-prone PCR); however, a mutation may occur at any region of the vector and the mutation rates are generally much lower.

It is also contemplated that a mutant delta-5 desaturase with altered or enhanced delta-5 desaturase activity may be constructed using the method of "gene shuffling" (U.S. Pat. 5,605,793; U.S. Pat. 5,811,238; U.S. Pat. 5,830,721; U.S. Pat. 5,837,458). The method of gene shuffling is particularly attractive due to its facile implementation and high rate of mutagenesis. The process of gene shuffling involves the restriction of a gene of interest into fragments of specific size in the presence of additional populations of DNA regions of both similarity to (or difference to) the gene of interest. This pool of fragments will denature and then reanneal to create a mutated gene. The mutated gene is then screened for altered activity. Any of these methods may be used to create delta-5 desaturase mutant enzymes having the substituted motifs HxGG (SEQ ID NO:32) or HPGx (SEQ ID NO:33), and HxASH (SEQ ID NO:35), HDxSH (SEQ ID NO:36), or HDAXH (SEQ ID NO:37), which may then be screened for suitable activity using the methods described herein.

It is expected that introduction of chimeric genes encoding the mutant delta-5 desaturases described herein (i.e., wherein said mutant delta-5 desaturase comprises at least one mutation in a region encoding an HPGG amino acid motif and at least one mutation in a region encoding an HDASH amino acid motif, and wherein said mutant delta-5 desaturase preferably has at least 64% delta-5 desaturase activity with respect to that of the corresponding wildtype delta-5 desaturase), under the control of the appropriate promoters will result in production of ARA and/or EPA in the transformed host organism, respectively. As such, disclosed herein are methods for the direct production of PUFAs comprising exposing a fatty acid substrate (i.e., DGLA and/or ETA) to a mutant desaturase described herein (e.g., any of SEQ ID NOs:139, 141, 143, 145, 147, 149, 151, 153, 157, 181, 183, 185, 187, 213, 215, 217, 255, 260, 271 and 276), such that the substrate is converted to the desired fatty acid product (i.e., ARA and/or EPA, respectively).

More specifically, described herein is a method for the production of a PUFA in a microbial host cell (e.g., bacteria, yeast, algae, euglenoids,

stramenopiles, oomycetes and fungi) or a plant host cell (e.g., an oilseed plant cell), wherein the microbial or plant host cell comprises:

- a) a polypeptide having delta-5 desaturase activity comprising a first amino acid motif selected from the group consisting of:
 5 SEQ ID NO:9 (HgGG), SEQ ID NO:10 (HhGG), SEQ ID NO:11 (HPGs), SEQ ID NO:12 (HcGG), SEQ ID NO:13 (HwGG) and SEQ ID NO:14 (HaGG), and a second amino acid motif selected from the group consisting of: SEQ ID NO:15 (HDgSH), SEQ ID NO:16 (HDsSH), SEQ ID NO:17 (HDAaH), SEQ ID
 10 NO:18 (HDAgH) and SEQ ID NO:19 (HeASH); and,
- b) a source of substrate fatty acid selected from the group consisting of DGLA and ETA;

wherein the host cell is grown under conditions such that the mutant delta-5 desaturase is expressed and the substrate fatty acid is converted
 15 to product PUFA, wherein DGLA is converted to ARA and/or ETA is converted to EPA; and wherein the product PUFA is optionally recovered.

Alternatively, each mutant delta-5 desaturase gene and its corresponding enzyme product described herein can be used indirectly for the production of various omega-6 and omega-3 PUFAs (see FIG. 1; U.S. Pat. 7,238,482; U.S. Pat. 7,678,560; U.S. Pat. 7,695,950). Indirect
 20 production of omega-3/ omega-6 PUFAs occurs wherein the fatty acid substrate is converted indirectly into the desired fatty acid product, via means of an intermediate step(s) or pathway intermediate(s). Thus, it is contemplated that the mutant delta-5 desaturases described herein may
 25 be expressed in conjunction with additional genes encoding enzymes of the PUFA biosynthetic pathway (e.g., delta-6 desaturases, C_{18/20} elongases, delta-17 desaturases, delta-8 desaturases, delta-15 desaturases, delta-9 desaturases, delta-12 desaturases, C_{14/16} elongases, C_{16/18} elongases, delta-9 elongases, delta-5 desaturases, delta-4
 30 desaturases, C_{20/22} elongases) to result in higher levels of production of longer-chain omega-3/ omega-6 fatty acids, such as e.g., ARA, EPA, DTA, DPAn-6, DPA and/or DHA.

Preferably, the delta-5 desaturases described herein will be expressed in conjunction with at least a delta-9 elongase and a delta-8 desaturase. The delta-5 desaturases could also be expressed in conjunction with at least a delta-6 desaturase and a delta-6 elongase.

5 However, the particular genes included within a particular expression cassette will depend on the host cell (and its PUFA profile and/or desaturase/elongase profile), the availability of substrate and the desired end product(s).

It is necessary to create and introduce a recombinant construct

10 comprising an ORF encoding a mutant delta-5 desaturase (i.e., wherein said mutant comprises a first amino acid motif selected from the group consisting of: SEQ ID NO:9 (HgGG), SEQ ID NO:10 (HhGG), SEQ ID NO:11 (HPGs), SEQ ID NO:12 (HcGG), SEQ ID NO:13 (HwGG) and SEQ ID NO:14 (HaGG), and a second amino acid motif selected from the group

15 consisting of: SEQ ID NO:15 (HDgSH), SEQ ID NO:16 (HDsSH), SEQ ID NO:17 (HDAaH), SEQ ID NO:18 (HDAgH) and SEQ ID NO:19 (HeASH)) into a suitable host cell.

One of skill in the art is aware of standard resource materials that describe: 1) specific conditions and procedures for construction,

20 manipulation and isolation of macromolecules, such as DNA molecules, plasmids, etc.; 2) generation of recombinant DNA fragments and recombinant expression constructs; and, 3) screening and isolating of clones or plant lines. See, Sambrook et al.; Silhavy et al.; Ausubel et al.; Maliga et al., *Methods in Plant Molecular Biology*, Cold Spring Harbor: NY

25 (1995); Birren et al., *Genome Analysis: Detecting Genes*, Vol. 1, Cold Spring Harbor: NY (1998); Birren et al., *Genome Analysis: Analyzing DNA*, Vol. 2, Cold Spring Harbor: NY (1998); *Plant Molecular Biology: A Laboratory Manual*, eds. Clark, Springer: NY (1997).

30 In general, the choice of sequences included in the construct depends on the desired expression products, the nature of the host cell and the proposed means of separating transformed cells versus non-transformed cells. The skilled artisan is aware of the genetic elements

that must be present on the plasmid vector to successfully transform, select and propagate host cells containing the chimeric gene. Typically, however, the vector or cassette contains sequences directing transcription and translation of the relevant gene(s), a selectable marker and
5 sequences allowing autonomous replication or chromosomal integration. Suitable expression cassettes typically comprise a promoter, the coding sequence of a selected gene, and a terminator. It is most preferred when both control regions are derived from genes from the transformed host cell.

Promoters useful for driving expression of the instant delta-5
10 desaturase ORFs in the desired microbial host cell or plant cell are well known. Virtually any promoter (i.e., native, synthetic, or chimeric) capable of directing expression of these genes in the selected host cell is suitable. Expression in a host cell can be accomplished in an induced or constitutive fashion. Induced expression occurs by inducing the activity of
15 a regulatable promoter operably linked to the gene of interest, while constitutive expression occurs by the use of a constitutive promoter.

As an example, U.S. Pat. Pub. No. 2009-0093543-A1 describes promoters for use in *Yarrowia lipolytica*. Any one of a number of promoters can be used, depending upon whether constitutive or induced
20 transcription is desired, the efficiency of the promoter in expressing the ORF of interest, the ease of construction and the like.

Nucleotide sequences surrounding the translational initiation codon 'ATG' have been found to affect expression in yeast cells. If the desired polypeptide is poorly expressed in yeast, the coding region of exogenous
25 genes can be modified to include an efficient yeast translation initiation sequence to obtain optimal gene expression. For expression in yeast, this can be done by site-directed mutagenesis of an inefficiently expressed gene or by fusing it in-frame to an endogenous yeast promoter, preferably a highly expressed promoter. Alternatively, the consensus translation
30 initiation sequence of the host can be engineered into heterologous genes for their optimal expression.

The terminator can be derived from the 3' region of the gene from which the promoter was obtained or from a different gene. A large number

of terminators are known and function satisfactorily in a variety of hosts, when utilized both in the same and different genera and species from which they were derived. The terminator usually is selected more as a matter of convenience rather than because of any particular property.

- 5 Terminators may be derived from various genes native to the preferred hosts. The terminator can also be synthetic, as one of skill in the art can utilize available information to design and synthesize a terminator. A terminator may be unnecessary, but is highly preferred.

- 10 Merely inserting a gene into a cloning vector does not ensure its expression at the desired rate, concentration, amount, etc. In response to the need for high level expression, many specialized expression vectors have been created by adjusting certain properties that govern transcription, RNA stability, translation, protein stability and location, as well as
- 15 include: the nature of the relevant transcriptional promoter and terminator sequences; the number of copies of the cloned gene (wherein additional copies may be cloned within a single expression construct and/or additional copies may be introduced into the host cell by increasing the plasmid copy number or by multiple integration of the cloned gene into the
- 20 genome); whether the gene is plasmid-borne or integrated into the host cell genome; the final cellular location of the synthesized foreign protein; the efficiency of translation and correct folding of the protein in the host organism; the intrinsic stability of the mRNA and protein of the cloned gene within the host cell; and, the codon usage within the cloned gene.
- 25 Each of these may be used in the methods and host cells described herein, to further optimize expression of the mutant delta-5 desaturases.

- After a recombinant construct is created comprising at least one chimeric gene comprising a promoter, a mutant delta-5 desaturase ORF and a terminator, it is placed in a plasmid vector capable of autonomous
- 30 replication in a host cell, or it is directly integrated into the genome of the host cell. Integration of expression cassettes can occur randomly within the host genome or can be targeted through the use of constructs containing regions of homology with the host genome sufficient to target

recombination within the host locus. Where constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.

Where two or more genes are expressed from separate replicating
5 vectors, it is desirable that each vector has a different means of selection and should lack homology to the other construct(s) to maintain stable expression and prevent reassortment of elements among constructs. Judicious choice of regulatory regions, selection means and method of propagation of the introduced construct(s) can be experimentally
10 determined so that all introduced genes are expressed at the necessary levels to provide for synthesis of the desired products.

Constructs comprising the gene(s) of interest may be introduced into a microbial host cell or plant host cell by any standard technique. These techniques include transformation, e.g., lithium acetate
15 transformation (*Methods in Enzymology*, 194:186-187 (1991)), bolistic impact, electroporation, microinjection, or any other method that introduces the gene(s) of interest into the host cell.

For convenience, a host cell that has been manipulated by any method to take up a DNA sequence, for example, in an expression
20 cassette, is referred to herein as "transformed", "transformant" or "recombinant". The transformed host will have at least one copy of the expression construct and may have two or more, depending upon whether the expression cassette is integrated into the genome, amplified, or is present on an extrachromosomal element having multiple copy numbers.
25 The transformed host cell can be identified by selection for a marker contained on the introduced construct. Alternatively, a separate marker construct may be co-transformed with the desired construct, as many transformation techniques introduce many DNA molecules into host cells.

Typically, transformed hosts are selected for their ability to grow on
30 selective media, which may incorporate an antibiotic or lack a factor necessary for growth of the untransformed host, such as a nutrient or growth factor. An introduced marker gene may confer antibiotic resistance, or encode an essential growth factor or enzyme, thereby permitting growth

on selective media when expressed in the transformed host. Selection of a transformed host can also occur when the expressed marker can be detected, either directly or indirectly. Additional selection techniques are described in U.S. Pat. 7,238,482, U.S. Pat. 7,259,255 and U.S. Pat. 5 7,932,077.

Following transformation, substrates suitable for the instant mutant delta-5 desaturases (and, optionally, other PUFA enzymes that are co-expressed within the host cell) may be produced by the host either naturally or transgenically, or they may be provided exogenously.

10 A variety of eukaryotic organisms are suitable as host, to thereby yield a transformant comprising mutant delta-5 desaturases as described herein, including bacteria, yeast, algae, stramenopiles, oomycetes, euglenoids, fungi and/or plants. This is contemplated because transcription, translation and the protein biosynthetic apparatus are highly 15 conserved. Thus, suitable hosts may include, but are not limited to, those that grow on a variety of feedstocks, including simple or complex carbohydrates, fatty acids, organic acids, oils, glycerols and alcohols, and/or hydrocarbons over a wide range of temperature and pH values.

Preferred microbial hosts are oleaginous organisms. These 20 oleaginous organisms are naturally capable of oil synthesis and accumulation, wherein the total oil content can comprise greater than about 25% of the dry cell weight ["DCW"], more preferably greater than about 30% of the DCW, more preferably greater than about 40% of the DCW, more preferably greater than about 50% of the DCW, and most 25 preferably greater than about 60% of the DCW. Various bacteria, algae, euglenoids, moss, fungi, yeast and stramenopiles are naturally classified as oleaginous. In alternate embodiments, a non-oleaginous organism can be genetically modified to become oleaginous, e.g., yeast such as *Saccharomyces cerevisiae* (see, Int'l. App. Pub. No. WO 2006/102342).

30 In more preferred embodiments, the microbial host cells are oleaginous yeast capable of producing at least 25% of the DCW as oil. Genera typically identified as oleaginous yeast include, but are not limited to: *Yarrowia*, *Candida*, *Rhodotorula*, *Rhodospiridium*, *Cryptococcus*,

Trichosporon and *Lipomyces*. More specifically, illustrative oil-synthesizing yeasts include: *Rhodospiridium toruloides*, *Lipomyces starkeyii*, *L. lipoferus*, *Candida revkaufi*, *C. pulcherrima*, *C. tropicalis*, *C. utilis*, *Trichosporon pullans*, *T. cutaneum*, *Rhodotorula glutinus*,
5 *R. graminis*, and *Yarrowia lipolytica*.

Most preferred is the oleaginous yeast *Yarrowia lipolytica*. In a further embodiment, most preferred are the *Y. lipolytica* strains designated as ATCC #20362, ATCC #8862, ATCC #18944, ATCC #76982 and/or LGAM S(7)1 (Papanikolaou S., and Aggelis G., *Bioresour. Technol.*,
10 82(1):43-9 (2002)).

Specific teachings applicable for transformation of oleaginous yeasts (e.g., *Yarrowia lipolytica*) include U.S. Pat. 4,880,741 and U.S. Pat. 5,071,764 and Chen, D. C. et al. (*Appl. Microbiol. Biotechnol.*, 48(2):232-235 (1997)). Specific teachings applicable for engineering ARA,
15 EPA and DHA production in *Y. lipolytica* are provided in U.S. Pat. 7,588,931, U.S. Pat. Appl. Publications No. 2009-0093543-A1 and No. 2010-0317072-A1 and U.S. Pat. 7,550,286, respectively.

The preferred method of expressing genes in this yeast is by integration of linear DNA into the genome of the host. Integration into
20 multiple locations within the genome can be particularly useful when high level expression of genes is desired, such as into the following gene loci: *Ura3*, *Leu2*, *Lys5*, *Aco2*, *Pox3*, *Lip1*, *Lip2*, *SCP2*, *Pex3*, *Pex16* and/or *Pex10* (see, e.g., U.S. Pat. Appl. Publications No. 2009-0093543-A1 and No. 2010-0317072-A1).

25 Preferred selection methods for use in *Yarrowia lipolytica* are resistance to kanamycin, hygromycin and the amino glycoside G418, as well as ability to grow on media lacking uracil, leucine, lysine, tryptophan or histidine. 5-fluoroorotic acid (5-fluorouracil-6-carboxylic acid monohydrate; "5-FOA") may also be especially useful for the selection of
30 yeast *Ura⁻* mutants (U.S. Pat. Appl. Pub. No. 2009-0093543-A1), or a native acetohydroxyacid synthase (or acetolactate synthase; E.C. 4.1.3.18) that confers sulfonyl urea herbicide resistance (U.S. Pat. 7,932,077) may be utilized for selection of transformants. A unique

method of “recycling” a pair of preferred selection markers for their use in multiple sequential transformations, by use of site-specific recombinase systems, is also taught in U.S. Pat. Appl. Pub. No. 2009-0093543-A1.

Based on the above, disclosed herein is a method of producing
5 either ARA or EPA, respectively, comprising:

- (a) providing an oleaginous yeast (e.g., *Yarrowia lipolytica*) comprising:
 - (i) a first recombinant nucleotide molecule encoding a mutant delta-5 desaturase polypeptide, operably linked
10 to at least one regulatory sequence; and,
 - (ii) a source of desaturase substrate consisting of DGLA and/or ETA, respectively; and,
- (b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the gene encoding the
15 mutant delta-5 desaturase polypeptide is expressed and DGLA is converted to ARA and/or ETA is converted to EPA, respectively; and,
- (c) optionally recovering the ARA and/or EPA, respectively, of step (b).

20 Substrate feeding may be required. In preferred embodiments, the mutant delta-5 desaturase polypeptide is selected from the group consisting of: SEQ ID NO:139 [EgD5R*-34g157g], SEQ ID NO:141 [EgD5R*-34g158a], SEQ ID NO:143 [EgD5R*-34g158g], SEQ ID NO:145 [EgD5R*-34h158a], SEQ ID NO:147 [EgD5R*-34h158g], SEQ ID NO:149 [EgD5R*-36s158a], SEQ ID NO:151 [EgD5R*-36s158g], SEQ ID NO:153 [EgD5M, codon-optimized EgD5R*-34g158g], SEQ ID NO:157 [EgD5M1, codon-optimized EgD5R*-34g158g347s], SEQ ID NO:181 [EgD5S-36s156e], SEQ ID NO:183 [EgD5S-36s157g], SEQ ID NO:185 [EgD5S-36s158a], SEQ ID NO:187 [EgD5S-36s158g], SEQ ID NO:213 [EaD5S-35a158g], SEQ ID NO:215 [EaD5S-35a158s], SEQ ID NO:217 [EaD5S-35a159g], SEQ ID NO:255 [EgD5R-34g158g], SEQ ID NO:260 [EgD5R-34g158a], SEQ ID NO:271 [EaD5-35g159g], and SEQ ID NO:276 [EaD5-35g159a]. Thus, for example, the nucleotide sequence of the gene
30

encoding the mutant delta-5 desaturase polypeptide may be, for example, selected from the group consisting of: SEQ ID NOs:138, 140, 142, 144, 146, 148, 150, 152, 156, 180, 182, 184, 186, 212, 214, 216, 254, 259, 270 and 275.

5 Since naturally produced PUFAs in oleaginous yeast are limited to 18:2 fatty acids (i.e., LA), and less commonly, 18:3 fatty acids (i.e., ALA), the oleaginous yeast may be genetically engineered to express multiple enzymes necessary for long-chain PUFA biosynthesis (thereby enabling production of e.g., DPA_n-6, DPA and DHA), in addition to the mutant
10 delta-5 desaturases described herein.

Specifically, an oleaginous yeast is contemplated herein, wherein said yeast comprises:

- a) a first recombinant DNA construct comprising an isolated polynucleotide encoding a mutant delta-5 desaturase polypeptide,
15 operably linked to at least one regulatory sequence; and,
- b) at least one additional recombinant DNA construct comprising an isolated polynucleotide, operably linked to at least one regulatory sequence, encoding a polypeptide selected from the group consisting of: delta-4 desaturase, delta-6 desaturase, delta-9 desaturase, delta-12
20 desaturase, delta-15 desaturase, delta-17 desaturase, delta-8 desaturase, delta-9 elongase, C_{14/16} elongase, C_{16/18} elongase, C_{18/20} elongase and C_{20/22} elongase.

Other suitable microbial hosts include oleaginous bacteria, algae, euglenoids, stramenopiles, oomycetes and fungi. Within this broad
25 group of microbial hosts, of particular interest are microorganisms that synthesize omega-3/ omega-6 fatty acids, or those that can be genetically engineered for this purpose. Thus, for example, transformation of *Mortierella alpina* (which is commercially used for production of ARA) with any of the present delta-5 desaturase genes under the control of inducible
30 or regulated promoters could yield a transformant organism capable of synthesizing increased quantities of ARA. The method of transformation of *M. alpina* is described by Mackenzie et al. (*Appl. Environ. Microbiol.*, 66:4655 (2000)). Similarly, methods for transformation of

Thraustochytriales microorganisms (e.g., *Thraustochytrium*, *Schizochytrium*) are disclosed in U.S. Pat. 7,001,772.

The delta-5 desaturase genes and gene products described herein may also be produced in cells within heterologous oleaginous plants, which are commonly referred to as "oilseed" plants. Examples of oilseed plants include, but are not limited to: soybean (*Glycine* and *Soja* sp.), flax (*Linum* sp.), rapeseed (*Brassica* sp.), maize, cotton, safflower (*Carthamus* sp.) and sunflower (*Helianthus* sp.).

In one embodiment, this invention concerns a recombinant construct comprising any one of the delta-5 desaturase polynucleotides of the invention operably linked to at least one regulatory sequence suitable for expression in a plant.

The plant promoter chosen to drive expression of the delta-5 desaturase coding sequence is not important as long as it has sufficient transcriptional activity to accomplish the invention by expressing translatable mRNA for the desired nucleic acid fragments in the desired host tissue at the right time. Either heterologous or non-heterologous (i.e., endogenous) promoters can be used to practice the invention. For example, suitable promoters include, but are not limited to: the alpha-prime subunit of 13-conglycinin promoter, the Kunitz trypsin inhibitor 3 promoter, the annexin promoter (also known as the P34 promoter; Int'l. App. Pub. No. WO 2004/071178), the GlyI promoter, the 13 subunit of 13-conglycinin promoter, the P34/ Gly Bd m 30K promoter, the albumin promoter, the Leg A1 promoter and the Leg A2 promoter.

The promoter is then operably linked in a sense orientation using conventional means well known to those skilled in the art.

The recombinant construct may then be introduced into one or more plant cells of choice by methods well known to those of ordinary skill in the art (e.g., transfection, transformation and electroporation). The transformed plant cell is then cultured and regenerated under suitable conditions permitting expression of the long-chain PUFA, which is then optionally recovered and purified.

Either transient or stable expression of at least one desired long-chain PUFA in a plant cell, may be accomplished as is described above. Such PUFAs can also be expressed in seeds, plant parts obtained from transformed plants or oil obtained from seeds of transformed plants.

5 Plant parts include differentiated and undifferentiated tissues including, but not limited to: roots, stems, shoots, leaves, pollen, seeds, tumor tissue and various forms of cells and culture (e.g., single cells, protoplasts, embryos and callus tissue). The plant tissue may be in plant or in a plant organ, tissue or cell culture.

10 The term "plant organ" refers to plant tissue or a group of tissues that constitute a morphologically and functionally distinct part of a plant.

Thus, this invention also concerns a method for transforming a cell, comprising transforming a cell with a recombinant construct of the invention and selecting those cells transformed with the recombinant
15 construct, wherein: said recombinant construct comprises a nucleotide sequence encoding a mutant polypeptide having delta-5 desaturase activity, wherein the amino acid sequence of the mutant polypeptide comprises an amino acid motif as set forth in SEQ ID NO:34 [HxGx], wherein SEQ ID NO:34 [HxGx] is not identical to SEQ ID NO:7 [HPGG];
20 and, an amino acid motif as set forth in SEQ ID NO:1 [HxxxH], wherein SEQ ID NO:1 [HxxxH] is not identical to SEQ ID NO:8 [HDASH].

Also of interest is a method for producing a transformed plant cell with the mutant delta-5 desaturase polynucleotides of the instant invention and regenerating a plant from the transformed plant cell.

25 Methods for transforming dicots (primarily by use of *Agrobacterium tumefaciens*) and obtaining transgenic plants have been published, among others, for: cotton (U.S. Pat. No. 5,004,863; U.S. Pat. No. 5,159,135); soybean (U.S. Pat. No. 5,569,834; U.S. Pat. No. 5,416,011); *Brassica* (U.S. Pat. No. 5,463,174); peanut (Cheng et al., *Plant Cell Rep.*, 15:653-
30 657 (1996); McKently et al., *Plant Cell Rep.*, 14:699-703 (1995)); papaya (Ling, K. et al., *Bio/technology*, 9:752-758 (1991)); and pea (Grant et al., *Plant Cell Rep.*, 15:254-258 (1995)). For a review of other commonly used methods of plant transformation see Newell, C. A. (*Mol. Biotechnol.*,

16:53-65 (2000)). One of these methods of transformation uses *Agrobacterium rhizogenes* (Tepfler, M. and Casse-Delbart, F., *Microbiol. Sci.*, 4:24-28 (1987)). Transformation of soybeans using direct delivery of DNA has been published using PEG fusion (Int'l. App. Pub. No. WO 92/17598),
5 electroporation (Chowrira, G. M. et al., *Mol. Biotechnol.*, 3:17-23 (1995); Christou, P. et al., *Proc. Natl. Acad. Sci. Sci. USA*, 84:3962-3966 (1987)), microinjection, or particle bombardment (McCabe, D. E. et al., *Bio/Technology*, 6:923 (1988); Christou et al., *Plant Physiol.*, 87:671-674 (1988)).

10 There are a variety of methods for the regeneration of plants from plant tissue. The particular method of regeneration will depend on the starting plant tissue and the particular plant species to be regenerated. The regeneration, development and cultivation of plants from single plant protoplast transformants or from various transformed explants is well
15 known in the art (Weissbach and Weissbach, In: *Methods for Plant Molecular Biology*, (Eds.), Academic: San Diego, CA (1988)). This regeneration and growth process typically includes the steps of selection of transformed cells and culturing those individualized cells through the usual stages of embryonic development through the rooted plantlet stage.
20 Transgenic embryos and seeds are similarly regenerated. The resulting transgenic rooted shoots are thereafter planted in an appropriate plant growth medium such as soil. Preferably, the regenerated plants are self-pollinated to provide homozygous transgenic plants. Otherwise, pollen obtained from the regenerated plants is crossed to seed-grown plants of
25 agronomically important lines. Conversely, pollen from plants of these important lines is used to pollinate regenerated plants. A transgenic plant of the present invention containing a desired polypeptide is cultivated using methods well known to one skilled in the art.

 In one embodiment this invention concerns an oilseed plant
30 comprising:

- a) a first recombinant DNA construct comprising an isolated polynucleotide encoding a mutant polypeptide having delta-5

desaturase activity, operably linked to at least one regulatory sequence; and,

- b) at least one additional recombinant DNA construct comprising an isolated polynucleotide, operably linked to at least one regulatory sequence, encoding a polypeptide selected from the group consisting of: a delta-4 desaturase, a delta-5 desaturase, delta-6 desaturase, a delta-9 desaturase, a delta-12 desaturase, a delta-15 desaturase, a delta-17 desaturase, a delta-9 elongase, a C_{14/16} elongase, a C_{16/18} elongase, a C_{18/20} elongase and a C_{20/22} elongase.

Such additional desaturases and elongase are discussed in numerous references in patent and public literature (e.g., U.S. Pat. No. 6,075,183, No. 5,968,809, No. 6,136,574, No. 5,972,664, No. 6,051,754, No. 6,410,288, No. 7,932,077 and Int'l. App. Pub. No. WO 98/46763, No. WO 98/46764, No. WO 00/12720, No. WO 00/40705).

The choice of combination of cassettes used depends in part on the PUFA profile and/or desaturase/elongase profile of the oilseed plant cells to be transformed and the long-chain PUFA(s) which is to be expressed.

In another aspect, this invention concerns a method for making long-chain PUFAs in a plant cell comprising:

- a) transforming a cell with a recombinant construct of the invention; and,
b) selecting those transformed cells that make long-chain PUFAs.

In still another aspect, this invention concerns a method for producing at least one PUFA in a plant cell comprising:

- (a) transforming a plant cell with a first recombinant DNA construct comprising:
i. an isolated polynucleotide encoding a mutant polypeptide having delta-5 desaturase activity, operably linked to at least one regulatory sequence; and,
ii. at least one additional recombinant DNA construct comprising an isolated polynucleotide, operably linked to at least one regulatory sequence, encoding a polypeptide

selected from the group consisting of: a delta-4
desaturase, a delta-5 desaturase, delta-6 desaturase, a
delta-9 desaturase, a delta-12 desaturase, a delta-15
desaturase, a delta-17 desaturase, a delta-9 elongase, a
5 C_{14/16} elongase, a C_{16/18} elongase, a C_{18/20} elongase and a
C_{20/22} elongase;

(b) regenerating a plant from the transformed cell of step (a); and,
(c) selecting those seeds obtained from the plants of step (b)
having an altered level of PUFAs when compared to the level in
10 seeds obtained from a nontransformed plant.

In particularly preferred embodiments, the at least one additional
recombinant DNA construct encodes polypeptides having delta-9
elongase activity and delta-8 desaturase activity.

Irrespective of the host selected for expression of the mutant
15 delta-5 desaturases described herein, multiple transformants must be
screened in order to obtain a strain or plant line displaying the desired
expression level and pattern. For example, Juretzek et al. (*Yeast*, 18:97-
113 (2001)) note that the stability of an integrated DNA fragment in
Yarrowia lipolytica is dependent on the individual transformants, the
20 recipient strain and the targeting platform used. Such screening may be
accomplished by Southern analysis of DNA blots (Southern, *J. Mol. Biol.*,
98:503 (1975)), Northern analysis of mRNA expression (Kroczeck, *J.*
Chromatogr. Biomed. Appl., 618(1-2):133-145 (1993)), Western and/or
Elisa analyses of protein expression, phenotypic analysis or GC analysis
25 of the PUFA products.

Knowledge of the sequences of the present mutant delta-5
desaturases will be useful for manipulating omega-3 and/or omega-6 fatty
acid biosynthesis in various host cells. Methods for manipulating
biochemical pathways are well known to those skilled in the art and it is
30 expected that numerous manipulations will be possible to maximize
omega-3 and/or omega-6 fatty acid biosynthesis in oleaginous yeasts,
particularly in *Yarrowia lipolytica*, and oilseed plants. This manipulation
may require metabolic engineering directly within the PUFA biosynthetic

pathway or additional manipulation of pathways that contribute carbon to the PUFA biosynthetic pathway. Methods useful for up-regulating desirable biochemical pathways and down-regulating undesirable biochemical pathways are well known to those skilled in the art.

5 For example, biochemical pathways competing with the omega-3 and/or omega-6 fatty acid biosynthetic pathways for energy or carbon, or native PUFA biosynthetic pathway enzymes that interfere with production of a particular PUFA end-product, may be eliminated by gene disruption or down-regulated by other means, e.g., antisense mRNA.

10 Detailed discussion of manipulations within the PUFA biosynthetic pathway as a means to increase ARA, EPA or DHA and associated techniques thereof are presented in U.S. Pat. 7,588,931, U.S. Pat. 7,932,077, U.S. Pat. Appl. Pub. No. 2009-0993543-A1, and U.S. Pat. 7,550,286, respectively, as are desirable manipulations in the TAG
15 biosynthetic pathway and the TAG degradation pathway (and associated techniques thereof).

It may be useful to modulate the expression of the fatty acid biosynthetic pathway by any one of the strategies described above. For example, provided herein are methods whereby genes encoding key
20 enzymes in the delta-9 elongase/ delta-8 desaturase biosynthetic pathway and delta-6 desaturase/ delta-6 elongase biosynthetic pathway are introduced into oleaginous yeasts or oilseed plants for the production of omega-3 and/or omega-6 fatty acids. It will be particularly useful to express the present mutant delta-5 desaturase genes in oleaginous
25 yeasts or oilseed plants that do not naturally possess omega-3 and/or omega-6 fatty acid biosynthetic pathways and coordinate the expression of these genes, to maximize production of preferred PUFA products using various means for metabolic engineering of the host organism.

The transformed microbial host cell is grown under conditions that
30 optimize expression of chimeric genes (e.g., desaturase, elongase) and produce the greatest and most economical yield of desired PUFAs. In general, media conditions that may be optimized include the type and amount of carbon source, the type and amount of nitrogen source, the

carbon-to-nitrogen ratio, the amount of different mineral ions, the oxygen level, growth temperature, pH, length of the biomass production phase, length of the oil accumulation phase and the time and method of cell harvest. Microorganisms of interest, such as oleaginous yeast (e.g.,
5 *Yarrowia lipolytica*), are generally grown in a complex medium such as yeast extract-peptone-dextrose broth ["YPD"] or a defined minimal media that lacks a component necessary for growth and thereby forces selection of the desired expression cassettes (e.g., Yeast Nitrogen Base (DIFCO Laboratories, Detroit, MI)).

10 Fermentation media for the methods and host cells described herein must contain a suitable carbon source such as are taught in U.S. Pat. 7,238,482 and U.S. Pat. Pub. No. 2011-0059204-A1. Although it is contemplated that the source of carbon utilized in the methods herein may encompass a wide variety of carbon-containing sources, preferred carbon
15 sources are sugars (e.g., glucose, invert sucrose, fructose and combinations of thereof), glycerols, and/or fatty acids.

Nitrogen may be supplied from an inorganic (e.g., $(\text{NH}_4)_2\text{SO}_4$) or organic (e.g., urea or glutamate or "yeast extract") source. In addition to appropriate carbon and nitrogen sources, the fermentation media must
20 also contain suitable minerals, salts, cofactors, buffers, vitamins and other components known to those skilled in the art suitable for the growth of the oleaginous host and promotion of the enzymatic pathways necessary for PUFA production. Particular attention is given to several metal ions, such as Fe^{+2} , Cu^{+2} , Mn^{+2} , Co^{+2} , Zn^{+2} and Mg^{+2} , that promote synthesis of
25 lipids and PUFAs (Nakahara, T. et al., *Ind. Appl. Single Cell Oils*, D. J. Kyle and R. Colin, eds. pp 61-97 (1992)).

Preferred growth media for the methods and host cells described herein are common commercially prepared media, such as Yeast Nitrogen Base (DIFCO Laboratories, Detroit, MI). Other defined or synthetic growth
30 media may also be used and the appropriate medium for growth of the transformant host cells will be known by one skilled in the art of microbiology or fermentation science. A suitable pH range for the fermentation is typically between about pH 4.0 to pH 8.0, wherein pH 5.5

to pH 7.5 is preferred as the range for the initial growth conditions. The fermentation may be conducted under aerobic or anaerobic conditions, wherein microaerobic conditions are preferred.

Typically, accumulation of high levels of PUFAs in oleaginous yeast
5 cells requires a two-stage process, since the metabolic state must be “balanced” between growth and synthesis/storage of fats. Thus, most preferably, a two-stage fermentation process is necessary for the production of PUFAs in oleaginous yeast (e.g., *Yarrowia lipolytica*). This approach is described in U.S. Pat. 7,238,482, as are various suitable
10 fermentation process designs (i.e., batch, fed-batch and continuous) and considerations during growth.

PUFAs may be found in host microorganisms as free fatty acids or in esterified forms such as acylglycerols, phospholipids, sulfolipids or glycolipids, and may be extracted from the host cells through a variety of
15 means well-known in the art. One review of extraction techniques, quality analysis and acceptability standards for yeast lipids is that of Z. Jacobs (*Critical Reviews in Biotechnology*, 12(5/6):463-491 (1992)). A brief review of downstream processing is also available by A. Singh and O. Ward (*Adv. Appl. Microbiol.*, 45:271-312 (1997)).

20 In general, means for the purification of PUFAs may include extraction (e.g., U.S. Pat. 6,797,303 and U.S. Pat. 5,648,564) with organic solvents, sonication, supercritical fluid extraction (e.g., using carbon dioxide), saponification and physical means such as presses, or combinations thereof. See U.S. Pat. 7,238,482 for additional details.

25 There are a plethora of food and feed products incorporating omega-3 and/or omega-6 fatty acids, particularly e.g., ALA, GLA, ARA, EPA, DPA and DHA. It is contemplated that the microbial or plant biomass comprising long-chain PUFAs, partially purified biomass comprising PUFAs, purified oil comprising PUFAs, and/or purified PUFAs
30 will function in food and feed products to impart the health benefits of current formulations. More specifically, oils containing omega-3 and/or omega-6 fatty acids will be suitable for use in a variety of food and feed products including, but not limited to: food analogs, meat products, cereal

products, baked foods, snack foods and dairy products (see e.g., U.S. Pat. 7,588,931).

The present compositions may be used in formulations to impart health benefit in medical foods including medical nutritionals, dietary
5 supplements, infant formula and pharmaceuticals. One of skill in the art of food processing and food formulation will understand how the amount and composition of the present oils may be added to the food or feed product. Such an amount will be referred to herein as an "effective" amount and will depend on the food or feed product, the diet that the product is intended to
10 supplement or the medical condition that the medical food or medical nutritional is intended to correct or treat.

The present compositions may also be used to improve animal's health; they may be used in animal food, feed and pharmaceuticals.

15 EXAMPLES

The present invention is further described in the following Examples, which illustrate reductions to practice of the invention but do not completely define all of its possible variations.

GENERAL METHODS

20 Standard recombinant DNA and molecular cloning techniques used in the Examples are well known in the art and are described by:
1) Sambrook et al.; 2) Silhavy et al.; and, 3) Ausubel et al.

Materials and methods suitable for the maintenance and growth of microbial cultures are well known in the art. Techniques suitable for use in
25 the following examples may be found as set out in Manual of Methods for General Bacteriology (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, Eds), American Society for Microbiology: Washington, D.C. (1994)); or by Thomas D. Brock in Biotechnology: A Textbook of Industrial
30 Microbiology, 2nd ed., Sinauer Associates: Sunderland, MA (1989). All reagents, restriction enzymes and materials used for the growth and maintenance of microbial cells were obtained from Aldrich Chemicals (Milwaukee, WI), DIFCO Laboratories (Detroit, MI), GIBCO/BRL

(Gaithersburg, MD), or Sigma Chemical Company (St. Louis, MO), unless otherwise specified. *E. coli* strains were typically grown at 37 °C on Luria Bertani ["LB"] plates.

General molecular cloning was performed according to standard
5 methods (Sambrook et al., *supra*). DNA sequence was generated on an
ABI Automatic sequencer using dye terminator technology (U.S. Pat.
5,366,860; EP 272,007) using a combination of vector and insert-specific
primers. Sequence editing was performed in Sequencher (Gene Codes
Corporation, Ann Arbor, MI). All sequences represent coverage at least
10 two times in both directions. Comparisons of genetic sequences were
accomplished using DNASTAR software (DNASTAR Inc., Madison, WI).

The meaning of abbreviations is as follows: "sec" means second(s),
"min" means minute(s), "h" or "hr" means hour(s), "d" means day(s), "μL"
means microliter(s), "mL" means milliliter(s), "L" means liter(s), "μM" means
15 micromolar, "mM" means millimolar, "M" means molar, "mmol" means
millimole(s), "μmole" mean micromole(s), "g" means gram(s), "μg" means
microgram(s), "ng" means nanogram(s), "U" means unit(s), "bp" means base
pair(s) and "kB" means kilobase(s).

Nomenclature For Expression Cassettes:

The structure of an expression cassette will be represented by a simple notation system of “X::Y::Z”, wherein X describes the promoter fragment, Y describes the gene fragment, and Z describes the terminator fragment, which are all operably linked to one another.

Transformation And Cultivation Of *Yarrowia lipolytica*:

Y. lipolytica strains with ATCC Accession Nos. #20362, #76982 and #90812 were purchased from the American Type Culture Collection (Rockville, MD). *Y. lipolytica* strains were typically grown at 28-30 °C in several media, according to the recipes shown below. Agar plates were prepared as required by addition of 20 g/L agar to each liquid media, according to standard methodology.

YPD agar medium (per liter): 10 g of yeast extract [Difco]; 20 g of Bacto peptone [Difco]; and 20 g of glucose.

Basic Minimal Media (MM) (per liter): 20 g glucose; 1.7 g yeast nitrogen base without amino acids; 1.0 g proline; and pH 6.1 (not adjusted).

Minimal Media + Leucine (MM+leucine or MMLeu) (per liter):

Prepare MM media as above and add 0.1 g leucine.

High Glucose Media (HGM) (per liter): 80 glucose; 2.58 g KH₂PO₄; and 5.36 g K₂HPO₄; pH 7.5 (do not need to adjust).

Transformation of *Y. lipolytica* was performed as described in U.S. Pat. Appl. Pub. No. 2009-0093543-A1, hereby incorporated herein by reference.

Fatty Acid Analysis of *Yarrowia lipolytica*:

For fatty acid analysis, cells were collected by centrifugation and lipids were extracted as described in Bligh, E. G. & Dyer, W. J. (*Can. J. Biochem. Physiol.*, 37:911-917 (1959)). FAMES were prepared by transesterification of the lipid extract with sodium methoxide (Roughan, G. and Nishida I., *Arch Biochem Biophys.*, 276(1):38-46 (1990)) and subsequently analyzed with a Hewlett-Packard 6890 GC fitted with a 30 m X 0.25 mm (i.d.) HP-INNOWAX (Hewlett-Packard) column. The oven temperature was from 170 °C (25 min hold) to 185 °C at 3.5 °C/min.

For direct base transesterification, *Yarrowia* culture (3 mL) was harvested, washed once in distilled water, and dried under vacuum in a Speed-Vac for 5-10 min. Sodium methoxide (100 μ L of 1%) was added to the sample, and then the sample was vortexed and rocked for 20 min.

- 5 After adding 3 drops of 1 M NaCl and 400 μ L hexane, the sample was vortexed and spun. The upper layer was removed and analyzed by GC as described above.

Alternately, a modification of the base-catalysed transesterification method described in *Lipid Analysis*, William W. Christie, 2003 was used
10 for routine analysis of the broth samples from either fermentation or flask samples. Specifically, broth samples were rapidly thawed in room temperature water, then weighed (to 0.1 mg) into a tarred 2 mL microcentrifuge tube with a 0.22 μ m Corning[®] Costar[®] Spin-X[®] centrifuge tube filter (Cat. No. 8161). Sample (75 - 800 μ L) was used, depending on
15 the previously determined DCW. Using an Eppendorf 5430 centrifuge, samples are centrifuged for 5-7 min at 14,000 rpm or as long as necessary to remove the broth. The filter was removed, liquid was drained, and ~500 μ L of deionized water was added to the filter to wash the sample. After centrifugation to remove the water, the filter was again removed, the liquid
20 drained and the filter re-inserted. The tube was then re-inserted into the centrifuge, this time with the top open, for ~3-5 min to dry. The filter was then cut approximately 1/2 way up the tube and inserted into a fresh 2 mL round bottom Eppendorf tube (Cat. No. 22 36 335-2). The filter was pressed to the bottom of the tube with an appropriate tool that only
25 touches the rim of the cut filter container and not the sample or filter material. A known amount of C15:0 TAG (*supra*) in toluene was added and 500 μ L of freshly made 1% sodium methoxide in methanol solution. The sample pellet was firmly broken up with the appropriate tool and the tubes were closed and placed in a 50 °C heat block (VWR Cat. No. 12621-
30 088) for 30 min. The tubes were then allowed to cool for at least 5 min. Then, 400 μ L of hexane and 500 μ L of a 1 M NaCl in water solution were added, the tubes were vortexed for 2x 6 sec and centrifuged for 1 min.

Approximately 150 µl of the top (organic) layer was placed into a GC vial with an insert and analyzed by GC.

Construction Of *Yarrowia lipolytica* Strain Y4036U

Y. lipolytica strain Y4036U (*Leu*⁻, *Ura*⁻), described in Int'l. App. Pub. No. WO 2008/073367, was used as the host in Examples 3-5, 7-8 and 10, *infra*.

Strain Y4036U was derived from *Y. lipolytica* ATCC #20362 via construction of strain Y2224 (*Ura*3⁻, a FOA resistant mutant from an autonomous mutation of the *Ura*3 gene), strain Y4001 (producing 17% EDA with a *Leu*⁻ phenotype), strain Y4001U1 (*Leu*⁻ and *Ura*⁻) and strain Y4036 (producing 18% DGLA with a *Leu*⁻ phenotype).

The final genotype of strain Y4036U with respect to wild type *Y. lipolytica* ATCC #20362 was *Ura*3⁻, YAT1::ME3S::Pex16, EXP1::EgD9eS::Lip1, FBAINm::EgD9eS::Lip2, GPAT::EgD9e::Lip2, FBAINm::EgD8M::Pex20, EXP1::EgD8M::Pex16, GPD::FmD12::Pex20, YAT1::FmD12::OCT (wherein FmD12 is a *Fusarium moniliforme* delta-12 desaturase gene [U.S. Pat. 7,504,259]; ME3S is a codon-optimized C_{16/18} elongase gene, derived from *Mortierella alpina* [U.S. Pat. 7,470,532]; EgD9e is a *Euglena gracilis* delta-9 elongase gene [U.S. Pat. 7,645,604]; EgD9eS is a codon-optimized delta-9 elongase gene, derived from *E. gracilis* [U.S. Pat. 7,645,604]; and, EgD8M is a synthetic mutant delta-8 desaturase [U.S. Pat. 7,709,239], derived from *E. gracilis* [U.S. Pat. 7,256,033]).

EXAMPLE 1

Development Of A Topological Model For The *Euglena gracilis* Delta-5 Desaturase ["EgD5"]

In order to better predict the possible importance of the HDASH motif within the delta-5 desaturase from *E. gracilis* ["EgD5"; U.S. Pat. 7,678,560], a topological model (FIG. 2) was developed based on the logic and analyses below.

First, an analysis of transmembrane domains of EgD5 was performed using the TMHMM program ("Prediction of transmembrane helices in proteins"; TMHMM Server v. 2.0, Center for Biological Sequence

Analysis, BioCentrum-DTU, Technical University of Denmark, DK-2800 Lyngby, Denmark). The prediction indicated six membrane-spanning helices (amino acid residues 103-125, 130-152, 165-187, 234-256, 280-302 and 306-328), with both the N- and C- termini located on the cytoplasmic side of the membrane.

A similar TMHMM analysis was performed using the following homologs of EgD5: GenBank Accession No. AAT09160 [*Nitzschia closterium f. minutissima*], GenBank Accession No. BAG71007 [*Oblongichytrium sp.* SEK 347], and GenBank Accession No. AAL92562 [*Phaeodactylum tricornutum*]. For each homolog, four transmembrane segments were predicted, which corresponded to the first two and the last two transmembrane domains predicted for EgD5.

The membrane-bound fatty acid desaturases belong to a superfamily of membrane di-iron proteins that feature three histidine-rich (His-rich) motifs: $HX_{(3-4)}H$ (SEQ ID NOs:1 and 2), $HX_{(2-3)}HH$ (SEQ ID NOs:3 and 4) and $(H/Q)X_{(2-3)}HH$ (SEQ ID NOs:5 and 6). These His-rich residues have been predicted to be located in the cytoplasmic face of the membrane and have been shown to be important for enzyme activity (Shanklin, J. et al., *Biochemistry*, 33:12787-12794 (1994); Shanklin, J., and Cahoon, E. B., *Annu. Rev. Plant Physiol. Plant Mol. Biol.*, 49:611-641 (1998)). Within EgD5, the first His-rich region (HDASH [SEQ ID NO:8]) is located before the third predicted transmembrane segment spanning amino acid residues 165-187, while the second His-rich region (HIMRHH [SEQ ID NO:4]) is located after this transmembrane segment. If the third transmembrane segment indeed spans the membrane, then the second His-rich region would be located in the periplasmic space---thus preventing its participation in the iron-active site. As a result, it was hypothesized that neither the third transmembrane segment (amino acid residues 165-187) nor the fourth transmembrane segment (amino acid residues 234-256) were membrane spanning. This was consistent with the TMHMM predictions for the three delta-5 desaturase homologs (i.e., GenBank Accession No. AAT09160, No. BAG71007 and No. AAL92562).

Because the delta-5 desaturase substrate (i.e., DGLA, ETA) is highly hydrophobic, it was assumed to likely partition in the lipid bilayer. Similarly, it was assumed that the active site assembled from the three His-rich clusters would likely occur at or very near the membrane surface. Thus, the third and fourth transmembrane segments found between residues 165-187 and 234-256, respectively, that were originally predicted by TMHMM to span through the membrane were instead predicted to lie near the membrane surface to ensure that the active site was positioned close to the membrane. The transmembrane regions at amino acid residues 103-125, 130-152, 280-302 and 306-328 remained as predicted by TMHMM.

Thus, the final topology model predicted for EgD5 is shown in FIG. 2. The vertical cylinders indicate membrane spanning domains, while the horizontal cylinders indicate the two highly hydrophobic regions that are not membrane spanning, but lie near the inner membrane surface. The circles correspond to the His residues presumably involved in the active site. The locations of the HPGG (SEQ ID NO:7) motif and HDASH (SEQ ID NO:8) motif are also identified. Finally, "IN" corresponds with the cytoplasmic space while "OUT" corresponds with the periplasmic space.

EXAMPLE 2

Determination Of Natural HDASH (SEQ ID NO:8) Motif Variation In Desaturases

Selected desaturase protein sequences were examined to determine whether natural variation occurred within the HDASH (SEQ ID NO:8) motif. Specifically, the desaturase proteins included the *Euglena gracilis* delta-5 desaturase ["EgD5"; U.S. Pat. 7,678,560], the *Mortierella alpina* delta-5 desaturase ["MaD5"; U.S. Pat. 5,972,664], and BLAST hits to other known delta-5 desaturases and/or delta-6 desaturases that are known to be closely related to delta-5 desaturases. The selected sequences were aligned using the MegAlign™ program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI), and the HDASH motif (or variant thereof) is summarized below in Table 4.

Table 4. Natural Variants Of The HDASH (SEQ ID NO:8) Motif

GenBank Accession No. or Patent Number	Organism	Variant HDASH Motif	SEQ ID NO
CBL59059.1 (gi_295016816)	<i>Mortierella alpina</i>	HDASH	8
CAL49887.1 (gi_116001271)	<i>Phytophthora sojae</i>	HDASH	8
CBL59057.1 (gi_295016812)	<i>Physcomitrella patens</i>	HDgnH	235
CAT16395.1 (gi_218101624)	<i>Euglena gracilis</i>	HDASH	8
CBL59055.1 (gi_295016808)	<i>Phaeodactylum tricornutum</i>	HDAnH	236
CBL59102.1 (gi_295016902)	<i>Thalassiosira pseudonana</i>	HDAnH	236
CAM55833.1 (gi_126633754)	<i>Thalassiosira pseudonana</i>	HDAnH	236
AAL13311.1 (gi_16033740)	<i>Pythium irregulare</i>	HDsSH	16
CAD53323.1 (gi_23894018)	<i>Phytophthora megasperma</i>	HDASH	8
BAD95486.1 (gi_62484905)	<i>Mortierella alpina</i>	HDASH	8
NP_501751.1 (gi_17542396)	<i>Caenorhabditis elegans</i>	HefaH	237
CAE65324.1 (gi_39585564)	<i>Caenorhabditis briggsae</i>	HeftH	238
AAM09687.1 (gi_20069123)	<i>Thraustochytrium</i> sp. ATCC 21685	HemgH	239
CAJ07076.1 (gi_68124314)	<i>Leishmania major</i> strain Friedlin	HeAgH	240
AAH26831.1 (gi_20070924)	<i>Mus musculus</i>	HDfgH	241
NP_571720.2 (gi_42476248)	<i>Danio rerio</i>	HDfgH	241
AAL82631.2 (gi_55846441)	<i>Salmo salar</i>	HDygH	242
AAL92562.1 (gi_19879687)	<i>Phaeodactylum tricornutum</i>	HDAnH	236
AAX14502.1 (gi_60172920)	<i>Thalassiosira pseudonana</i>	HDAnH	236
AAT09160.1 (gi_47028617)	<i>Nitzschia closterium</i> f. minutissima	HDAnH	236
AAT85663.1 (gi_50882495)	<i>Marchantia polymorpha</i>	HDgnH	235
XP_638329.1 (gi_66809213)	<i>Dictyostelium discoideum</i> AX4	HDsch	243
XP_640331.1 (gi_66812304)	<i>Dictyostelium discoideum</i> AX4	HDAcH	244
U.S. Pat. 7,678,560	<i>Euglena gracilis</i>	HDASH	8
U.S. Pat. 5,972,664	<i>Mortierella alpina</i>	HDASH	8

Based on the above analysis, it appeared that the Asp ["D"] residue of the HDASH (SEQ ID NO:8) motif could possibly be substituted with a Glu residue ["E"], the Ala ["A"] residue could possibly be substituted with a Gly ["G"], Ser ["S"], Phe ["F"], Tyr ["Y"] or Met ["M"] residue and/or the Ser ["S"] residue of the HDASH (SEQ ID NO:8) motif could possibly be substituted with a Cys ["C"], Asn ["N"], Gly ["G"], Ala ["A"] or Thr ["T"] residue.

EXAMPLE 3

Sequence Of Wild-Type *Euglena gracilis* Delta-5 Desaturase ["EgD5"]

U.S. Pat. 7,678,560 describes the isolation and cloning of a delta-5 desaturase from *E. gracilis* (i.e., EgD5, SEQ ID NO:21). Recently, more

detailed analyses of the cloned EgD5 therein have identified one more variant “wildtype” *E. gracilis* delta-5 desaturase sequence, designated as EgD5R and set forth herein as SEQ ID NO:25, that was previously not appreciated. Instead of a Ser amino acid residue at position 347 of EgD5
5 as described in U.S. Pat. 7,678,560, EgD5R (SEQ ID NO:25) comprises an Arg residue at position 347. It is hypothesized that this discrepancy arose as a result of PCR or cDNA generation methodologies.

Specifically, EgD5 (SEQ ID NO:20, corresponding to SEQ ID NO:1 of U.S. Pat. 7,678,560) was obtained using 5'- and 3'-RACE techniques
10 with double-stranded cDNA of *E. gracilis* as the template (Examples 4-5 of U.S. Pat. 7,678,560). Then, the ORF encoding the *E. gracilis* delta-5 desaturase was amplified by PCR using *E. gracilis* cDNA as the template, purified, subjected to restriction digestion and then directionally ligated into an appropriate vector to yield pDMW367 (Example 6 of U.S. Pat.
15 7,678,560). The sequence of pDMW367 was provided as SEQ ID NO:23 in U.S. Pat. 7,678,560 (corresponding to SEQ ID NO:38 herein). Although it was reported in U.S. Pat. 7,678,560 that pDMW367 comprised a chimeric FBAIN::EgD5::Pex20 gene, it is now appreciated that the delta-5 desaturase sequence within this chimeric gene was actually the nucleotide
20 sequence of EgD5R (SEQ ID NO:24).

An alignment of EgD5 (SEQ ID NO:20) and EgD5R (SEQ ID NO:24) (FIGs. 3A, 3B, 3C and 3D) shows four nucleotide differences, wherein the mutations with respect to SEQ ID NO:20 are G819A, T948C, C1041A and G1349A. The G1349A mutation is attributed to the specific
25 primer sequence utilized to amplify EgD5 for cloning into pDMW367. Alignment of the translated products of EgD5 (SEQ ID NO:21) and EgD5R (i.e., SEQ ID NO:25) reveals a single amino acid difference, i.e., the S347R mutation.

U.S. Pat. 7,678,560, Example 9 also describes the creation of a
30 synthetic delta-5 desaturase derived from EgD5 and codon-optimized for expression in *Yarrowia lipolytica* (i.e., EgD5S; SEQ ID NOs:22 and 23). Codon-optimization of EgD5 resulted in modification of 196 bp of the 1350 bp coding region (14.5%) and optimization of 189 codons of the total 449

codons (42%). The protein sequence encoded by the codon-optimized EgD5S gene (i.e., SEQ ID NO:23) was identical to that of the wildtype protein sequence (i.e., SEQ ID NO:21), wherein the amino acid at 347 position is Ser.

5

EXAMPLE 4

Generation Of Construct pDMW367-M4, Comprising Wild-Type EgD5R With Four Restriction Endonuclease Sites Eliminated ["EgD5R*"]

The present Example describes the construction of plasmid pDMW367-M4, comprising a chimeric FBAIN::EgD5R*:Pex20 gene.

10 EgD5R* (SEQ ID NO:26) was a modified variant of wildtype EgD5R (SEQ ID NO:24) created to facilitate subsequent cloning procedures, wherein the modifications resulted in removal of four restriction enzymes sites (i.e., *EcoRI*, *HindIII*, *BglII* and *NcoI*) from the wildtype EgD5R coding region. The amino acid sequences of EgD5R (SEQ ID NO:25) and EgD5R* (SEQ
15 ID NO:27) are identical.

Specifically, plasmid pDMW367-M4 (SEQ ID NO:39; FIG. 4C) was derived from pDMW367 (SEQ ID NO:38, Example 3; FIG. 4A). The native *EcoRI* *HindIII*, *BglII* and *NcoI* restriction enzymes sites were sequentially eliminated from the EgD5R coding region to generate pDMW367-M4.

20 First, the *EcoRI* and *BglII* sites were eliminated by *in vitro* mutagenesis using pDMW367 (SEQ ID NO:38) as template, and two pairs of oligonucleotides as primers. Primer pair YL813 (SEQ ID NO:40) and YL814 (SEQ ID NO:41) enabled mutation of the *EcoI* site, while primer pair YL815 (SEQ ID NO:42) and YL816 (SEQ ID NO:43) enabled mutation
25 of the *BglII* site. These reactions generated construct pDMW367-M2 (FIG. 4B; SEQ ID NO:44). Sequence analysis confirmed that the amino acid sequence of the variant EgD5R in pDMW367-M2 was identical to the amino acid sequence of EgD5R in pDMW367.

Then, the *HindIII* and *NcoI* sites were eliminated by *in vitro*
30 mutagenesis using pDMW367-M2 as template, and two pairs of oligonucleotides as primers. Primer pair YL829 (SEQ ID NO:45) and YL830 (SEQ ID NO:46) enabled mutation of the *HindIII* site, while primer pair YL831 (SEQ ID NO:47) and YL832 (SEQ ID NO:48) enabled mutation

of the *Nco*I site. This resulted in generation of pDMW367-M4. Again, sequence analysis confirmed that the amino acid sequence of the variant EgD5 (i.e., EgD5R*) in pDMW367-M4 was identical to the amino acid sequence of EgD5R in pDMW367.

5 For subsequent examples, reference to the wildtype EgD5 will effectively include reference to EgD5R (SEQ ID NOs:24 and 25) and EgD5R* (SEQ ID NOs:26 and 27), unless otherwise specified.

EXAMPLE 5

Identification Of HDxSH (SEQ ID NO:36) Mutations That Result In Similar 10 Delta-5 Desaturase Activity To The Delta-5 Desaturase Activity Of EgD5R*

The HDASH (SEQ ID NO:8) motif spans from amino acid residues 155 to 159 of EgD5R* (SEQ ID NO:27). Single amino acid mutations were carried out using pDMW367-M4 (Example 4) as the template and 19 pairs
15 of oligonucleotides (SEQ ID NOs:49-86; Table 5, *infra*) as primers to individually mutate the Ala residue of the HDASH (SEQ ID NO:8) motif of EgD5R* by site-directed mutagenesis (QuickChange Kit, Stratagene, CA), thereby generating all amino acid substitutions possible (i.e., HDxSH [SEQ ID NO:36] mutants). Plasmids from each mutation were transformed into
20 *E. coli* XL2Blue cells. Three colonies from each of the 19 transformations were picked and grown individually in liquid media at 37 °C overnight. Plasmids (i.e., 57 total) were isolated from these cultures and sequenced individually to confirm the mutations.

The wild type pDMW367-M4 plasmid and the isolated mutant
25 plasmids were transformed into *Y. lipolytica* strain Y4036U1 individually, as described in the General Methods. The transformants were selected on MMLeu plates. After 2 days growth at 30 °C, three transformants from each transformation reaction were streaked out onto new MMLeu plates and incubated for an additional 2 days at 30 °C. The colonies were then
30 used to inoculate 3 mL of MMLeu in a 24 well Qiagen block. The blocks were incubated in a 30 °C incubator shaking at 200 rpm. After the cultures were incubated for 2 days, the blocks were centrifuged, the supernatant was removed and 3 mL of HGM was added. The blocks were placed back

The delta-5 desaturase activity (average of 3 transformants) attributed to each mutant HDxSH (SEQ ID NO:36) motif is summarized below in Table 5. Transformants comprising mutant pDMW367-M4 constructs, wherein the mutant constructs comprise EgD5R* mutants, are designated according to the amino acid substitution that occurred for the Ala residue at position 157 within EgD5R* (i.e., transformant pDMW367M4-157c comprises a mutant delta-5 desaturase designated as EgD5R*-157c, and having a Cys for Ala substitution at position 157, thereby yielding a HDcSH [SEQ ID NO:277] motif; transformant pDMW367M4-157g comprises a mutant delta-5 desaturase designated as EgD5R*-157g, and having a Gly for Ala substitution, thereby yielding a HDgSH [SEQ ID NO:15] motif, etc.). The conversion efficiency ("Avg. Conv. Effic.") was measured according to the following formula:
$$\left(\frac{[\text{product}]}{[\text{substrate} + \text{product}]}\right) \times 100$$
 where 'product' includes the immediate product and all products in the pathway derived from it. Results are compared to that of the wildtype EgD5R* (SEQ ID NO:26) within plasmid pDMW367-M4, wherein GC analysis determined 10.8% DGLA and 3.6% ARA of total lipids were produced by the transformants (i.e., average conversion efficiency was 24.8%).

25 Table 5. Delta-5 Desaturase Activity In EgD5R And HDxSH
(SEQ ID NO:36) Motif Mutants

Y4036U1 Transformant *	SEQ ID NOs Of Primers	Sequence of Mutant HDASH Motif	Avg. Conv. Effic.	Percent Activity **
pDMW367-M4	--	HDASH (SEQ ID NO:8)	24.8%	100
pDMW367M4-157c	49 and 50	HDcSH (SEQ ID NO:277)	10.7%	43.1%
pDMW367M4-157d	51 and 52	HDdSH (SEQ ID NO:278)	1.0%	4.0%
pDMW367M4-157e	53 and 54	HDeSH	0.9%	3.6%

		(SEQ ID NO:279)		
pDMW367M4-157f	55 and 56	HDfSH (SEQ ID NO:280)	1.0%	4.0%
pDMW367M4-157g	57 and 58	HDgSH (SEQ ID NO:15)	23.8%	96%
pDMW367M4-157h	59 and 60	HDhSH (SEQ ID NO:281)	1.0%	4.0%
pDMW367M4-157i	61 and 62	HDiSH (SEQ ID NO:282)	0.9%	3.6%
pDMW367M4-157k	63 and 64	HDkSH (SEQ ID NO:283)	1.0%	4.0%
pDMW367M4-157l	65 and 66	HDlSH (SEQ ID NO:284)	1.1%	4.4%
pDMW367M4-157m	67 and 68	HDmSH (SEQ ID NO:285)	1.0%	4.0%
pDMW367M4-157n	69 and 70	HDnSH (SEQ ID NO:286)	1.1%	4.4%
pDMW367M4-157p	71 and 72	HDpSH (SEQ ID NO:287)	2.3%	9.3%
pDMW367M4-157q	73 and 74	HDqSH (SEQ ID NO:288)	0.6%	2.4%
pDMW367M4-157r	75 and 76	HDrSH (SEQ ID NO:289)	0.8%	3.2%
pDMW367M4-157s	77 and 78	HDsSH (SEQ ID NO:16)	23.3%	94%
pDMW367M4-157t	79 and 80	HDtSH (SEQ ID NO:290)	1.0%	4.0%
pDMW367M4-157v	81 and 82	HDvSH (SEQ ID NO:291)	0.3%	1.2%
pDMW367M4-157w	83 and 84	HDwSH (SEQ ID NO:292)	0.9%	3.6%
pDMW367M4-157y	85 and 86	HDySH (SEQ ID NO:293)	0.7%	2.8%

* Each EgD5R* gene (mutant or wildtype) was expressed within pDMW367-M4.

** Percent Activity is with respect to EgD5R*.

Based on the above, it is clear that the Ala residue within the

5 HDASH (SEQ ID NO:8) motif can be substituted with either Gly or Ser

without substantially affecting the delta-5 desaturase activity of EgD5R*.

Specifically, EgD5R*-157g (SEQ ID NO:87) in pDMW367M4-157g

transformants was able to convert DGLA to ARA with 23.8% conversion

efficiency, while EgD5R*-157s (SEQ ID NO:88) in pDMW367M4-157s

10 transformants was able to convert DGLA to ARA with 23.3% conversion

efficiency.

EXAMPLE 6

Identification Of HDAxH (SEQ ID NO:37) Mutations That Result In Similar Delta-5 Desaturase Activity To The Delta-5 Desaturase Activity Of EgD5R*

5 Single amino acid mutations were carried out using pDMW367-M4
(Example 4) as the template and 19 pairs of oligonucleotides (SEQ ID
NOs:89-126; Table 6, *infra*) as primers to individually mutate the Ser
residue of the HDASH (SEQ ID NO:8) motif of EgD5R* (SEQ ID NO:27)
by site-directed mutagenesis (QuickChange Kit, Stratagene, CA), thereby
10 generating all amino acid substitutions possible (i.e., HDAxH [SEQ ID
NO:37] mutants). Following mutagenesis, plasmids were transformed into
Y. lipolytica Y4036U1, transformants were selected and grown in MMLeu
and HGM, and FAMES were prepared and analyzed by GC, as described
in Example 5.

15 The delta-5 desaturase activity (average of 3 transformants)
attributed to each mutation within the HDASH (SEQ ID NO:8) motif is
summarized below in Table 6. Transformants comprising mutant
pDMW367-M4 constructs, wherein the mutant constructs comprise
EgD5R* mutants, are designated according to the amino acid substitution
20 that occurred for the Ser residue at position 158 within EgD5R* (i.e.,
transformant pDMW367M4-158a comprises a mutant delta-5 desaturase
designated as EgD5R*-158a, and having an Ala for Ser substitution at
position 158, thereby yielding a HDAaH [SEQ ID NO:17] motif;
transformant pDMW367M4-158r comprises a mutant delta-5 desaturase
25 designated as EgD5R*-158r, and having an Arg for Ser substitution,
thereby yielding a HDArH [SEQ ID NO:306] motif, etc.). Conversion
efficiency was measured according to the formula described in Example 5.
Results are compared to that of the wildtype EgD5R* (SEQ ID NO:26)
within plasmid pDMW367-M4, wherein GC analysis determined 11.3%
30 DGLA and 3.4% ARA of total lipids were produced by the transformants
(i.e., average conversion efficiency was 23.3%).

Table 6. Delta-5 Desaturase Activity In EgD5R* And HDAxH
(SEQ ID NO:37) Motif Mutants

Y4036U1 Transformant *	SEQ ID NOs Of Primers	Sequence of Mutant HDASH Motif	Avg. Conv. Effic.	Percent Activity **
pDMW367-M4	--	HDASH (SEQ ID NO:8)	23.3%	100%
pDMW367M4- 158a	89 and 90	HDAaH (SEQ ID NO:17)	23.5%	100.9%
pDMW367M4- 158c	91 and 92	HDAcH (SEQ ID NO:294)	17.9%	76.8%
pDMW367M4- 158d	93 and 94	HDA dH (SEQ ID NO:295)	2.8%	12.0%
pDMW367M4- 158e	95 and 96	HDAeH (SEQ ID NO:296)	1.9%	8.2%
pDMW367M4- 158f	97 and 98	HDAfH (SEQ ID NO:297)	1%	4.3%
pDMW367M4- 158g	99 and 100	HDAgH (SEQ ID NO:18)	25.1%	107.7%
pDMW367M4- 158h	101 and 102	HDAhH (SEQ ID NO:298)	1.6%	6.9%
pDMW367M4- 158i	103 and 104	HDAiH (SEQ ID NO:299)	1.1%	4.7%
pDMW367M4- 158k	105 and 106	HDAkH (SEQ ID NO:300)	1%	4.3%
pDMW367M4- 158l	107 and 108	HDA lH (SEQ ID NO:301)	1.1%	4.7%
pDMW367M4- 158m	109 and 110	HDA mH (SEQ ID NO:302)	2.3%	9.9%
pDMW367M4- 158n	111 and 112	HDA nH (SEQ ID NO:303)	16.5%	70.8%
pDMW367M4- 158p	113 and 114	HDApH (SEQ ID NO:304)	1.2%	5.2%
pDMW367M4- 158q	115 and 116	HDAqH (SEQ ID NO:305)	10.4%	44.6%
pDMW367M4- 158r	117 and 118	HDArH (SEQ ID NO:306)	10.0%	42.9%
pDMW367M4- 158t	119 and 120	HDA tH (SEQ ID NO:307)	9.6%	41.2%
pDMW367M4- 158v	121 and 122	HDAvH (SEQ ID NO:308)	1.5%	6.4%
pDMW367M4- 158w	123 and 124	HDAwH (SEQ ID NO:309)	9.3%	40.0%
pDMW367M4- 158y	125 and 126	HDAyH (SEQ ID NO:310)	1.1%	4.7%

* Each EgD5R* gene (mutant or wildtype) was expressed within pDMW367-M4.

5 ** Percent Activity is with respect to EgD5R*.

The results demonstrated that the Ser residue within the HDASH (SEQ ID NO:8) motif can be substituted with either Ala or Gly without substantially affecting the delta-5 desaturase activity of EgD5R*. Specifically, EgD5R*-158a (SEQ ID NO:127) in pDMW367M4-158a transformants was able to convert DGLA to ARA with 23.5% conversion efficiency, while EgD5R*-158g (SEQ ID NO:128) in pDMW367M4-158g transformants was able to convert DGLA to ARA with 25.1% conversion efficiency.

EXAMPLE 7

Identification Of HxGx (SEQ ID NO:34) And HDxxH (SEQ ID NO:311) Mutations That Result In Similar Delta-5 Desaturase Activity To The Delta-5 Desaturase Activity Of EgD5R*

U.S. Pat. Pub. No. 2010-0075386-A1 describes mutant delta-5 desaturases which possess at least one mutation within the HPGG (SEQ ID NO:7) motif of the cytochrome *b*₅-like domain (i.e., HxGx [SEQ ID NO:34] mutations). The HPGG (SEQ ID NO:7) motif spans from amino acid residues 33 to 36 of EgD5R (SEQ ID NO:25).

The present Example introduces mutations within the HPGG (SEQ ID NO:7) motif of EgD5R*-157g (Example 5, SEQ ID NO:87), EgD5R*-158a (Example 6, SEQ ID NO:127) and EgD5R*-158g (Example 6, SEQ ID NO:128) to see the effect of double mutations within the HPGG (SEQ ID NO:7) and HDASH (SEQ ID NO:8) domains.

Single amino acid mutations were carried out using pDMW367M4-157g (Example 5, SEQ ID NO:129), pDMW367M4-158a (Example 6, SEQ ID NO:130) and pDMW367-158g (Example 6, SEQ ID NO:131) as the template and several pairs of oligonucleotides (SEQ ID NOs:132-137; Table 7) as primers to individually mutate either the Pro residue or the second Gly residue of the HPGG (SEQ ID NO:7) motif of the mutant delta-5 desaturase gene by site-directed mutagenesis (QuickChange Kit, Stratagene, CA), thereby generating double mutations within the HPGG (SEQ ID NO:7) and HDASH (SEQ ID NO:8) motifs. Following mutagenesis, plasmids were transformed into *Y. lipolytica* strain Y4036U1,

transformants were selected and grown in MMLeu and HGM, and FAMES were prepared and analyzed by GC, as described in Example 5.

The delta-5 desaturase activity of mutant delta-5 desaturases with both HxGx (SEQ ID NO:34) and HDxxH (SEQ ID NO:311) mutations are
5 summarized below in Table 7. Transformants comprising mutant pDMW367M4 constructs, wherein the mutant constructs comprise EgD5R* mutants, are designated according to the amino acid substitution for the Pro residue or the second Gly residue within the HPGG (SEQ ID NO:7) motif of EgD5R*, combined with the amino acid substitution for the
10 Ala residue or Ser residue within the HDASH (SEQ ID NO:8) motif of EgD5R*. That is, e.g., transformant pDMW367-34g158g comprises a mutant delta-5 desaturase designated as EgD5R*-34g158g, having a Gly for Pro substitution at position 34 (thereby yielding a HgGG [SEQ ID NO:9] motif) and having a Gly for Ser substitution at position 158 (thereby
15 yielding a HDAgG [SEQ ID NO:18] motif), etc. Conversion efficiency was measured according to the formula described in Example 5. Results are compared to that of the wild-type EgD5R* within plasmid pDMW367-M4, wherein GC analysis determined 11.7% DGLA and 4.4% ARA of total lipids were produced by the transformants (i.e., average conversion
20 efficiency was 27.5%).

Table 7. Delta-5 Desaturase Activity In EgD5R* Mutants Simultaneously Comprising HxGx (SEQ ID NO:34) And HDxxH (SEQ

ID NO:311) Motifs

Y4036U1 Transformant	Mutant Gene	SEQ ID NOs Of Primers	Sequence Of Mutant HPGG Motif	Sequence Of Mutant HDASH Motif	Average Conversion Efficiency	Percent Activity With Respect to EgD5R*
pDMW367-M4		--	HPGG (SEQ ID NO:7)	HDASH (SEQ ID NO:8)	27.5%	100%
pDMW367-34g157g	EgD5R*-34g157g (SEQ ID NOs:138 and 139)	132 and 133	HgGG (SEQ ID NO:9)	HDgSH (SEQ ID NO:15)	22.9%	83%
pDMW367-34g158a	EgD5R*-34g158a (SEQ ID NOs:140 and 141)	132 and 133	HgGG (SEQ ID NO:9)	HDAaH (SEQ ID NO:17)	24.3%	88%
pDMW367-34g158g	EgD5R*-34g158g (SEQ ID NOs:142 and 143)	132 and 133	HgGG (SEQ ID NO:9)	HDAgH (SEQ ID NO:18)	26.8%	97%
pDMW367-34h158a	EgD5R*-34h158a (SEQ ID NOs:144 and 145)	134 and 135	HhGG (SEQ ID NO:10)	HDAaH (SEQ ID NO:17)	18.7%	68%
pDMW367-34h158g	EgD5R*-34h158g (SEQ ID NOs:146 and 147)	134 and 135	HhGG (SEQ ID NO:10)	HDAgH (SEQ ID NO:18)	22%	80%
pDMW367-36s158a	EgD5R*-34s158a (SEQ ID NOs:148 and 149)	136 and 137	HPGs (SEQ ID NO:11)	HDAaH (SEQ ID NO:17)	17.5%	64%
pDMW367-36s158g	EgD5R*-34s158g (SEQ ID NOs:150 and 151)	136 and 137	HPGs (SEQ ID NO:11)	HDAgH (SEQ ID NO:18)	18.9%	69%

* Each EgD5R* gene (mutant or wildtype) was expressed within pDMW367-M4.

The results demonstrated that although the HPGG (SEQ ID NO:7) motif and the HDASH (SEQ ID NO:8) motif are important to delta-5 desaturase enzymatic activity, desaturases may be constructed having HxGx (SEQ ID NO:34) and HDxxH (SEQ ID NO:311) motifs that retain at least 64% of delta-5 desaturase activity when compared to the wildtype. Specifically, the Pro residue within the HPGG (SEQ ID NO:7) motif can be substituted with Gly with simultaneous substitution of either: 1) the Ala residue within the HDASH (SEQ ID NO:8) motif for Gly; or, 2) the Ser residue within the HDASH (SEQ ID NO:8) motif for Ala or Gly. The Pro residue within the HPGG (SEQ ID NO:7) motif can also be substituted with His with simultaneous substitution of the Ser residue within the HDASH (SEQ ID NO:8) motif for either Ala or Gly. And, the second Gly residue within the HPGG (SEQ ID NO:7) motif can be substituted with Ser with simultaneous substitution of Ser within the HDASH (SEQ ID NO:8) motif for either Ala or Gly.

Preferred double mutants were EgD5R*-34g157g (SEQ ID NO:139; capable of converting DGLA to ARA with 22.9% conversion efficiency in pDMW367-34g157g transformants), EgD5R*-34g158a (SEQ ID NO:141; capable of converting DGLA to ARA with 24.3% conversion efficiency in pDMW367-34g158a transformants) and EgD5R*-34g158g (SEQ ID NO:143; capable of converting DGLA to ARA with 26.8% conversion efficiency in pDMW367-34g158g transformants).

EXAMPLE 8

Synthesis Of An N-Terminal Codon-Optimized Mutant Delta-5 Desaturase Gene ("EgD5M") For Expression In *Yarrowia lipolytica*, Derived From EgD5R*-34g158g

The codon usage of the 5' portion of EgD5R*-34g158g (SEQ ID NO:142, Example 7) was optimized for expression in *Y. lipolytica*, in a manner similar to that described in U.S. Pat. 7,125,672. Specifically, the first 204 bp of EgD5R*-34g158g were codon-optimized, to result in synthesis of a codon-optimized delta-5 desaturase gene designated "EgD5M" (SEQ ID NOs:152 and 153). EgD5M was designed based on the coding sequence of the delta-5 desaturase gene of EgD5R*-34g158g,

according to the *Yarrowia* codon usage pattern (U.S. Pat. 7,125,672), the consensus sequence around the 'ATG' translation initiation codon, and the general rules of RNA stability (Guhanियogi, G. and J. Brewer, *Gene*, 265(1-2):11-23 (2001)). In addition to modification of the translation initiation site, 52 bp of the 204 bp within the N-terminus of the coding region were modified (25.5%; FIG. 5), and 45 codons of the 68 amino acids within the N-terminus of the desaturase protein were optimized (66.2%). A *NcoI* site and *NotI* sites were incorporated around the translation initiation codon and after the stop codon of EgD5M, respectively. The protein sequence encoded by the codon-optimized EgD5M gene (i.e., SEQ ID NO:153) is identical to that of the wildtype EgD5R*-34g158g protein sequence (i.e., SEQ ID NO:143). The designed EgD5M gene (SEQ ID NO:152) was synthesized by GenScript Corporation (Piscataway, NJ) and cloned into pUC57 (GenBank Accession No. Y14837) to generate pEgD5M (FIG. 6A; SEQ ID NO:154).

EXAMPLE 9

Generation Of Construct pDMW367-5M, Comprising EgD5M

The present Example describes the construction of plasmid pDMW367-5M comprising a chimeric FBAIN::EgD5M::Pex20 gene.

Plasmid pDMW367-5M (FIG. 6B; SEQ ID NO:155) was constructed by replacing the *NcoI/NotI* EgD5R* fragment of pDMW367-M4 (FIG. 4; SEQ ID NO:39) with the *NcoI/NotI* EgD5M fragment from pEgD5M (FIG. 6A; SEQ ID NO:154). The product of this ligation was pDMW367-5M, which thereby contained the following components:

Table 8. Components Of Plasmid pDMW367-5M (SEQ ID NO:155)

RE Sites And Nucleotides Within SEQ ID NO:155	Description Of Fragment And Chimeric Gene Components

<i>EcoR I/BsWI</i> (6063-318)	FBAIN::EgD5M::Pex20, comprising: <ul style="list-style-type: none"> • FBAIN: <i>Yarrowia lipolytica</i> FBAIN promoter (U.S. Pat. 7,202,356); • EgD5M: synthetic mutant N-terminal codon-optimized EgD5R*-34g158g ["EgD5M"] delta-5 desaturase (SEQ ID NO:152), derived from <i>Euglena gracilis</i>; • Pex20: Pex20 terminator sequence of <i>Yarrowia</i> Pex20 gene (GenBank Accession No. AF054613)
1354-474	ColE1 plasmid origin of replication
2284-1424	ampicillin-resistance gene (Amp ^R) for selection in <i>E. coli</i>
3183-4476	<i>Yarrowia</i> autonomous replication sequence (ARS18; GenBank Accession No. A17608)
6020-4533	<i>Yarrowia Ura 3</i> gene (GenBank Accession No. AJ306421)

EXAMPLE 10

Generation Of Construct pDMW367-5M1, Comprising Variant "EgD5M1" Of The N-Terminal Codon-Optimized Mutant Delta-5 Desaturase Gene

5 The present Example describes the construction of plasmid pDMW367-5M1 comprising a chimeric FBAIN::EgD5M1::Pex20 gene. The nucleotide sequence of EgD5M1 (SEQ ID NO:156) is identical to that of EgD5M (SEQ ID NO:152), except the CGA codon for Arg at position 347 in EgD5M was changed to encode an AGC codon for Ser in EgD5M1.

10 This modification was designed to analyze the effect of the R347S mutation (described in Example 3) on delta-5 desaturase activity.

 The designed EgD5M1 gene (also referred to as "EgD5R*-34g158g347S"; SEQ ID NO:156) was synthesized by GenScript Corporation (Piscataway, NJ) and cloned into pUC57 (GenBank

15 Accession No. Y14837) to generate pEgD5M1 (SEQ ID NO:158).

 Plasmid pDMW367-5M1 (SEQ ID NO:159) was constructed by replacing the *NcoI/NotI* EgD5R* fragment of pDMW367-M4 (FIG. 4; SEQ ID NO:39) with the *NcoI/NotI* EgD5M1 fragment from pEgD5M1 (SEQ ID NO:158). The product of this ligation was pDMW367-5M1, comprising a

20 chimeric FBAIN::EgD5M1::Pex20 gene.

EXAMPLE 11

Functional Analyses Of EgD5M And EgD5M1 Delta-5 Desaturases In *Yarrowia lipolytica* Strain Y4036U1

Control plasmid pDMW367-M4 (SEQ ID NO:39; Example 4) and plasmids pDMW367-5M (SEQ ID NO:155; Example 9) and pDMW367-5M1 (SEQ ID NO:159; Example 10) were each separately transformed into *Y. lipolytica* strain Y4036U1. Transformants were selected and grown in MMLeu and HGM, and FAMEs were prepared and analyzed by GC, as described in Example 5.

The delta-5 desaturase activity (average of 3 transformants) of EgD5R*, EgD5M and EgD5M1 are summarized below in Table 9. Conversion efficiency ("Conv. Effic.") was measured according to the formula described in Example 5. Results are compared to that of the wild-type EgD5R* (SEQ ID NO:26) within plasmid pDMW367-M4, wherein GC analysis determined 10.8% DGLA and 3.6% ARA of total lipids were produced by the transformants (i.e., average conversion efficiency was 24.8%).

Table 9. Delta-5 Desaturase Activity In EgD5R*, EgD5M And EgD5M1

Plasmid Transformed into Y4036U1	Delta-5 Desaturase	Sequence Of Mutant HPGG and HDASH Motifs	Amino Acid At Residue 347	Average Conv. Effic.
pDMW367-M4	EgD5R* (SEQ ID NOs: 26 and 27)	HPGG (SEQ ID NO:7), HDASH (SEQ ID NO:8)	R	24.8%
pDMW367-5M	EgD5M (SEQ ID NOs: 152 and 153)	HgGG (SEQ ID NO:9), HDAgH (SEQ ID NO:18)	R	26.5%
pDMW367-5M1	EgD5M1 (SEQ ID NOs: 156 and 157)	HgGG (SEQ ID NO:9), HDAgH (SEQ ID NO:18)	S	27.6%

The results demonstrated that both EgD5M (SEQ ID NO:153) and EgD5M1 (SEQ ID NO:157) had higher delta-5 desaturase activity than the wild-type EgD5R* (SEQ ID NO:27). The improved delta-5 desaturase activity of EgD5M1, when compared to EgD5M, demonstrates that amino acid residue 347 does affect the protein's delta-5 desaturase activity, with Ser preferred as opposed to Arg.

EXAMPLE 12

Identification Of HPGs (SEQ ID NO:11) And HxxxH (SEQ ID NO:1)
Mutations In A Synthetic Delta-5 Desaturase Gene ("EgD5S") Derived
 5 From *Euglena gracilis* And Codon-Optimized For Expression In
Yarrowia lipolytica

The present Example introduces mutations within the HDASH (SEQ ID NO:8) motif of a mutant EgD5S-36s (or "EgD5S-HPGs") gene to determine the effect of double mutations within the HPGG (SEQ ID NO:7) and HDASH (SEQ ID NO:8) conserved domains.

EgD5S (SEQ ID NOs:22 and 23) is a synthetic delta-5 desaturase derived from EgD5 (Example 3) and codon-optimized for expression in *Y. lipolytica* (U.S. Pat. 7,678,560). Although the amino acid sequence of EgD5S was identical to EgD5, the nucleotide sequences differ; specifically, 15 in addition to modification of the translation initiation site, 196 bp of the 1350 bp coding region were modified (14.5%) and 189 codons were optimized (42%). The GC content was reduced from 55.5% within the wild type gene (i.e., EgD5) to 54.4% within the synthetic gene (i.e., EgD5S). And, a *Nco*I site and *Not*I sites were incorporated around the translation 20 initiation codon and after the stop codon of EgD5S, respectively.

Examples 1 through 4 of U.S. Pat. Pub. No. 2010-0075386-A1 describe the identification of mutant EgD5S-36s (SEQ ID NO:160), using EgD5S as a template in site-directed mutagenesis reactions targeted to modify the second Gly residue of the HPGG (SEQ ID NO:7) motif of 25 EgD5S, which spans from amino acid residues 33 to 36 of the cytochrome *b*₅-like domain (i.e., HPGx [SEQ ID NO:33] mutations). Thus, mutant EgD5S-36s comprised an HPGs (SEQ ID NO:11) motif, wherein the second Gly residue of the HPGG (SEQ ID NO:7) motif was substituted with Ser using EgD5S (SEQ ID NO:23) as a template. The delta-5 30 desaturase activity of EgD5S-36s (U.S. Pat. Pub. No. 2010-0075386-A1) was about 106.9% of the delta-5 desaturase activity of EgD5S. Plasmid pDMW369S (SEQ ID NO:161) contains the mutant EgD5S-36s gene; the vector components are similar to those of pDME367-5M (FIG. 6B herein),

with the exception of the mutant EgD5S-36s gene in place of the EgD5M gene).

Based on the successful generation of double EgD5R* mutants in Example 7 (i.e., simultaneously comprising mutant HPGG [SEQ ID NO:7] and mutant HDASH [SEQ ID NO:8] motifs), it was anticipated that similar HxxxH (SEQ ID NO:1) mutations would be tolerated when introduced into EgD5S-36s. Specifically, single amino acid mutations were carried out using pDMW369S (comprising a chimeric FBAIN::EgD5S-36S::Pex20 gene) as the template and 9 pairs of oligonucleotides (SEQ ID NOs:162-179; Table 10) as primers to individually mutate either the Asp, Ala or Ser residue within the HDASH (SEQ ID NO:8) motif of EgD5S-36s (SEQ ID NO:160) by site-directed mutagenesis (QuickChange Kit, Stratagene, CA), thereby generating 9 selected amino acid substitutions. Following mutagenesis, plasmids were transformed into *Y. lipolytica* strain Y4036U1, transformants were selected and grown in MMLeu and HGM, and FAMES were prepared and analyzed by GC, as described in Example 5.

The delta-5 desaturase activity (average of 3 transformants) of mutant delta-5 desaturases with both HPGs (SEQ ID NO:11) and HxxxH (SEQ ID NO:1) mutations are summarized below in Table 10.

Transformants comprising mutant pDMW369S constructs, wherein the mutant constructs comprise mutants of EgD5S-36s, are designated according to the amino acid substitution that occurred for the Asp, Ala or Ser residue within the HDASH (SEQ ID NO:8) motif (i.e., transformant pDMW369S-156e comprises a mutant delta-5 desaturase designated as EgD5S-36s156e, and having a Glu for Asp substitution at position 156, thereby yielding a HeASH [SEQ ID NO:19] motif; transformant pDMW369S-157g comprises a mutant delta-5 desaturase designated as EgD5S-36s157g, and having a Gly for Ala substitution, thereby yielding a HDgSH [SEQ ID NO:15] motif, etc.). Conversion efficiency was measured according to the formula described in Example 5. Results are compared to that of EgD5S-36s (SEQ ID NO:160) within plasmid pDMW369S, wherein GC analysis determined 8.1% DGLA and 6.8% ARA of total lipids

were produced by the transformants (i.e., average conversion efficiency was 45.8%).

Table 10. Delta-5 Desaturase Activity In EgD5S Mutants Simultaneously Comprising HPGs (SEQ ID NO:11) And Mutant HxxxH

(SEQ ID NO:1) Motifs

Y4036U1 Transformant	Mutant Gene	SEQ ID NOs Of Primers	Sequence Of Mutant HDASH Motif	Average Conversion Efficiency	Percent Activity With Respect to EgD5S-36S
pDMW369S	EgD5S-36s (SEQ ID NO:160)	--	HDASH (SEQ ID NO:8)	45.8%	100%
pDMW369S-157f	EgD5S-36s157f	162 and 163	HDfSH (SEQ ID NO:280)	3.4%	7.4%
pDMW369S-157m	EgD5S-36s157m	164 and 165	HDmSH (SEQ ID NO:285)	2.4%	5.2%
pDMW369S-157g	EgD5S-36s157g (SEQ ID NOs:182 and 183)	166 and 167	HDgSH (SEQ ID NO:15)	36.6%	79.9%
pDMW369S-157S	EgD5S-36s157s	168 and 169	HDsSH (SEQ ID NO:16)	17.9%	39.1%
pDMW369S-158a	EgD5S-36s158a (SEQ ID NOs:184 and 185)	170 and 171	HDAaH (SEQ ID NO:17)	39.1%	85.4%
pDMW369S-158n	EgD5S-36s158n	172 and 173	HDAnH (SEQ ID NO:303)	13.0%	28.4%
pDMW369S-158t	EgD5S-36s158t	174 and 175	HDAtH (SEQ ID NO:307)	4.5%	9.8%
pDMW369S-158g	EgD5S-36s158g (SEQ ID NOs:186 and 187)	176 and 177	HDAGH (SEQ ID NO:18)	34.3%	74.9%
pDMW369S-156e	EgD5S-36s156e (SEQ ID NOs:180 and 181)	178 and 179	HeASH (SEQ ID NO:19)	36.2%	79.0%

The results demonstrated that the codon-optimized EgD5S delta-5 desaturase could be modified to comprise both mutant HPGG (SEQ ID NO:7) and mutant HDASH (SEQ ID NO:8) motifs, while still retaining reasonable delta-5 desaturase activity when compared to mutant EgD5S-36s having only a mutant HPGG motif (i.e., HPGs [SEQ ID NO:11]). Preferred double mutants were EgD5S-36s156e (SEQ ID NOs:180 and 181; capable of converting DGLA to ARA with 36.2% conversion efficiency in pDMW369S-156e transformants), EgD5S-36s157g (SEQ ID NOs:182 and 183; capable of converting DGLA to ARA with 36.6% conversion efficiency in pDMW369S-157g transformants), EgD5S-36s158a (SEQ ID NOs:184 and 185; capable of converting DGLA to ARA with 39.1% conversion efficiency in pDMW369S-158a transformants), and EgD5S-36s158g (SEQ ID NOs:186 and 187; capable of converting DGLA to ARA with 34.3% conversion efficiency in pDMW369S-158g transformants).

15 EXAMPLE 13

Identification Of HaGG (SEQ ID NO:14) And HxxxH (SEQ ID NO:1) Mutations In A Synthetic Delta-5 Desaturase Gene ("EaD5S") Derived From *Euglena anabaena* And Codon-Optimized For Expression In *Yarrowia lipolytica*

20 The present Example introduces mutations within the HDASH (SEQ ID NO:8) motif of a mutant EaD5S-35a (or "EaD5S-HaGG") gene to determine the effect of double mutations within the HPGG (SEQ ID NO:7) and HDASH (SEQ ID NO:8) conserved domains.

U.S. Pat. 7,943,365 describes the isolation and cloning of a delta-5 desaturase from *E. anabaena* (i.e., EaD5; SEQ ID NO:28). This gene was then codon-optimized for expression in *Y. lipolytica*, resulting in the synthetic delta-5 desaturase EaD5S (SEQ ID NO:30). Although the amino acid sequence of EaD5S was identical to EaD5, the nucleotide sequences differ; specifically, in addition to modification of the translation initiation site, 183 bp of the 1362 bp coding region were modified (13.4%) and 174 codons were optimized (38.3%). The GC content was reduced from 57.6% within the wild type gene (i.e., EaD5) to 54.6% within the synthetic gene (i.e., EaD5S). And, a *NcoI* site and *NotI* sites were incorporated

around the translation initiation codon and after the stop codon of EaD5S, respectively.

Example 6 of U.S. Pat. Pub. No. 2010-0075386-A1 describes the identification of mutant EaD5S-35a (SEQ ID NO:188), using EaD5S as a
5 template in site-directed mutagenesis reactions targeted to modify the Pro residue of the HPGG (SEQ ID NO:7) motif of EaD5S, which spans from amino acid residues 34 to 37 of the cytochrome *b*₅-like domain (i.e., HxGG [SEQ ID NO:32] mutations). Thus, mutant EaD5S-35a (SEQ ID NO:188) comprised a HaGG (SEQ ID NO:14) motif, wherein the Pro residue of the
10 HPGG (SEQ ID NO:7) motif was substituted with Ala using EaD5S (SEQ ID NO:31) as a template. The delta-5 desaturase activity of EaD5S-35a (U.S. Pat. Pub. No. 2010-0075386-A1) was about 99.2% of the delta-5 desaturase activity of the EaD5S. Plasmid pZuFmEaD5S-A(S) (SEQ ID NO:189) contains the mutant EaD5S-35a gene; the vector components
15 are identical to those of pDMW367-5M (FIG. 6B herein), with the exception of the mutant EaD5S-35a gene in place of the EgD5M gene).

Based on the successful generation of double EgD5R* mutants in Example 7 and double EgD5S mutants in Example 12 (i.e., simultaneously comprising mutant HPGG [SEQ ID NO:7] and mutant HDASH [SEQ ID
20 NO:8] motifs), it was anticipated that similar HxxxH (SEQ ID NO:1) mutations would be tolerated when introduced into EaD5S-35a. The HDASH (SEQ ID NO:8) motif, spans from amino acid residues 156 to 160 of EaD5S and EaD5S-35a.

Single amino acid mutations were carried out using pZuFmEaD5S-
25 A(S) (comprising a chimeric FBAIN::EaD5S-35a::Pex20 gene) as the template and 9 pairs of oligonucleotides (SEQ ID NOs:190-211; Table 11) as primers to individually mutate Asp, Ala or Ser within the HDASH (SEQ ID NO:8) motif of EaD5S-35a (SEQ ID NO:188) by site-directed mutagenesis (QuickChange Kit, Stratagene, CA), thereby generating 9
30 selected amino acid substitutions. Following mutagenesis, plasmids were transformed into *Y. lipolytica* strain Y4036U1, transformants were selected and grown in MMLeu and HGM, and FAMES were prepared and analyzed by GC, as described in Example 5.

The delta-5 desaturase activity (average of 3 transformants) of mutant delta-5 desaturases comprising HaGG (SEQ ID NO:14) and HxxxH (SEQ ID NO:1) mutations are summarized below in Table 11. Transformants comprising mutant pZuFmEaD5S-A(S) constructs, wherein
5 the mutant constructs comprise mutants of EaD5S-35a, are designated according to the amino acid substitution that occurred for the Asp, Ala or Ser residue within the HDASH (SEQ ID NO:8) motif. That is, e.g., transformant pZuFmEaD5S-A(S)-157e comprises a mutant delta-5 desaturase designated as EaD5S-35a157e, and having a Glu for Asp
10 substitution at position 157, thereby yielding a HeASH (SEQ ID NO:19) motif; transformant pZuFmEaD5S-A(S)-158g comprises a mutant delta-5 desaturase designated as EaD5S-35a158g, and having a Gly for Ala substitution, thereby yielding a HDgSH (SEQ ID NO:15) motif, etc. Conversion efficiency was measured according to the formula described in
15 Example 5. Results are compared to that of EaD5S-35a (SEQ ID NO:188) within plasmid pZuFmEaD5S-A(S), wherein GC analysis determined 8.6% DGLA and 5.1% ARA of total lipids were produced by the transformants (i.e., average conversion efficiency was 37.2%).

Table 11.Delta-5 Desaturase Activity In EaD5S Mutants Simultaneously Comprising HaGG (SEQ ID NO:14) And Mutant HxxxH

(SEQ ID NO:1) Motifs

Y4036U1 Transformant	Mutant Gene	SEQ ID NOs Of Primers	Sequence Of Mutant HDASH Motif	Average Conversion Efficiency	Percent Activity With Respect to EaD5S-35a
pZuFmEaD5S-A(S)	EaD5S-35a (SEQ ID NO:188)	--	HDASH (SEQ ID NO:8)	37.2%	100%
pZuFmEaD5S-A(S)- 157e	EaD5S-35a157e	190 and 191	HeASH (SEQ ID NO:19)	14.0%	37.6%
pZuFmEaD5S-A(S)- 158f	EaD5S-35a157f	192 and 193	HDfSH (SEQ ID NO:280)	2.1%	5.6%
pZuFmEaD5S-A(S)- 158g	EaD5S-35a158g (SEQ ID NOs:212 and 213)	194 and 195	HDgSH (SEQ ID NO:15)	28.4%	76.3%
pZuFmEaD5S-A(S)- 158m	EaD5S-35a 158m	196 and 197	HDmSH (SEQ ID NO:285)	1.8%	4.8%
pZuFmEaD5S-A(S)- 158s	EaD5S-35a158s (SEQ ID NOs:214 and 215)	198 and 199	HDsSH (SEQ ID NO:16)	27.4%	73.7%
pZuFmEaD5S-A(S)- 158y	EaD5S-35a158y	200 and 201	HDySH (SEQ ID NO:293)	1.9%	5.1%
pZuFmEaD5S-A(S)- 159a	EgD5S-35a159a	202 and 203	HDAaH (SEQ ID NO:17)	2.0%	5.4%
pZuFmEaD5S-A(S)- 159c	EaD5S-35a159c	204 and 205	HDAcH (SEQ ID NO:294)	14.2%	38.2%
pZuFmEaD5S-A(S)- 159g	EaD5S-35a159g (SEQ ID NOs:216 and 217)	206 and 207	HDaGH (SEQ ID NO:18)	26.5%	71.2%
pZuFmEaD5S-A(S)- 159n	EaD5S-35a159n	208 and 209	HDAnH (SEQ ID NO:303)	4.2%	11.3%
pZuFmEaD5S-A(S)- 159t	EaD5S-35a159t	210 and 211	HDAtH (SEQ ID NO:307)	9.8%	26.3%

The results demonstrated that the codon-optimized EaD5S delta-5 desaturase can be modified to comprise both mutant HPGG (SEQ ID NO:7) and mutant HDASH (SEQ ID NO:8) motifs, while still retaining reasonable delta-5 desaturase activity when compared to the mutant
 5 EaD5S-35a having only a mutant HPGG motif (i.e., HaGG [SEQ ID NO:14]). Preferred double mutants were EaD5S-35a158g (SEQ ID NOs:212 and 213; capable of converting DGLA to ARA with 28.4% conversion efficiency in pZuFmEaD5S-A(S)-158g transformants), EaD5S-35a158s (SEQ ID NOs:214 and 215; capable of converting DGLA to ARA
 10 with 27.4% conversion efficiency in pZuFmEaD5S-A(S)-158s transformants), and EaD5S-35a159g (SEQ ID NOs:216 and 217; capable of converting DGLA to ARA with 26.5% conversion efficiency in pZuFmEaD5S-A(S)-159g transformants).

EXAMPLE 14

15 Generation Of *Yarrowia lipolytica* Strain Z1978 To Produce About 58.7% EPA Of Total Fatty Acids

The present Example describes the construction of strain Z1978, derived from *Yarrowia lipolytica* ATCC #20362, capable of producing about 58.7% EPA relative to the total fatty acids ["EPA % TFAs"] with
 20 38.3% total lipid content ["TFAs % DCW"] via expression of a delta-9 elongase/ delta-8 desaturase pathway.

Genotype Of *Yarrowia lipolytica* Strain Y9502

The generation of strain Y9502 is described in U.S. Pat. Appl. Pub. No. 2010-0317072-A1. Strain Y9502, derived from *Y. lipolytica* ATCC
 25 #20362, was capable of producing about 57.0% EPA relative to the total lipids via expression of a delta-9 elongase/delta-8 desaturase pathway (FIG. 7).

The final genotype of strain Y9502 with respect to wildtype *Y. lipolytica* ATCC #20362 was *Ura+*, *Pex3-*, *unknown 1-*, *unknown 2-*,
 30 *unknown 3-*, *unknown 4-*, *unknown 5-*, *unknown6-*, *unknown 7-*, *unknown 8-*, *unknown9-*, *unknown 10-*, YAT1::ME3S::Pex16, GPD::ME3S::Pex20, YAT1::ME3S::Lip1, FBAINm::EgD9eS::Lip2, EXP1::EgD9eS::Lip1, GPAT::EgD9e::Lip2, YAT1::EgD9eS::Lip2, FBAINm::EgD8M::Pex20,

EXP1::EgD8M::Pex16, FBAIN::EgD8M::Lip1, GPD::EaD8S::Pex16 (2 copies), YAT1::E389D9eS/EgD8M::Lip1, YAT1::EgD9eS/EgD8M::Aco, FBAINm::EaD9eS/EaD8S::Lip2, GPD::FmD12::Pex20, YAT1::FmD12::Oct, EXP1::FmD12S::Aco, GPDIN::FmD12::Pex16, EXP1::EgD5M::Pex16, 5 FBAIN::EgD5SM::Pex20, GPDIN::EgD5SM::Aco, GPM::EgD5SM::Oct, EXP1::EgD5SM::Lip1, YAT1::EaD5SM::Oct, FBAINm::PaD17::Aco, EXP1::PaD17::Pex16, YAT1::PaD17S::Lip1, YAT1::YICPT1::Aco, YAT1::MCS::Lip1, FBA::MCS::Lip1, YAT1::MaLPAAT1S::Pex16.

Abbreviations are as follows: FmD12 is a *Fusarium moniliforme* delta-12 10 desaturase gene [U.S. Pat. No. 7,504,259]; FmD12S is a codon-optimized delta-12 desaturase gene, derived from *F. moniliforme* [U.S. Pat. No. 7,504,259]; ME3S is a codon-optimized C_{16/18} elongase gene, derived from *Mortierella alpina* [U.S. Pat. No. 7,470,532]; EgD9e is a *Euglena gracilis* delta-9 elongase gene [U.S. Pat. No. 7,645,604]; EgD9eS is a 15 codon-optimized delta-9 elongase gene, derived from *E. gracilis* [U.S. Pat. No. 7,645,604]; EgD8M is a synthetic mutant delta-8 desaturase gene [U.S. Pat. No. 7,709,239], derived from *E. gracilis* [U.S. Pat. No. 7,256,033]; EaD8S is a codon-optimized delta-8 desaturase gene, derived from *Euglena anabaena* [U.S. Pat. No. 7,790,156]; E389D9eS/EgD8M is a 20 DGLA synthase created by linking a codon-optimized delta-9 elongase gene (“E389D9eS”), derived from *Eutreptiella* sp. CCMP389 (U.S. Pat. No. 7,645,604) to the delta-8 desaturase “EgD8M” (*supra*) [U.S. Pat. Appl. Pub. No. 2008-0254191-A1]; EgD9eS/EgD8M is a DGLA synthase created by linking the delta-9 elongase “EgD9eS” (*supra*) to the delta-8 desaturase 25 “EgD8M” (*supra*) [U.S. Pat. Appl. Pub. No. 2008-0254191-A1]; EaD9eS/EgD8M is a DGLA synthase created by linking a codon-optimized delta-9 elongase gene (“EaD9eS”), derived from *E. anabaena* [U.S. Pat. No. 7,794,701] to the delta-8 desaturase “EgD8M” (*supra*) [U.S. Pat. Appl. Pub. No. 2008-0254191-A1]; EgD5M and EgD5SM are synthetic mutant 30 delta-5 desaturase genes comprising a mutant HPGs (SEQ ID NO:11) motif [U.S. Pat. App. Pub. 2010-0075386-A1], derived from *E. gracilis* [U.S. Pat. No. 7,678,560]; EaD5SM is a synthetic mutant delta-5 desaturase gene comprising a mutant HaGG (SEQ ID NO:14) motif [U.S. Pat. App.

Pub. 2010-0075386-A1], derived from *E. anabaena* [U.S. Pat. No. 7,943,365]; PaD17 is a *Pythium aphanidermatum* delta-17 desaturase gene [U.S. Pat. No. 7,556,949]; PaD17S is a codon-optimized delta-17 desaturase gene, derived from *P. aphanidermatum* [U.S. Pat. No. 7,556,949]; YICPT1 is a *Yarrowia lipolytica* diacylglycerol cholinephosphotransferase gene [U.S. Pat. No. 7,932,077]; MCS is a codon-optimized malonyl-CoA synthetase gene, derived from *Rhizobium leguminosarum* bv. viciae 3841 [U.S. Pat. App. Pub. 2010-0159558-A1], and, MaLPAAT1S is a codon-optimized lysophosphatidic acid acyltransferase gene, derived from *Mortierella alpina* [U.S. Pat. No. 7,879,591].

For a detailed analysis of the total lipid content and composition in strain Y9502, a flask assay was conducted wherein cells were grown in 2 stages for a total of 7 days. Based on analyses, strain Y9502 produced 3.8 g/L DCW, 37.1 TFAs % DCW, 21.3 EPA % DCW, and the lipid profile was as follows, wherein the concentration of each fatty acid is as a weight percent of TFAs [% TFAs]: 16:0 (palmitate)—2.5, 16:1 (palmitoleic acid)—0.5, 18:0 (stearic acid)—2.9, 18:1 (oleic acid)—5.0, 18:2 (LA)—12.7, ALA—0.9, EDA—3.5, DGLA—3.3, ARA—0.8, ETrA—0.7, ETA—2.4, EPA—57.0, other—7.5.

Generation Of *Yarrowia lipolytica* Strain Z1978 From Strain Y9502

The development of strain Z1978 from strain Y9502 is shown in FIG. 7 and described in U.S. Provisional Appl. No. 61/377248 (Attorney Docket Number CL4783USPRV, filed August 26, 2010), hereby incorporated herein by reference.

Specifically, to disrupt the *Ura3* gene in strain Y9502, *SalI/PacI*-digested construct pZKUM (FIG. 8A; SEQ ID NO:218; described in Table 15 of U.S. Pat. Appl. Pub. No. 2009-0093543-A1, hereby incorporated herein by reference) was used to integrate an *Ura3* mutant gene into the *Ura3* gene of strain Y9502, according to the General Methods. A total of 27 transformants (selected from a first group comprising 8 transformants, a second group comprising 8 transformants, and a third group comprising 11 transformants) were grown on Minimal Media + 5-fluoroorotic acid

["MM+ 5-FOA"] selection plates and maintained at 30 °C for 2 to 5 days.

Further experiments determined that only the third group of transformants possessed a real *Ura*- phenotype.

The *Ura*- cells were scraped from the MM + 5-FOA plates and
 5 subjected to fatty acid analysis, according to the General Methods. In this way, GC analyses showed that there were 28.5%, 28.5%, 27.4%, 28.6%, 29.2%, 30.3% and 29.6% EPA of TFAs in pZKUM-transformants #1, #3, #6, #7, #8, #10 and #11 of group 3, respectively. These seven strains were designated as strains Y9502U12, Y9502U14, Y9502U17, Y9502U18,
 10 Y9502U19, Y9502U21 and Y9502U22, respectively (collectively, Y9502U).

Construct pZKL3-9DP9N (FIG. 8B; SEQ ID NO:219) was generated to integrate one delta-9 desaturase gene, one choline-phosphate cytidylyl-transferase gene, and one delta-9 elongase mutant gene into the *Yarrowia* YALI0F32131p locus (GenBank Accession No. XM_506121) of strain
 15 Y9502U. The pZKL3-9DP9N plasmid contained the following components:

Table 12. Description of Plasmid pZKL3-9DP9N (SEQ ID NO:219)

RE Sites And Nucleotides Within SEQ ID NO:219	Description Of Fragment And Chimeric Gene Components
<i>Ascl</i> / <i>Bs</i> WI (887-4)	884 bp 5' portion of YALI0F32131p locus (GenBank Accession No. XM_506121, labeled as "Lip3-5" in Figure)
<i>PacI</i> / <i>SphI</i> (4396-3596)	801 bp 3' portion of YALI0F32131p locus (GenBank Accession No. XM_506121, labeled as "Lip3-3" in Figure)
<i>Swal</i> / <i>Bs</i> WI (11716 - 1)	YAT1::EgD9eS-L35G::Pex20, comprising: <ul style="list-style-type: none"> • YAT1: <i>Yarrowia lipolytica</i> YAT1 promoter (labeled as "YAT" in Figure; U.S. Pat. Appl. Pub. No. 2010-0068789-A1); • EgD9eS-L35G: Synthetic mutant of delta-9 elongase gene (SEQ ID NO:220; U.S. Provisional Pat. No. 61/377248), derived from <i>Euglena gracilis</i> ("EgD9eS"; U.S. Pat. 7,645,604) (labeled as "EgD9ES-24" in Figure); • Pex20: Pex20 terminator sequence from <i>Yarrowia Pex20</i> gene (GenBank Accession No. AF054613)
<i>PmeI</i> / <i>Swal</i> (8759-11716)	GPDIN::YID9::Lip1, comprising: <ul style="list-style-type: none"> • GPDIN: <i>Yarrowia lipolytica</i> GPDIN promoter (U.S. Pat. 7,459,546; labeled as "GPDPro+Intron" in Figure); • YID9: <i>Yarrowia lipolytica</i> delta-9 desaturase gene (GenBank Accession No. XM_501496; SEQ ID NO:222); • Lip1: Lip1 terminator sequence from <i>Yarrowia Lip1</i> gene (GenBank Accession No. Z50020)
<i>Clal</i> / <i>PmeI</i>	EXP1::YIPCT::Pex16, comprising:

(6501-8759)	<ul style="list-style-type: none"> • EXP1: <i>Yarrowia lipolytica</i> export protein (EXP1) promoter (labeled as "EXP" in Figure; U.S. Pat. 7,932,077); • YIPCT: <i>Yarrowia lipolytica</i> choline-phosphate cytidylyl-transferase ["PCT"] gene (GenBank Accession No. XM_502978; SEQ ID NO:224); • Pex16: Pex16 terminator sequence from <i>Yarrowia Pex16</i> gene (GenBank Accession No. U75433)
<i>Sall</i> / <i>EcoRI</i> (6501-4432)	<i>Yarrowia</i> Ura3 gene (GenBank Accession No. AJ306421)

The pZKL3-9DP9N plasmid was digested with *Ascl*/*SphI* and then used for transformation of strain Y9502U17, according to the General Methods. The transformant cells were plated onto MM plates and maintained at 30 °C for 3 to 4 days. Single colonies were re-streaked onto MM plates and then inoculated into liquid MM at 30 °C and shaken at 250 rpm/min for 2 days. The cells were collected by centrifugation, resuspended in HGM and then shaken at 250 rpm/min for 5 days. The cells were subjected to fatty acid analysis, *supra*.

GC analyses showed that most of the selected 96 strains of Y9502U17 with pZKL3-9DP9N produced 50-56% EPA of TFAs. Five strains (i.e., #31, #32, #35, #70 and #80) that produced about 59.0%, 56.6%, 58.9%, 56.5%, and 57.6% EPA of TFAs were designated as Z1977, Z1978, Z1979, Z1980 and Z1981, respectively.

The final genotype of these pZKL3-9DP9N transformant strains with respect to wildtype *Yarrowia lipolytica* ATCC #20362 was *Ura*+, *Pex3*-, *unknown 1*-, *unknown 2*-, *unknown 3*-, *unknown 4*-, *unknown 5*-, *unknown6*-, *unknown 7*-, *unknown 8*-, *unknown9*-, *unknown 10*-, *unknown 11*-, YAT1::ME3S::Pex16, GPD::ME3S::Pex20, YAT1::ME3S::Lip1, FBAINm::EgD9eS::Lip2, EXP1::EgD9eS::Lip1, GPAT::EgD9e::Lip2, YAT1::EgD9eS::Lip2, YAT::EgD9eS-L35G::Pex20, FBAINm::EgD8M::Pex20, EXP1::EgD8M::Pex16, FBAIN::EgD8M::Lip1, GPD::EaD8S::Pex16 (2 copies), YAT1::E389D9eS/EgD8M::Lip1, YAT1::EgD9eS/EgD8M::Aco, FBAINm::EaD9eS/EaD8S::Lip2, GPDIN::YID9::Lip1, GPD::FmD12::Pex20, YAT1::FmD12::Oct, EXP1::FmD12S::Aco, GPDIN::FmD12::Pex16, EXP1::EgD5M::Pex16, FBAIN::EgD5SM::Pex20, GPDIN::EgD5SM::Aco, GPM::EgD5SM::Oct, EXP1::EgD5SM::Lip1, YAT1::EaD5SM::Oct, FBAINm::PaD17::Aco,

EXP1::PaD17::Pex16, YAT1::PaD17S::Lip1, YAT1::YICPT1::Aco,
 YAT1::MCS::Lip1, FBA::MCS::Lip1, YAT1::MaLPAAT1S::Pex16,
 EXP1::YIPCT::Pex16.

Knockout of the YALI0F32131p locus (GenBank Accession No.
 5 XM_50612) in strains Z1977, Z1978, Z1979, Z1980 and Z1981 was not
 confirmed in any of these EPA strains produced by transformation with
 pZKL3-9DP9N.

Cells from YPD plates of strains Z1977, Z1978, Z1979, Z1980 and
 Z1981 were grown and analyzed for total lipid content and composition
 10 (*supra*). Table 13 below summarizes the total DCW, the tTFAs % DCW,
 the concentration of each fatty acid as a weight percent of TFAs [%
 TFAs] and the EPA % DCW of strains Z1977, Z1978, Z1979, Z1980 and
 Z1981, as determined by flask assays. Fatty acids are 16:0 (palmitate),
 16:1 (palmitoleic acid), 18:0 (stearic acid), 18:1 (oleic acid), 18:2 (linoleic
 15 acid), ALA (α -linolenic acid), EDA (eicosadienoic acid), DGLA (dihomo- γ -
 linolenic acid), ARA (arachidonic acid), ETrA (eicosatrienoic acid), ETA
 (eicosatetraenoic acid), EPA (eicosapentaenoic acid) and other.

Table 13. Total Lipid Content And Composition In *Yarrowia* Strains Z1977, Z1978, Z1979, Z1980 and Z1981 By Flask Assay

Strain	DCW (g/L)	TFAs % DCW	% TFAs													EPA % DCW
			16:0	16:1	18:0	18:1	18:2	ALA	EDA	DGLA	ARA	EtrA	ETA	EPA	other	
Z1977	3.8	34.3	2.0	0.5	1.9	4.6	11.2	0.7	3.1	3.3	0.9	0.7	2.2	59.1	9.9	20.3
Z1978	3.9	38.3	2.4	0.4	2.4	4.8	11.1	0.7	3.2	3.3	0.8	0.6	2.1	58.7	9.5	22.5
Z1979	3.7	33.7	2.3	0.4	2.4	4.1	10.5	0.6	3.2	3.6	0.9	0.6	2.2	59.4	9.8	20.0
Z1980	3.6	32.7	2.1	0.4	2.2	4.0	10.8	0.6	3.1	3.5	0.9	0.7	2.2	59.5	10.0	19.5
Z1981	3.5	34.3	2.2	0.4	2.1	4.2	10.6	0.6	3.3	3.4	1.0	0.8	2.2	58.5	10.7	20.1

Subsequent to the filing of U.S. Provisional Appl. No. 61/377248 (Attorney Docket Number CL4783USPRV, filed August 26, 2010), strain Z1978 was subjected to partial genome sequencing. This work determined that instead of six delta-5 desaturase genes integrated into the *Yarrowia* genome, the engineered strain actually possessed only four.

More specifically, two separate plasmid fragments (or portions thereof) were not detected in strain Z1978, as described further below.

- (1) Construct pZKL2-5mB89C (see U.S. Pat. Appl. Pub. No. 2010-0317072-A1, SEQ ID NO:131 therein) was intended to integrate one delta-5 desaturase gene into the *Lip2* loci of strain Y8069U. However, sequencing of the genome failed to detect the Lip2.3N end portion of the pZKL2-5mB89C fragment and the GPDIN::EgD5SM::Aco chimeric gene. DNA re-arrangement could have resulted in loss of the GPDIN::EgD5SM::Aco cassette during the generation of the Y8154 strain (FIG. 7).
- (2) Construct pZKL1-2SR9G85 (see U.S. Pat. Appl. Pub. No. 2010-0317072-A1, SEQ ID NO:132 therein) was intended to integrate one delta-5 desaturase gene into the *Lip1* loci of strain Y8154U1. However, neither genome sequencing nor PCR amplification was able to detect the delta-5 desaturase gene in strain Z1978. DNA re-arrangement could have resulted in loss of the GPM::EgD5SM::Oct cassette during the generation of strain Y8269 (FIG. 7).

Additionally, it was determined that construct pZSCP-Ma83 (see U.S. Pat. Appl. Pub. No. 2010-0317072-A1, SEQ ID NO:133 therein) and construct pZP2-85m98F (see U.S. Pat. Appl. Pub. No. 2010-0317072-A1, SEQ ID NO:135 therein) both integrated into the YALI0B21890g locus.

Thus, the true genotype of strain Z1978 with respect to wildtype *Yarrowia lipolytica* ATCC #20362 was as follows: *Ura+*, *Pex3-*, *unknown 1-*, *unknown 2-*, *unknown 3-*, *unknown 4-*, *YALI0E12947g-*, *unknown6-*, *YALI0B21890g-*, *unknown 8-*, *unknown 10-*, *unknown 11-*, YAT1::ME3S::Pex16, GPD::ME3S::Pex20, YAT1::ME3S::Lip1, FBAINm::EgD9eS::Lip2, EXP1::EgD9eS::Lip1, GPAT::EgD9e::Lip2,

YAT1::EgD9eS::Lip2, YAT1::EgD9eS-L35G::Pex20,
 FBAINm::EgD8M::Pex20, EXP1::EgD8M::Pex16, FBAIN::EgD8M::Lip1,
 GPD::EaD8S::Pex16 (2 copies), YAT1::E389D9eS/EgD8M::Lip1,
 YAT1::EgD9eS/EgD8M::Aco, FBAINm::EaD9eS/EaD8S::Lip2,
 5 GPDIN::YID9::Lip1, GPD::FmD12::Pex20, YAT1::FmD12::Oct,
 EXP1::FmD12S::Aco, GPDIN::FmD12::Pex16, EXP1::EgD5M::Pex16,
 FBAIN::EgD5SM::Pex20, EXP1::EgD5SM::Lip1, YAT1::EaD5SM::Oct,
 FBAINm::PaD17::Aco, EXP1::PaD17::Pex16, YAT1::PaD17S::Lip1,
 YAT1::YICPT1::Aco, YAT1::MCS::Lip1, FBA::MCS::Lip1,
 10 YAT1::MaLPAAT1S::Pex16, EXP1::YIPCT::Pex16.

EXAMPLE 15

Generation Of *Yarrowia lipolytica* Strains Comprising Double Delta-5 Desaturase Mutants And Producing More Than 50 EPA % TFAs

The present Example describes the construction of a suite of
 15 strains, derived from *Yarrowia lipolytica* strain Z1978 (Example 14),
 capable of producing more than 50 EPA % TFAs with more than 35
 TFAs % DCW via expression of a delta-9 elongase/ delta-8 desaturase
 pathway. The EPA strains included the following mutant delta-5
 desaturases comprising double mutations in both the HPGG (SEQ ID
 20 NO:7) and HDASH (SEQ ID NO:8) motifs: EgD5S-36s157g (SEQ ID
 NO:183; Example 12) and EaD5S-35a158g (SEQ ID NO:213; Example
 13), as well as either EgD5M (i.e., EgD5R*-34g158g; SEQ ID NO:153;
 Examples 9 and 11) or EgD5M1 (i.e., EgD5R*-34g158g347s; SEQ ID
 NO:157; Examples 10 and 11).

25 The strains were generated in a two-step method as shown in FIG.
 9, wherein the original delta-5 desaturase genes in strain Z1978 were first
 deleted to result in strains Y0S9017 (Ura-) and YOS9019 (Ura-) which
 produced at least about 56% ETA, but were no longer capable of
 producing EPA. Then, the double mutant delta-5 desaturases *supra* were
 30 integrated into the chromosome of strains Y0S9017 (Ura-) and YOS9019
 (Ura-), thereby restoring the ability of the transformant strains to produce
 EPA.

More specifically, the four delta-5 desaturase genes in strain Z1978 were originally integrated into the chromosome from two different constructs: pZKSL-5S5A5 (SEQ ID NO:226; see also U.S. Pat. Appl. Pub. No. 2010-0317072-A1, FIG. 4A and Table 6 therein) comprised chimeric
 5 EXP1::EgD5M::Pex16, FBAIN::EgD5SM::Pex20 and
 YAT1::EaD5SM::OCT genes, while pZP2-85m98F (SEQ ID NO:227; see also U.S. Pat. Appl. Pub. No. 2010-0317072-A1, FIG. 7B and Table 13 therein) comprised a chimeric EXP1::EgD5SM::Lip1 gene. Three
 separate homologous recombination events were required to remove
 10 these four chimeric genes.

First, the chimeric FBAIN::EgD5SM::Pex20 gene and a large portion of the *Leu* gene (i.e., from pZKSL-5S5A5) in the genome of strain Z1978U was replaced by homologous recombination (FIG. 10A) with a 993 bp stuffer DNA fragment (SEQ ID NO:228) within plasmid pYPS234
 15 (FIG. 10B; SEQ ID NO:229), wherein the 993 bp stuffer comprised 5' and 3' portions of the *Yarrowia* carnitine/acyl carnitine carrier gene. More specifically, the pYSP234 plasmid contained the following components.

Table 14. Description of Plasmid pYPS234 (SEQ ID NO:229)

RE Sites And Nucleotides Within SEQ ID NO:229	Description Of Fragment And Chimeric Gene Components
<i>Swa</i> I/ <i>Pac</i> I (1-1498)	<i>Yarrowia</i> Ura3 gene (GenBank Accession No. AJ306421)
2494-3354	Ampicillin-resistance gene for selection in <i>E. coli</i>
<i>Bsi</i> W I/ <i>Pme</i> I (4239-4964)	YAT1: <i>Yarrowia lipolytica</i> YAT1 promoter (labeled as "YAT" in Figure; U.S. Pat. Appl. Pub. No. 2010-0068789-A1)
4968-5320	Leu fragment: 353 bp fragment of Leu2 gene (GenBank Accession No. AF260230)
5327-6319	180 Stuffer: 993 bp DNA fragment (SEQ ID NO:228), comprising 5' and 3' portions of <i>Yarrowia</i> carnitine/acyl carnitine carrier gene (GenBank Accession No XP_501358)
<i>Bam</i> HI/ <i>Bsi</i> WI	Pex20: Pex20 terminator sequence from <i>Yarrowia</i> Pex20 gene (GenBank Accession No. AF054613)
<i>Hind</i> III/ <i>Swa</i> I (6638-7338)	Lys5-5': 720 bp 5' portion of <i>Yarrowia</i> Lys5 gene (GenBank Accession No. M34929; labeled as "lys5 5' region" in Figure)

The first crossover event occurred within the Lys5-5' DNA fragment, while the second crossover event occurred within the YAT1 promoter region. Strain YOS9001 was generated from this homologous recombination, having a Leu-, Ura- phenotype and three delta-5
 5 desaturase genes within its genome.

Then, the chimeric EXP1::EgD5M::Pex16 and YAT1::EaD5SM::OCT genes in the genome of strain YOS9001 were replaced by homologous recombination (FIG. 11A) with a 1019 bp stuffer DNA fragment (SEQ ID NO:230) within plasmid pYPS233 (FIG. 11B; SEQ
 10 ID NO:231), wherein the 1019 bp stuffer comprised 5' and 3' portions of the *Yarrowia ALK2* gene. The pYSP233 plasmid contained the following components:

Table 15. Description of Plasmid pYPS233 (SEQ ID NO:231)

RE Sites And Nucleotides Within SEQ ID NO:231	Description Of Fragment And Chimeric Gene Components
<i>Swa</i> I/ <i>Pac</i> I (1-1498)	<i>Yarrowia</i> Ura3 gene (GenBank Accession No. AJ306421)
2494-3354	Ampicillin-resistance gene for selection in <i>E. coli</i>
<i>Sph</i> I/ <i>Pac</i> I (4214-4901)	Lys5-3: 684 bp 3' portion of <i>Yarrowia Lys5</i> gene (GenBank Accession No. M34929; labeled as "Lys5-3' region" in Figure)
<i>Mlu</i> I/ <i>Bsi</i> WI (5229-6263)	171 stuffer: 1019 bp DNA fragment (SEQ ID NO:230), comprising 5' and 3' portions of the <i>Yarrowia ALK2</i> gene (GenBank Accession No. BAA31434)
<i>Bsi</i> WI/ <i>Pme</i> I (6263-6988)	YAT1: <i>Yarrowia lipolytica</i> YAT1 promoter (U.S. Pat. Appl. Pub. No. 2010-0068789-A1)
<i>Pme</i> I/ <i>Swa</i> I (6988/1)	Leu fragment: 353 bp fragment of Leu2 gene (GenBank Accession No. AF260230)

15

The first crossover event occurred within the Lys5-3' DNA fragment, while the second crossover event occurred within either the 3' Leu or YAT1 promoter region. Strains YOS9006 and YOS9009 (corresponding to two separate colonies having identical genotypes) were generated from
 20 this homologous recombination, each having a Leu-, Ura- phenotype and one delta-5 desaturase gene within the genome.

Finally, the chimeric EXP1::EgD5SM::Lip1 gene in the genomes of strain YOS9006 and YOS9009 was replaced by homologous

recombination (FIG. 12A) with a functional Leu2 gene within plasmid of pYSP241 (FIG. 12B; SEQ ID NO:232). The pYSP241 plasmid contained the following components:

5 Table 16. Description of Plasmid pYPS241 (SEQ ID NO:232)

RE Sites And Nucleotides Within SEQ ID NO:232	Description Of Fragment And Chimeric Gene Components
<i>Clal/ PmeI</i> (1-2134)	LeuL: <i>Yarrowia</i> Leu2 gene encoding isopropylmalate dehydrogenase (GenBank Accession No. AF260230)
<i>SwaI/PmeI</i> (3893-2134)	EaD8S::Pex20, comprising: <ul style="list-style-type: none"> • EaD8S: Synthetic delta-8 desaturase derived from <i>Euglena anabaena</i> (U.S. Pat. 7,790,156), codon-optimized for expression in <i>Yarrowia lipolytica</i> ("EaD8S"); • Pex20: Pex20 terminator sequence from <i>Yarrowia</i> Pex20 gene (GenBank Accession No. AF054613)
<i>SphI/Clal</i> (8107-9209)	B21890 arm A: Upstream DNA sequence of <i>Yarrowia</i> ORF B21890 (GenBank Accession XP_501199).

The first crossover event occurred in the region between position 2870148 and 2871250 of chromosome B, while the second crossover event occurred in the EaD8S region of plasmid pYSP241, thereby
 10 generating strains YOS9017 (Ura-) and YOS9019 (Ura-). Strains YOS9017 and YOS9019 (corresponding to two separate colonies having identical genotypes) were generated from this homologous recombination, each having a Ura- phenotype and no delta-5 desaturase genes within the genome.

15 To analyze the fatty acid composition and oil content of strains YOS9001 (Leu-, Ura-), YOS9006 (Leu-, Ura-), YOS9009 (Leu-, Ura-), YOS9017 (Ura-), YOS9019 (Ura-) and the Z1978U (Ura-) control, triplicate flask assays (identified as samples "A", "B" and "C") were carried out according to the methodology of Example 14.

20 Table 17 summarizes the concentration of each fatty acid as a weight percent of TFAs [% TFAs]. Fatty acids are as in Table 13, while 20:4 (5,11,14,17) refers to juniperonic acid. The sum of all fatty acids in each sample totaled 100.

Table 18 summarizes the total dry DCW, the TFAs % DCW, and the EPA % DCW.

Strain (# of Δ5 Desaturase Genes)	Sample	% TFAs													
		16:0	16:1	18:0	18:1	18:2	ALA	EDA	DGLA	ARA	ETra	20:4 (5,11, 14,17)	ETA	EPA	Other
YOS9001 (3 Δ5 genes)	A	2.2	0.5	1.5	2.2	7.9	0.0	2.4	5.1	1.3	0.5	0.5	2.8	58.2	14.8
	B	2.3	0.5	1.4	2.3	8.1	0.0	2.5	5.0	1.4	0.4	0.7	2.8	57.7	14.8
	C	2.6	0.5	1.5	2.3	8.4	0.0	2.5	4.8	1.5	0.4	0.6	2.8	56.9	15.1
	Avg	2.4	0.5	1.5	2.3	8.2	0.0	2.5	5.0	1.4	0.4	0.6	2.8	57.6	14.9
	A	2.3	0.4	1.8	3.1	9.9	0.5	3.1	7.9	0.9	0.4	0.3	6.3	53.1	9.9
YOS9006 (1 Δ5 gene)	B	2.3	0.4	1.8	3.1	10.0	0.6	3.1	7.8	1.0	0.4	0.3	6.2	52.9	10.1
	C	2.2	0.5	1.8	3.3	10.2	0.5	3.2	7.9	1.0	0.4	0.4	6.3	52.6	9.9
	Avg	2.3	0.4	1.8	3.2	10.0	0.5	3.2	7.9	1.0	0.4	0.3	6.3	52.9	10.0
	A	2.1	0.4	1.8	2.9	9.9	0.5	2.8	8.8	1.0	0.4	0.4	7.3	51.6	10.1
	B	2.1	0.4	1.8	2.9	9.9	0.3	2.6	8.6	1.0	0.4	0.3	7.3	52.2	10.2
YOS9009 (1 Δ5 gene)	C	2.0	0.5	1.7	2.8	9.7	0.3	2.5	8.8	1.0	0.4	0.3	7.4	52.1	10.5
	Avg	2.1	0.4	1.8	2.9	9.8	0.3	2.7	8.7	1.0	0.4	0.4	7.3	52.0	10.3
	A	2.3	1.0	2.4	6.5	10.7	0.7	3.7	10.0	0.1	0.7	0.0	56.6	0.0	5.0
	B	2.4	0.9	2.4	6.6	10.7	0.8	3.6	9.8	0.2	0.7	0.0	55.7	0.0	6.0
	C	2.3	0.9	2.4	6.6	10.6	0.7	3.6	9.9	0.2	0.7	0.0	56.1	0.0	6.0
YOS9017 (zero Δ5 genes)	Avg	2.3	0.9	2.4	6.6	10.6	0.7	3.6	9.9	0.2	0.7	0.0	56.1	0.0	5.7
	A	2.1	0.9	2.3	6.9	10.7	0.8	3.8	9.5	0.2	0.8	0.0	56.3	0.0	5.7
	B	2.1	0.9	2.2	6.8	10.7	0.8	3.7	9.6	0.2	0.8	0.0	56.5	0.0	5.6
	C	2.1	0.9	2.3	7.0	10.8	0.8	3.8	9.4	0.1	0.8	0.0	56.2	0.0	5.8
	Avg	2.1	0.9	2.3	6.9	10.7	0.8	3.8	9.5	0.2	0.8	0.0	56.3	0.0	5.7
YOS9019 (zero Δ5 genes)	A	2.1	0.9	2.3	6.9	10.7	0.8	3.8	9.5	0.2	0.8	0.0	56.3	0.0	5.7
	B	2.1	0.9	2.2	6.8	10.7	0.8	3.7	9.6	0.2	0.8	0.0	56.5	0.0	5.6
	C	2.1	0.9	2.3	7.0	10.8	0.8	3.8	9.4	0.1	0.8	0.0	56.2	0.0	5.8
	Avg	2.1	0.9	2.3	6.9	10.7	0.8	3.8	9.5	0.2	0.8	0.0	56.3	0.0	5.7
	A	2.4	0.6	2.8	6.6	13.4	0.9	4.8	3.4	0.7	0.9	0.8	2.6	52.3	7.9
Z1978U (4 Δ5	B	2.4	0.6	2.8	6.5	13.4	0.9	4.8	3.4	0.8	1.0	0.8	2.6	52.2	7.8
	C	2.4	0.6	2.8	6.6	13.4	0.9	4.8	3.4	0.8	0.9	0.8	2.6	52.3	7.8

genes)	Avg	2.4	0.6	2.8	6.6	13.4	0.9	4.8	3.4	0.8	0.9	0.8	2.6	52.3	7.8
--------	-----	-----	-----	-----	-----	------	-----	-----	-----	-----	-----	-----	-----	------	-----

Table 18. Total Lipid Content In *Yarrowia* Strains YOS9001, YOS9006, YOS9009, YOS9017, YOS9019 And Z1978U

Strain (# of $\Delta 5$ Desaturase Genes)	Sample	DCW (g/L)	Fame (% DCW)	EPA (% DCW)
YOS9001 (3 $\Delta 5$ genes)	A	1.16	15.9	9.3
	B	1.25	15.1	8.7
	C	1.44	15.0	8.5
	Avg	1.28	15.3	8.8
YOS9006 (1 $\Delta 5$ gene)	A	1.88	18.9	10.1
	B	1.97	18.8	10.0
	C	1.98	18.9	9.9
	Avg	1.94	18.9	10.0
YOS9009 (1 $\Delta 5$ gene)	A	1.82	19.3	9.9
	B	1.90	18.3	9.6
	C	1.82	18.6	9.7
	Avg	1.85	18.7	9.7
YOS9017 (zero $\Delta 5$ genes)	A	4.4	27.9	0.0
	B	4.4	28.2	0.0
	C	4.5	28.3	0.0
	Avg	4.44	28.1	0.0
YOS9019 (zero $\Delta 5$ genes)	A	4.5	30.3	0.0
	B	5.0	29.9	0.0
	C	4.6	29.3	0.0
	Avg	4.69	29.8	0.0
Z1978U (4 $\Delta 5$ genes)	A	5.4	34.1	17.8
	B	5.4	33.9	17.7
	C	5.4	33.3	17.4
	Avg	5.40	33.8	17.7

The data of the flask experiment demonstrated that strain YOS9001 (Leu-, Ura-), comprising three delta-5 desaturase genes within the genome, produced about 57 EPA % TFAs, while strains YOS9006 (Leu-, Ura-) and YOS9009 (Leu-, Ura-), comprising only one delta-5 desaturase gene in their genomes, produced about 52.0 EPA % TFAs. In contrast, strains YOS9017 (Ura-) and YOS9019 (Ura-) were not able to produce any EPA but did produce about 56% ETA. The lack of delta-5 desaturase activity in strains YOS9017 (Ura-) and YOS9019 (Ura-) was validated by the total fatty acid analysis above; PCR analyses also confirmed the lack of any DNA sequence encoding a delta-5 desaturase.

Construct pZR5AU-555 (FIG. 13A; SEQ ID NO:233) was generated to integrate three chimeric mutant delta-5 desaturase genes (i.e., FBAIN::EgD5S-36s157g::Pex20 [Example 12], YAT1::EaD5S-35a158g::Oct [Example 13], and EXP1::EgD5M (EgD5R*-34g158g)::Pex16 [Examples 9 and 11] into the region between 1685392 and 1687267 of chromosome C of strain YOS9017 and YOS9019, to thereby enable production of EPA.

The pZR5AU-555 plasmid contained the following components:

10 Table 19. Description of Plasmid pZR5AU-555 (SEQ ID NO:233)

RE Sites And Nucleotides Within SEQ ID NO:233	Description Of Fragment And Chimeric Gene Components
<i>Ascl/BsWI</i> (7713-6820)	890 bp DNA fragment between 1685392 and 1686281 of <i>Yarrowia</i> chromosome C (labeled as "R5-5' region" in Figure)
<i>PacI/Ascl</i> (11396-10436)	967 bp DNA fragment between 1686300 and 1687260 of <i>Yarrowia</i> chromosome C (labeled as "R5-3' region" in Figure)
<i>PmeI / Clal</i> (2476-1)	YAT1::EaD5S-35a158g::Oct, comprising: <ul style="list-style-type: none"> • YAT1: <i>Yarrowia lipolytica</i> YAT1 promoter (labeled as "YAT" in Figure; U.S. Pat. Appl. Pub. No. 2010-0068789-A1); • EaD5S-35a158g: Synthetic mutant delta-5 desaturase comprising mutant HaGG [SEQ ID NO:14] and HDgSH [SEQ ID NO:15] motifs (SEQ ID NO:212), derived from <i>Euglena anabaena</i>; • OCT: OCT terminator sequence of <i>Yarrowia</i> OCT gene (GenBank Accession No. X69988)
<i>EcoRI/BsWI</i> (4127-6820)	FBAIN::EgD5S-36s157g::Pex20, comprising: <ul style="list-style-type: none"> • FBAIN: <i>Yarrowia lipolytica</i> FBAIN promoter (labeled as "FBA1+Intron" in Figure; U.S. Pat. 7,202,356); • EgD5S-36s157g: Synthetic mutant delta-5 desaturase comprising mutant HPGs [SEQ ID NO:11] and HDgSH [SEQ ID NO:15] motifs (SEQ ID NO:182), derived from <i>Euglena gracilis</i> (labeled as "EgD5S" in Figure); • Pex20: Pex20 terminator sequence from <i>Yarrowia</i> Pex20 gene (GenBank Accession No. AF054613)
<i>PacI/Clal</i> (11396-1)	EXP1::EgD5M (EgD5R-34g158g)::Pex16, comprising: <ul style="list-style-type: none"> • EXP1: <i>Yarrowia lipolytica</i> export protein (EXP1) promoter (labeled as "EXP" in Figure; U.S. Pat. 7,932,077); • EgD5M (EgD5R-34g158g): Synthetic mutant delta-5 desaturase comprising mutant HgGG [SEQ ID NO:9] and HDAgH [SEQ ID NO:18] motifs (SEQ ID NO:152), derived from <i>Euglena gracilis</i> (labeled as "EgD5M" in Figure); • Pex16: Pex16 terminator sequence from <i>Yarrowia</i> Pex16 gene (GenBank Accession No. U75433)
<i>PmeI/EcoRI</i> (2476-4127)	<i>Yarrowia</i> Ura3 gene (GenBank Accession No. AJ306421)

Construct pZR5AU-555M (FIG. 13B; SEQ ID NO:234) was identical to pZR5AU-555, with the exception that the chimeric EXP1::EgD5M1 (EgD5R*-34g158g347s)::Pex16 gene [Examples 10 and 11] was used in place of the chimeric EXP1::EgD5M (EgD5R*-34g158g)::Pex16 gene of pZR5AU-555.

The pZR5AU-555 and pZR5AU-555M plasmids were digested separately with *Ascl* and then used for transformation of strains YOS9017 and YOS9019 individually according to the General Methods. The transformant cells were plated onto MM plates and maintained at 30 °C for 4 to 5 days. Single colonies were then re-streaked onto MM plates and subsequently inoculated into liquid MM at 30 °C and shaken at 250 rpm/min for 2 days. The cells were collected by centrifugation, resuspended in HGM and then shaken at 250 rpm/min for 5 days. The cells were subjected to fatty acid analysis, according to the General Methods.

GC analyses of 96 pZR5AU-555 transformants into strain YOS9017 identified twenty strains (i.e., #9, #17, #22, #27, #31, #32, #42, #44, #46, #52, #53, #63, #68, #72, #74, #75, #77, #79, #80, #84 and #89) that produced more than 48% EPA of TFAs; these strains were designated as strains Z8001 to Z8020, respectively.

GC analyses of 82 pZR5AU-555M transformants into strain YOS9017 identified ten strains (i.e., #1, #27, #29, #33, #39, #41, #44, #49, #69 and #82) that produced more than 48% EPA of TFAs; these strains were designated as strains Z8021 to Z8030, respectively.

GC analyses of 84 pZR5AU-555 transformants into strain YOS9019 identified twelve strains (i.e., #28, #31, #39, #41, #42, #45, #63, #71, #73, #75, #78 and #84) that produced more than 48% EPA of TFAs; these strains were designated as strains Z8031 to Z8042, respectively.

And, GC analyses of 76 pZR5AU-555M transformants into strain YOS9019 identified twelve strains (i.e., #2, #24, #28, #30, #38, #46, #50, #66, #67, #69, #72 and #73) that produced more than 48% EPA of TFAs; these strains were designated as strains Z8043 to Z8054, respectively.

To analyze the fatty acid composition and oil content of these new EPA strains, duplicate flask assays were carried out for 13 representative strains (i.e., Z8001, Z8005, Z8007, Z8011, Z8014, Z8018, Z8020, Z8022, Z8024, Z8026, Z8035, Z8048 and Z8049). Table 20 summarizes the total
5 DCW, the TFAs % DCW, the concentration of each fatty acid as a weight percent of TFAs [% TFAs] and the EPA (% DCW). Fatty acids are as in Table 13 and Table 17.

All 13 strains were capable of producing greater than 53 EPA % TFAs, with greater than 37 TFAs % DCW. Strains Z8024 and Z8035
10 produced 58.5 EPA % TFAs and 57.9 EPA % TFAs, with 40.8 TFAs % DCW and 37.8 TFAs % DCW, respectively.

Table 20. Fatty Acid Composition and Total Lipid Content In *Yarrowia* Strains Z8001, Z8005, Z8007, Z8011, Z8014, Z8018, Z8020, Z8022, Z8024, Z8026, Z8035, Z8048 and Z8049 Comprising Mutant Delta-5 Desaturases Simultaneously Comprising HxGx (SEQ ID NO:34) and HDxxH (SEQ ID NO:311) Mutant Motifs

Sample	DCW (g/L)	TFAs % DCW	% Total Fatty Acids												EPA % DCW	
			16:0	16:1	18:0	18:1	18:2	ALA	EDA	DGLA	ARA	ETra	20:4 (5,11,14,17)	EPA		
Z8001	4.0	41.2	2.4	0.5	2.7	4.8	11.5	0.6	2.7	5.0	1.0	0.0	0.6	3.8	54.6	22.5
Z8005	3.7	41.5	2.5	0.5	2.6	4.6	11.5	0.6	2.6	5.7	1.0	0.0	0.6	4.6	53.4	22.2
Z8007	3.7	41.2	2.6	0.5	2.9	4.7	11.4	0.7	2.6	5.7	0.9	0.0	0.6	4.8	53.1	21.9
Z8011	4.0	41.7	2.4	0.6	3.5	5.8	11.9	0.8	3.4	3.1	0.8	1.0	0.9	2.9	53.4	22.2
Z8014	3.8	37.8	2.4	0.5	2.6	4.5	11.3	0.6	2.6	5.3	1.0	0.0	0.6	4.1	54.9	20.8
Z8018	3.2	40.8	2.4	0.4	2.6	4.5	11.3	0.6	2.7	6.1	0.9	0.0	0.6	4.9	53.4	21.8
Z8020	3.2	41.3	2.4	0.4	2.7	4.5	11.4	0.6	2.6	5.9	0.9	0.0	0.6	4.9	53.7	22.1
Z8022	3.1	41.5	2.4	0.4	2.6	4.3	11.2	0.6	2.7	5.2	1.0	0.0	0.6	3.7	55.5	23.0
Z8024	3.2	40.8	2.5	0.4	2.6	4.4	11.6	0.6	3.0	2.5	1.2	0.0	1.4	1.4	58.5	23.9
Z8026	3.1	40.8	2.4	0.4	2.7	4.4	11.2	0.6	2.7	5.6	1.0	0.0	0.6	4.2	54.5	22.3
Z8035	3.0	37.8	2.3	0.5	2.2	4.6	11.7	0.7	3.2	3.9	0.7	0.5	0.4	2.7	57.9	21.9
Z8048	3.9	37.4	2.3	0.5	2.4	4.8	11.9	0.6	3.0	5.0	1.1	0.3	0.7	3.7	54.4	20.3
Z8049	3.7	37.5	2.3	0.5	2.3	4.4	11.4	0.6	2.6	6.0	1.0	0.0	0.7	4.9	53.8	20.2

EXAMPLE 16Generation Of HgGG (SEQ ID NO:9) And HDAxH (SEQ ID NO:37)
Mutations In The Variant *Euglena gracilis* Delta-5 Desaturase ["EgD5R"]
For Cloning Into Plant Expression Vectors

Table 7 of Example 7 summarizes the delta-5 desaturase activity from various EgD5R* variants which comprise mutations that alter both the HPGG (SEQ ID NO:7) and HDASH (SEQ ID NO:8) motifs. In Table 7, the EgD5R* proteins having either modified HgGG (SEQ ID NO:9) and HDAgH (SEQ ID NO:18) motifs (as in EgD5R*-34g158g; SEQ ID NO:143) or modified HgGG (SEQ ID NO:9) and HDAaH (SEQ ID NO:17) motifs (as in EgD5R*-34g158a; SEQ ID NO:141) have at least 88% of the activity of the EgD5R* protein (which is identical to the EgD5R protein).

The present Example describes methods used to introduce similar mutations into the DNA sequence of EgD5R (SEQ ID NO:24), flanked by *NotI* sites for easy cloning into existing plant expression vectors (*infra*, Example 18), using PCR-based mutagenesis with oligonucleotides that contain the desired nucleotide changes. More specifically, the double mutants were introduced into a delta-5 desaturase gene through two rounds of PCR amplification, each PCR performed using the Phusion™ High-Fidelity DNA Polymerase (Cat. No. F553S, Finnzymes Oy, Finland) following the manufacturer's protocol. Products were separated by agarose gel electrophoresis and purified using the Zymoclean™ Gel DNA Recovery Kit (Zymo Research, Orange, CA), following the manufacturer's protocol, unless otherwise specified.

Introducing A HgGG (SEQ ID NO:9) Mutation Into EgD5R Flanked By *NotI* Sites

A HgGG (SEQ ID NO:9) mutation was introduced into the EgD5R gene (SEQ ID NO:24) through two rounds of PCR amplification using plasmid pKR1032 as a DNA template. Plasmid pKR1032 was previously described in U.S. Patent No. 7,678,560 and comprises the EgD5R gene (SEQ ID NO:24), flanked by *NotI* sites. The 5' end of EgD5R (SEQ ID NO:24) was amplified from pKR1032 with oligonucleotide primer EgD5-5 (SEQ ID NO:245) and primer EgD5 M1-3 (SEQ ID NO:246), designed to

introduce a DNA change coding for a HgGG (SEQ ID NO:9) mutation. The 3' end of EgD5R (SEQ ID NO:24) was similarly amplified from vector pKR1032 with oligonucleotide primer EgD5 M1-5 (SEQ ID NO:247), designed to introduce a DNA change coding for the HgGG (SEQ ID NO:9) mutation and being perfectly complementary to EgD5 M1-3 (SEQ ID NO:246), and primer EgD5-3 (SEQ ID NO:248). The resulting DNA fragments were separated and purified.

The two purified DNA fragments were then combined and the full-length gene having a DNA change coding for a HgGG (SEQ ID NO:9) mutation was amplified in a second round of PCR with oligonucleotide primers EgD5-5 (SEQ ID NO:245) and EgD5-3 (SEQ ID NO:248). The resulting DNA fragment was purified.

The full-length delta-5 desaturase DNA sequence comprising the HgGG (SEQ ID NO:9) motif is shown in SEQ ID NO:249, while the encoded protein is set forth as SEQ ID NO:250.

Combining A HgGG (SEQ ID NO:9) Mutation With A HDAgH (SEQ ID NO:18) Mutation In EgD5R Flanked By *NotI* Sites

A HDAgH (SEQ ID NO:18) mutation was introduced into the DNA sequence encoding the delta-5 desaturase of SEQ ID NO:250 through two additional rounds of PCR amplification, using the methodologies described above and using the purified DNA fragment containing the HgGG (SEQ ID NO:9) mutation as template. Specifically, the 5' end of SEQ ID NO:249 was amplified with oligonucleotide primer EgD5-5 (SEQ ID NO:245) and primer EgD5 M2-3 (SEQ ID NO:251), designed to introduced a DNA change coding for a HDAgH (SEQ ID NO:18) mutation; the 3' end of SEQ ID NO:249 was amplified with oligonucleotide primer EgD5 M2-5 (SEQ ID NO:252), designed to introduce a DNA change coding for a HDAgH (SEQ ID NO:18) mutation and being perfectly complementary to EgD5 M2-3 (SEQ ID NO:251), and primer EgD5-3 (SEQ ID NO:248). The resulting DNA fragments were separated and purified, as described above.

The two purified DNA fragments were then combined and the full-length gene having a DNA change coding for a HgGG (SEQ ID NO:9) and a HDAgH (SEQ ID NO:18) mutation was amplified in a second round of

PCR with oligonucleotide primers EgD5-5 (SEQ ID NO:245) and EgD5-3 (SEQ ID NO:248). The resulting PCR product was cloned into the pCR-Blunt® cloning vector using the Zero Blunt® PCR Cloning Kit (Invitrogen Corporation), following the manufacturer's protocol, to produce pLF336 (SEQ ID NO:253).

The resulting delta-5 desaturase DNA sequence comprising a HgGG (SEQ ID NO:9) motif and a HDAgH (SEQ ID NO:18) motif in pLF336 is shown in SEQ ID NO:254, while the encoded protein is set forth as SEQ ID NO:255.

Combining A HgGG (SEQ ID NO:9) Mutation With A HDAaH (SEQ ID NO:17) Mutation In EgD5R Flanked By *NotI* Sites

A HDAaH (SEQ ID NO:17) mutation was introduced into the DNA sequence encoding the delta-5 desaturase of SEQ ID NO:250 through two additional rounds of PCR amplification, using the methodologies described above and using the purified DNA fragment containing the HgGG (SEQ ID NO:9) mutation as template. Specifically, the 5' end of SEQ ID NO:249 was amplified with oligonucleotide primer EgD5-5 (SEQ ID NO:245) and primer EgD5 M3-3 (SEQ ID NO:256), designed to introduced a DNA change coding for the HDAaH (SEQ ID NO:17) mutation; the 3' end of SEQ ID NO:249 was similarly amplified with oligonucleotide primer EgD5 M3-5 (SEQ ID NO:257), designed to introduce a DNA change coding for the HDAaH (SEQ ID NO:17) mutation and being perfectly complementary to EgD5 M3-3 (SEQ ID NO:256), and primer EgD5-3 (SEQ ID NO:248). The resulting DNA fragments were separated and purified, as described above.

The two purified DNA fragments were then combined and the full-length gene having a DNA change coding for a HgGG (SEQ ID NO:9) and a HDAaH (SEQ ID NO:17) mutation was amplified in a second round of PCR with oligonucleotide primers EgD5-5 (SEQ ID NO:245) and EgD5-3 (SEQ ID NO:248). The resulting PCR product was cloned into the pCR-Blunt® cloning vector using the Zero Blunt® PCR Cloning Kit (Invitrogen Corporation), following the manufacturer's protocol, to produce pLF337 (SEQ ID NO:258).

The resulting delta-5 desaturase DNA sequence comprising a HgGG (SEQ ID NO:9) motif and a HDAaH (SEQ ID NO:17) motif in pLF337 is shown in SEQ ID NO:259, while the encoded protein is set forth as SEQ ID NO:260.

EXAMPLE 17

Generation Of HgGG (SEQ ID NO:9) And HDAxH (SEQ ID NO:37) Mutations In The *Euglena anabaena* Delta-5 Desaturase [“EaD5”] For Cloning Into Plant Expression Vectors

The present Example describes introduction of a HgGG (SEQ ID NO:9) mutation and either a HDAgH (SEQ ID NO:18) or a HDAaH (SEQ ID NO:17) mutation into the DNA sequence of EaD5 (SEQ ID NO:28) by PCR amplification, in an analogous manner as described in Example 16. The resulting genes were flanked by *NotI* sites to allow for cloning into a set of existing plant expression vectors (Example 18, *infra*); specifically, the double mutants were introduced into the delta-5 desaturase gene through two rounds of PCR amplification, each PCR performed using the Phusion™ High-Fidelity DNA Polymerase (Cat. No. F553S, Finnzymes Oy, Finland) following the manufacturer's protocol. Products were separated by agarose gel electrophoresis and purified using the Zymoclean™ Gel DNA Recovery Kit (Zymo Research, Orange, CA), following the manufacturer's protocol, unless otherwise specified.

Introducing A HgGG (SEQ ID NO:9) Mutation Into EaD5 Flanked By *NotI* Sites

A HgGG (SEQ ID NO:9) mutation was introduced into the EaD5 gene (SEQ ID NO:28) through two rounds of PCR amplification using plasmid pKR1136 as a DNA template. Plasmid pKR1136 was previously described in U.S. Pat. Appl. Pub. No. 2008-0254191-A1 and comprises the EaD5 gene (SEQ ID NO:28) flanked by *NotI* sites. The 5' end of EaD5 (SEQ ID NO:28) was amplified from pKR1136 with oligonucleotide primer EaD5-5 (SEQ ID NO:261) and primer EaD5 M1-3 (SEQ ID NO:262), designed to introduced a DNA change coding for a HgGG (SEQ ID NO:9) mutation. The 3' end of EaD5 (SEQ ID NO:28) was similarly amplified from vector pKR1136 with oligonucleotide primer EaD5 M1-5 (SEQ ID

NO:263), designed to introduce a DNA change coding for the HgGG (SEQ ID NO:9) mutation and being perfectly complementary to EaD5 M1-3 (SEQ ID NO:262), and EaD5-3 (SEQ ID NO:264). The resulting DNA fragments were separated and purified.

The two purified DNA fragments were then combined and the full-length gene having a DNA change coding for a HgGG (SEQ ID NO:9) mutation was amplified in a second round of PCR with oligonucleotide primers EaD5-5 (SEQ ID NO:261) and EaD5-3 (SEQ ID NO:264). The resulting DNA fragment was purified.

The resulting delta-5 desaturase DNA sequence comprising the HgGG motif (SEQ ID NO:9) is shown in SEQ ID NO:265, while the encoded protein is set forth as SEQ ID NO:266.

Combining A HgGG (SEQ ID NO:9) Mutation With A HDAgH (SEQ ID NO:18) Mutation In EaD5 Flanked By *NotI* Sites

A HDAgH (SEQ ID NO:18) mutation was introduced into the DNA sequence encoding the delta-5 desaturase of SEQ ID NO:265 through two additional rounds of PCR amplification, using the methodologies described above and using the purified DNA fragment containing the HgGG (SEQ ID NO:9) mutation as template. The 5' end of SEQ ID NO:265 was amplified with oligonucleotide primer EaD5-5 (SEQ ID NO:261) and primer EaD5 M2-3 (SEQ ID NO:267), designed to introduced a DNA change coding for the HDAgH (SEQ ID NO:18) mutation; the 3' end of SEQ ID NO:265 was similarly amplified with oligonucleotide primer EaD5 M2-5 (SEQ ID NO:268), designed to introduce a DNA change coding for a HDAgH (SEQ ID NO:18) mutation and being perfectly complementary to EaD5 M2-3 (SEQ ID NO:267), and primer EaD5-3 (SEQ ID NO:264). The resulting DNA fragments were separated and purified, as described above.

The two purified DNA fragments were then combined and the full-length gene having a DNA change coding for a HgGG (SEQ ID NO:9) and a HDAgH (SEQ ID NO:18) mutation was amplified in a second round of PCR with oligonucleotide primers EaD5-5 (SEQ ID NO:261) and EaD5-3 (SEQ ID NO:264). The resulting PCR product was cloned into the pCR-Blunt® cloning vector using the Zero Blunt® PCR Cloning Kit (Invitrogen

Corporation), following the manufacturer's protocol, to produce pLF338 (SEQ ID NO:269).

The resulting delta-5 desaturase DNA sequence comprising a HgGG (SEQ ID NO:9) motif and a HDAgH (SEQ ID NO:18) motif in pLF338 is shown in SEQ ID NO:270, while the encoded protein is set forth as SEQ ID NO:271.

Combining A HgGG (SEQ ID NO:9) Mutation With A HDAaH (SEQ ID NO:17) Mutation In EaD5 Flanked By *NotI* Sites

A HDAaH mutation was introduced into the DNA sequence encoding the delta-5 desaturase of SEQ ID NO:270 through two additional rounds of PCR amplification and using the purified DNA fragment containing the HgGG (SEQ ID NO:9) mutation as template. The 5' end of SEQ ID NO:270 was amplified with oligonucleotide primer EaD5-5 (SEQ ID NO:261) and primer EaD5 M3-3 (SEQ ID NO:272), designed to introduced a DNA change coding for the HDAaH (SEQ ID NO:17) mutation; the 3' end of SEQ ID NO:270 was similarly amplified with oligonucleotide primer EaD5 M3-5 (SEQ ID NO:273), designed to introduce a DNA change coding for the HDAaH (SEQ ID NO:17) mutation and being perfectly complementary to EaD5 M3-3 (SEQ ID NO:272), and primer EaD5-3 (SEQ ID NO:264). The resulting DNA fragments were separated and purified, as described above.

The two purified DNA fragments were then combined and the full-length gene having a DNA change coding for a HgGG (SEQ ID NO:9) and a HDAaH (SEQ ID NO:17) mutation was amplified in a second round of PCR with oligonucleotide primers EaD5-5 (SEQ ID NO:261) and EaD5-3 (SEQ ID NO:264). The resulting PCR product was cloned into the pCR-Blunt® cloning vector using the Zero Blunt® PCR Cloning Kit (Invitrogen Corporation), following the manufacturer's protocol, to produce pLF339 (SEQ ID NO:274).

The resulting delta-5 desaturase DNA sequence comprising a HgGG (SEQ ID NO:9) motif and a HDAaH (SEQ ID NO:17) motif in in pLF339 is shown in SEQ ID NO:275, while the encoded protein is set forth as SEQ ID NO:276.

EXAMPLE 18

Construction Of Soybean Expression Vectors For Co-Expression Of The EgD5R Or EaD5 Double Delta-5 Desaturase Mutants With A Delta-9 Elongase And A Delta-8 Desaturase In Soy

The present Example describes construction of soybean vectors for co-expression of the EgD5R or EaD5 double delta-5 desaturase mutants, comprising either HgGG (SEQ ID NO:9) and HDAgH (SEQ ID NO:18) motifs or HgGG (SEQ ID NO:9) and HDAAH (SEQ ID NO:17) motifs as described in Examples 16 and 17, respectively, with a suitable delta-9 elongase and delta-8 desaturase in soy.

The EgD5R mutants from pLF336 and pLF337 (described in Example 16), and the EaD5 mutants from pLF338 and pLF339 (described in Example 17) can be released from their respective vectors by digestion with *NotI*. This would then allow the delta-5 desaturase to readily be cloned into any number of existing soy expression vectors behind strong, seed-specific promoters.

For example, the *NotI* fragments comprising each of the mutated delta-5 desaturases can be cloned into the *NotI* fragment of pKR974, previously described in PCT Publication No. WO 2007/136877 (the contents of which are hereby incorporated by reference). In this way, the mutant delta-5 desaturases can be expressed behind the soy glycinin (Gy1) promoter for strong, seed-specific expression.

These vectors are then digested with *SbfI* and the fragments containing the mutated delta-5 desaturase are cloned into the *SbfI* site of pKR913, previously described in PCT Publication No. WO 2008/137516, the contents of which are hereby incorporated by reference. In this way, the mutated delta-5 desaturases can be co-expressed with the *Euglena gracilis* delta-8 desaturase ["EgD8"] and the *E. gracilis* delta-9 elongase ["EgD9e"] behind strong, seed-specific promoters.

Any of the vectors thus generated are purified and either the vector or an *AscI* fragment of the vector is co-transformed with vectors designed to increase omega-3 PUFAs, such as, but not limited to, pKR328 (described in PCT Publication No. WO 04/071467) comprising the

Saprolegnia diclina delta-17 desaturase ["SdD17"] under control of the annexin promoter and having a hygromycin resistance gene for selection in plants, into soy embryo cultures as described in PCT Publication No. WO 2008/137516. After transformation, transgenic soy embryos are selected, matured, analyzed for fatty acid profiles and plants are regenerated.

In this way, embryos or seeds expressing the mutated delta-5 desaturases can be obtained which comprise long-chain PUFAs such as EPA and/or ARA.

Alternatively, the vectors, or fragments derived from them, co-expressing the mutated delta-5 desaturases along with the EgD9 and EgD8 genes can be co-transformed, with other vectors containing a suitable selectable marker, such as pKR325, described in U.S. Pat. 7,659,120. Embryos are matured and analyzed and plants regenerated in exactly the same way and thus alternate fatty acids profiles, such as increased ARA and reduced EPA, can be achieved in the seeds of the resulting plants.

Plasmids expressing the mutated delta-5 desaturases along with the EgD9 and EgD8 genes can be also co-transformed with vectors comprising genes or DNA fragments or artificial microRNAs designed to silence the endogenous soy *fad3* genes, such as, but not limited to, pKR1189 or pKR1249 or other constructs previously described in U.S. Pat. Appl. Pub. No. 2008-0194685 A1. In this way, higher concentration of ARA and lower EPA in soy seeds can be achieved.

In addition to the genes, promoters, terminators and gene cassettes described herein, one skilled in the art can appreciate that other promoter/gene/terminator cassette combinations can be synthesized in a way similar to, but not limited to, that described herein for expression of delta-5 desaturase mutants. Similarly, it may be desirable to express other PUFA genes (such as those described below in Table 23), for co-expression with the delta-5 desaturase of the present invention.

For instance, PCT Publication Nos. WO 2004/071467 and WO 2004/071178 describe the isolation of a number of promoter and

transcription terminator sequences for use in embryo-specific expression in soybean. Furthermore, PCT Publication Nos. WO 2004/071467, WO 2005/047479 and WO 2006/012325 describe the synthesis of multiple promoter/gene/terminator cassette combinations by ligating individual promoters, genes and transcription terminators together in unique combinations. Generally, a *NotI* site flanked by the suitable promoter (such as those listed in, but not limited to, Table 21) and a transcription terminator (such as those listed in, but not limited to, Table 22) is used to clone the desired gene. *NotI* sites can be added to a gene of interest such as those listed in, but not limited to, Table 23 using PCR amplification with oligonucleotides designed to introduce *NotI* sites at the 5' and 3' ends of the gene. The resulting PCR product is then digested with *NotI* and cloned into a suitable promoter/*NotI*/terminator cassette.

In addition, PCT Publication Nos. WO 2004/071467, WO 2005/047479 and WO 2006/012325 describe the further linking together of individual gene cassettes in unique combinations, along with suitable selectable marker cassettes, in order to obtain the desired phenotypic expression. Although this is done mainly using different restriction enzymes sites, one skilled in the art can appreciate that a number of techniques can be utilized to achieve the desired promoter/gene/transcription terminator combination. In so doing, any combination of embryo-specific promoter/gene/transcription terminator cassettes can be achieved. One skilled in the art can also appreciate that these cassettes can be located on individual DNA fragments or on multiple fragments where co-expression of genes is the outcome of co-transformation of multiple DNA fragments.

Furthermore, U.S. Pat. Appl. Pub. No. 2008-0254191-A1 describes the creation of a number of vectors that co-express individual delta-9 elongases with delta-8 desaturases, as well as the fusion of these genes to create multizymes. Any of the mutant delta-5 desaturases described herein can be co-expressed with the vectors described in U.S. Pat. Appl. Pub. No. 2008-0254191-A1, either by cloning into the described expression vectors or by co-transformation of suitable expression vectors

as plasmid(s) or fragment(s) to achieve soy seeds that produce PUFAs such as, but not limited to, ARA, EPA, DPA and DHA.

Table 21. Seed-specific Promoters

Promoter	Organism	Promoter Reference
β -conglycinin α' -subunit	soybean	Beachy et al., <i>EMBO J.</i> 4:3047-3053 (1985)
kunitz trypsin inhibitor	soybean	Jofuku et al., <i>Plant Cell</i> 1:1079-1093 (1989)
Annexin	soybean	WO 2004/071467
glycinin Gy1	soybean	WO 2004/071467
albumin 2S	soybean	U.S. Patent No. 6,177,613
legumin A1	pea	Rerie et al., <i>Mol. Gen. Genet.</i> 225:148-157 (1991)
β -conglycinin β -subunit	soybean	WO 2004/071467
BD30 (also called P34)	soybean	WO 2004/071467
legumin A2	pea	Rerie et al., <i>Mol. Gen. Genet.</i> 225:148-157 (1991)

Table 22. Transcription Terminators

Transcription Terminator	Organism	Reference
phaseolin 3'	bean	WO 2004/071467
kunitz trypsin inhibitor 3'	soybean	WO 2004/071467
BD30 (also called P34) 3'	soybean	WO 2004/071467
legumin A2 3'	pea	WO 2004/071467
albumin 2S 3'	soybean	WO 2004/071467

Table 23. PUFA Biosynthetic Pathway Genes

Gene	Organism	Reference
delta-6 desaturase	<i>Saprolegnia diclina</i>	WO 2002/081668
delta-6 desaturase	<i>Mortierella alpina</i>	U.S. Patent No. 5,968,809
elongase	<i>Mortierella alpina</i>	WO 2000/12720 U.S. Patent No. 6,403,349
delta-5 desaturase	<i>Mortierella alpina</i>	U.S. Patent No. 6,075,183
delta-5 desaturase	<i>Saprolegnia diclina</i>	WO 2002/081668
delta-5 desaturase	<i>Peridinium</i> sp.	U.S. Patent No. 7,695,950
delta-5 desaturase	<i>Euglena gracilis</i>	U.S. Patent No. 7,678,560
delta-15 desaturase	<i>Fusarium moniliforme</i>	U.S. Patent No. 7,659,120
delta-17 desaturase	<i>Saprolegnia diclina</i>	WO 2002/081668
elongase	<i>Thraustochytrium aureum</i>	WO 2002/08401 U.S. Patent No. 6,677,145
elongase	<i>Pavlova</i> sp.	Pereira et al., <i>Biochem. J.</i> 384:357-366 (2004)
delta-4 desaturase	<i>Schizochytrium</i>	WO 2002/090493

	<i>aggregatum</i>	U.S. Patent No. 7,045,683
delta-4 desaturase	<i>Isochrysis galbana</i>	WO 2002/090493 U.S. Patent No. 7,045,683
delta-4 desaturase	<i>Thraustochytrium aureum</i>	WO 2002/090493 U.S. Patent No. 7,045,683
delta-4 desaturase	<i>Euglena gracilis</i>	U.S. Patent No. 7,629,503
delta-9 elongase	<i>Isochrysis galbana</i>	WO 2002/077213
delta-9 elongase	<i>Euglena gracilis</i>	U.S. Patent No. 7,645,604
delta-9 elongase	<i>Eutreptiella</i> sp. CCMP389	U.S. Patent No. 7,645,604
delta-8 desaturase	<i>Euglena gracilis</i>	WO 2000/34439 U.S. Patent No. 6,825,017 U.S. Patent No. 7,709,239 WO 2004/057001 WO 2006/012325
delta-8 desaturase	<i>Acanthamoeba castellanii</i>	Sayanova et al., <i>FEBS Lett.</i> 580:1946-1952 (2006)
delta-8 desaturase	<i>Pavlova salina</i>	WO 2005/103253
delta-8 desaturase	<i>Pavlova lutheri</i>	U.S. Patent No. 7,943,823
delta-8 desaturase	<i>Tetruetreptia pomquetensis</i> CCMP1491	U.S. Patent No. 7,863,502
delta-8 desaturase	<i>Eutreptiella</i> sp. CCMP389	U.S. Patent No. 7,863,502
delta-8 desaturase	<i>Eutreptiella cf. gymnastica</i> CCMP1594	U.S. Patent No. 7,863,502

CLAIMS

What is claimed is:

1. A mutant polypeptide having delta-5 desaturase activity comprising:
 - (a) an amino acid motif as set forth in SEQ ID NO:34 [HxGx], wherein SEQ ID NO:34 [HxGx] is not identical to SEQ ID NO:7 [HPGG]; and,
 - (b) an amino acid motif as set forth in SEQ ID NO:1 [HxxxH], wherein SEQ ID NO:1 [HxxxH] is not identical to SEQ ID NO:8 [HDASH].
2. The mutant polypeptide of Claim 1, wherein:
 - (a) said amino acid motif of (a) is selected from the group consisting of: SEQ ID NO:9 [HgGG], SEQ ID NO:10 [HhGG], SEQ ID NO:11 [HPGs], SEQ ID NO:12 [HcGG], SEQ ID NO:13 [HwGG], and SEQ ID NO:14 [HaGG]; and,
 - (b) said amino acid motif of (b) is selected from the group consisting of: SEQ ID NO:15 [HDgSH], SEQ ID NO:16 [HDsSH], SEQ ID NO:17 [HDAaH], SEQ ID NO:18 [HDAgH] and SEQ ID NO:19 [HeASH].
3. The mutant polypeptide of Claim 2, wherein said mutant polypeptide has at least 90% sequence identity based on a BLASTP method of alignment when compared to a polypeptide having a sequence selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:25 and SEQ ID NO:29.
4. The mutant polypeptide of Claim 3 having the amino acid sequence selected from the group consisting of: SEQ ID NO:139 [EgD5R*-34g157g], SEQ ID NO:141 [EgD5R*-34g158a], SEQ ID NO:143 [EgD5R*-34g158g], SEQ ID NO:145 [EgD5R*-34h158a], SEQ ID NO:147

[EgD5R*-34h158g], SEQ ID NO:149 [EgD5R*-36s158a], SEQ ID NO:151 [EgD5R*-36s158g], SEQ ID NO:153 [EgD5M, codon-optimized EgD5R*-34g158g], SEQ ID NO:157 [EgD5M1, codon-optimized EgD5R*-34g158g347s], SEQ ID NO:181 [EgD5S-36s156e], SEQ ID NO:183 [EgD5S-36s157g], SEQ ID NO:185 [EgD5S-36s158a], SEQ ID NO:187 [EgD5S-36s158g], SEQ ID NO:213 [EaD5S-35a158g], SEQ ID NO:215 [EaD5S-35a158s], SEQ ID NO:217 [EaD5S-35a159g], SEQ ID NO:255 [EgD5R-34g158g], SEQ ID NO:260 [EgD5R-34g158a], SEQ ID NO:271 [EaD5-35g159g], and SEQ ID NO:276 [EaD5-35g159a].

5. The mutant polypeptide of any one of Claims 1-4 wherein the mutant polypeptide has a dihomo-gamma-linolenic acid to arachidonic acid conversion efficiency that is at least 64% of the dihomo-gamma-linolenic acid to arachidonic acid conversion efficiency of the parent polypeptide, said parent polypeptide comprising an amino acid motif identical to SEQ ID NO:7 [HPGG] and an amino acid motif identical to SEQ ID NO:8 [HDASH].


6. An isolated nucleic acid molecule encoding the polypeptide of Claim 1.

7. The isolated nucleic acid molecule of Claim 6 having the nucleotide sequence selected from the group consisting of: SEQ ID NO:138 [EgD5R*-34g157g], SEQ ID NO:140 [EgD5R*-34g158a], SEQ ID NO:142 [EgD5R*-34g158g], SEQ ID NO:144 [EgD5R*-34h158a], SEQ ID NO:146 [EgD5R*-34h158g], SEQ ID NO:148 [EgD5R*-36s158a], SEQ ID NO:150 [EgD5R*-36s158g], SEQ ID NO:152 [EgD5M, codon-optimized EgD5R*-34g158g], SEQ ID NO:156 [EgD5M1, codon-optimized EgD5R*-34g158g347s], SEQ ID NO:180 [EgD5S-36s156e], SEQ ID NO:182 [EgD5S-36s157g], SEQ ID NO:184 [EgD5S-36s158a], SEQ ID NO:186 [EgD5S-36s158g], SEQ ID NO:212 [EaD5S-35a158g], SEQ ID NO:214 [EaD5S-35a158s], SEQ ID NO:216 [EaD5S-35a159g], SEQ ID NO:254


[EgD5R-34g158g], SEQ ID NO:259 [EgD5R-34g158a], SEQ ID NO:270 [EaD5-35g159g], and SEQ ID NO:275 [EaD5-35g159a].

8. A transformed host cell expressing the polypeptide of Claim 1.
9. The transformed host cell of Claim 8 selected from the group consisting of microbes and plants.
10. The transformed host cell of Claim 9 wherein the microbial host cell is an oleaginous yeast.
11. The transformed host cell of Claim 10 wherein the oleaginous yeast is *Yarrowia lipolytica*.
12. The transformed host cell of Claim 9 wherein the cell comprises a genetic construct comprising a gene selected from the group consisting of: SEQ ID NO:152, SEQ ID NO:156, SEQ ID NO:182 and SEQ ID NO:212.
13. The transformed host cell of Claim 9 wherein the cell expresses a protein having a sequence selected from the group consisting of: SEQ ID NO:153, SEQ ID NO:157, SEQ ID NO:183 and SEQ ID NO:213.
14. The transformed host cell of either of Claims 8 or 11 wherein the host cell produces a polyunsaturated fatty acid selected from the group consisting of omega-6 fatty acids and omega-3 fatty acids.
15. The transformed host cell of Claim 9 wherein the plant host cell is an oilseed plant cell.

1/17



2/17






FIG. 2

4/17

EgD5 (SEQ ID NO. 20) ATGGCTCTCAGTCTTACCAACAGAACAGCTGTTAGAACGCCCTGATTTGGTTGGGATTGATGGCATCCCTCT
EgD5R (SEQ ID NO. 24) ATGGCTCTCAGTCTTACCAACAGAACAGCTGTTAGAACGCCCTGATTTGGTTGGGATTGATGGCATCCCTCT

EgD5 (SEQ ID NO. 20) ACGACCTTGAAGGGCTTGCCAAAGTTCATCCAGGAGGAGATTGATTCTCGCTTCTGGTGGCTCTGATGC
EgD5R (SEQ ID NO. 24) ACGACCTTGAAGGGCTTGCCAAAGTTCATCCAGGAGGAGATTGATTCTCGCTTCTGGTGGCTCTGATGC

EgD5 (SEQ ID NO. 20) CTCCCCCTCTCTTTTCAATGCATCCATACGTCAAACCGGAGAAATCCAAATTTGCTTCAACAGTTCGTC
EgD5R (SEQ ID NO. 24) CTCCCCCTCTCTTTTCAATGCATCCATACGTCAAACCGGAGAAATCCAAATTTGCTTCAACAGTTCGTC

EgD5 (SEQ ID NO. 20) CGAGGGAAGCATGACCGCACCTCGAAGGACATTGTCTACACGATGATTCTCCCTTCGCACAAGACGTTA
EgD5R (SEQ ID NO. 24) CGAGGGAAGCATGACCGCACCTCGAAGGACATTGTCTACACGATGATTCTCCCTTCGCACAAGACGTTA

EgD5 (SEQ ID NO. 20) AGCGGACAATGCCGAGGTGATGAAGGAGGAAGTGGTACGCAACCCCTGGCTTCTGGTCCGACCCGT
EgD5R (SEQ ID NO. 24) AGCGGACAATGCCGAGGTGATGAAGGAGGAAGTGGTACGCAACCCCTGGCTTCTGGTCCGACCCGT

FIG. 3A




FIG. 3B




FIG. 3C







FIG. 3D

8/17






FIG. 5

10/17




FIG. 6A




FIG. 6B

FIG. 7

12/17




FIG. 8A




FIG. 8B




FIG. 9





FIG. 10A





FIG. 10B



15/17

FIG. 11A




FIG. 11B




FIG. 12B

FIG. 12A

